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Abstract 
Mantle cell lymphoma (MCL) is a rare, aggressive and incurable type of cancer 
with a high incidence of systemic dissemination and poor survival outcomes.  
Understanding the genetics and biology of MCL is necessary for development of suitable 
biomarkers and therapies. A limited number of sequencing-based studies were performed 
on MCL recently, which improved the knowledge on causal mutations and molecular 
mechanisms of MCL. However, because of the small cohort sizes of these studies and use 
of outdated computational tools and databases have limited the findings of these studies. 
The objective of our study was to identify the genetic alterations and molecular pathways 
that are associated with the development, progression, and dissemination of MCL by using 
leading-edge bioinformatics tools, up-to-date molecular biology databases, and a large 
sample size. Presented here is a meta-analysis of whole exome sequencing data from tumor 
biopsies of 67 MCL patients, which resulted in the identification of several novel candidate 
driver genes that were targets of recurrent mutations in MCL such as SP140, S1PR1, 
PTPRD, HNRNPH1, LRP1B, FAT1, MAP3K14, and DST. Our analysis revealed four 
mutation hotspots in the first exon of MAP3K14 in MCL, five other types of B-cell 
lymphoma and leukemia, and canine lymphoma. We further proposed that the recurrent 
mutations of MAP3K14, which have activting effect on the protein, are potentially 
associated with a higher likelihood of relapse. This finding suggests that the recurrent 
mutations of MAP3K14 may have application for prediction of disease outcome, response 
to therapy, and the tanformation of the leukemic variant of MCL to the more aggressive 
subtype. 
Finally, we detected a significant accumulation of mutations in signaling pathways with 
roles in mechanisms of tumor metastasis, such as Rho GTPase mediated signaling, focal 
adhesion, G-protein coupled receptor signaling, cAMP-PKA signaling, ERK-MAPK 
signaling, ROBO-Slit signaling, and JAK-STAT signaling. These findings offer new 
insights into the understanding of the driver genes and molecular mechanisms underlying 
the aggressive clinical course of MCL and may have implications for the development of 
therapies. 
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Chapter 1. Introduction 
1.1. Cancer as a disease of the genome 
Cancer is a disease caused by genetic alterations that result in the uncontrolled proliferation 
of immortal cells. Identifying abnormalities and molecular mechanisms of pathogenesis of 
cancer are crucial for prevention and early detection of cancer, prediction of clinical course 
and treatment outcome, and development of effective therapies. Since the first discovery 
of genetic alterations in cancer, our knowledge improved significantly by advances in 
technologies (Hanahan and Weinberg 2011a). The advent of Next Generation Sequencing 
(NGS) revolutionized our understanding of cancer genome. In the last decade, NGS-based 
studies identified a large number of genes and pathways involved in the biology of primary 
and relapsed tumors. These findings are leading to identifications of biological biomarkers, 
better therapeutic choices, and prevention of resistance to therapy (Bea et al. 2009; 
Hartmann et al. 2010; Rahal et al. 2014). In this study, we used NGS methodologies and 
state-of-art bioinformatics algorithms to identify somatic point mutations, copy number 
variations and altered pathways that are the underlying pathogenic mechanisms of the 
development and progress of an aggressive type of B-cell lymphoma. This chapter covers 
a brief introduction to the genetics of cancer, NGS platforms, and several of the 
bioinformatics tools that were used in this study.  
1.2. Multistage development of cancer 
Mutations are alterations of the nucleotides and DNA structure causing permanent changes 
to DNA sequence and genetic information. Mutations are induced in the genome by 
internal mechanisms such as cytosine deamination, errors during DNA replication and 
repair or external mechanisms such as pyrimidine dimer formation and deamination which 
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are results of environmental factors (Lehninger, Nelson, and Cox 2008). As the 
consequence of these mechanisms, mutations arise continuously in the genomic DNA of 
somatic and germline cells. Mutations in germline cells and somatic cells are called 
germline mutations and somatic mutations, respectively (Lehninger, Nelson, and Cox 
2008). Some mutations may be harmful or advantageous for the cell, the individual or the 
organism. These mutations are the driving forces of evolution, genetic diseases, and cancer. 
Despite the high frequency of mutations, only a small range of mutations can promote 
tumor initiation and progression (Lehninger, Nelson, and Cox 2008). Some genetic 
alterations can provide growth advantages for the cells that can result in the positive 
selection of cells carrying these mutations (cancer driver mutations). However, the majority 
of mutations that occur randomly do not have any advantage for the cells (passenger 
mutations) (Lehninger, Nelson, and Cox 2008). Passenger mutations are considerably 
higher in number than driver mutations (Greenman et al. 2007). Driver mutations initiate 
the neoplastic transformation of the mutated cells by providing fitness advantages to the 
cells. The better fitness of the mutated cells over the neighboring cells leads to selection, 
survival, and accumulation of the mutated cells. An initial driver mutation is necessary for 
the neoplastic transformation of the normal cell but often not sufficient for the full 
transformation to a malignant tumor cell. Malignant transformation of normal cells to 
cancer cells is a complex and multistage evolutionary process that requires sequential and 
spontaneous accumulation of mutations in a substantial amount of time (Shpak and Lu 
2016; Yates and Campbell 2012). Therefore, random mutations continue to arise 
generating more genetic diversity in the population of cells (Nowell 1976). Subsequently, 
driver mutations will occur in some cells resulting in the selection, clonal expansion, and 
domination of these cell over the others in the population of cells (Weinberg 2013; Yates 
and Campbell 2012). The clonal expansion of the cells carrying driver mutations forms a 
homogenous population of cells. This evolutionary model is called “Linear evolution” 
which is the classical model of tumorigenesis (Weinberg 2013; Yates and Campbell 2012). 
However, development and progress of many cancers are more complex than a series of 
linear and sequentially acquired mutations. Driver mutations can arise in different cells and 
give rise to genetically distinct subclones of cells with various selective advantages 
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(Weinberg 2013; Yates and Campbell 2012). These genetically distinct subclones of cells 
share some mutations that were present in the initiator cell (tumor progenitor cell) or the 
ancestral clone. This model of tumor development is called “branched evolution” 
(Weinberg 2013; Yates and Campbell 2012). Cancers that evolve through branched 
evolution are genetically diverse and heterogeneous. Genetic heterogeneity gives a 
dynamic nature to tumor cells enabling them to survival new microenvironments such as 
therapy.  
In this project, we studied a genetically heterogeneous type of lymphoma (Mantle cell 
lymphoma) which has a high frequency of relapse and resistance to therapy. The focus of 
our study was to identify driver somatic mutations and the selective advantages associated 
with these mutations that are involved in development, progression and possibly metastasis 
of Mantle cell lymphoma (MCL). 
1.3. Genetic variants in cancer 
The human genome is composed of protein-coding and non-protein-coding sequences (T. 
E. P. Consortium 2012). The noncoding DNA, which takes more than 98% of the genome, 
contains regulatory sequences, noncoding RNA sequences, introns and repetitive 
sequences. The protein coding DNA, which is more evolutionary conserved than the 
noncoding sequences, takes less than 2% of the genome. Coding sequences (i.e., exons) 
produce proteins that often have critical functions in the cell. Genes are one of the 
functional units of the genomic DNA and consist of protein coding sequences (exons), 
noncoding sequences (introns), regulatory elements such as promoter and enhancer in the 
3’ and 5’ untranslated (UTR) and flanking regions, and splicing motifs within introns and 
exons (Alberts 2015). Exons are the most conserved part of a gene, and therefore mutations 
arizing in these sequences are less frequent and might have dramatic impacts on proteins 
than the rest of the genome. Effects of variants on DNA/mRNA/protein depends on their 
size and location which are two criteria that are used for the classifications of variants (den 
Dunnen et al. 2016). The main classes of variants are namely, single nucleotide variants 
(SNVs = 1 bp), small insertions and deletions (indels < 50 bp), copy number variants 
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(CNVs >50 bp) including gains/amplifications and heterozygous/homozygous deletions, 
structural variants (SVs) and Loss of heterozygosity (LOH) (Ciriello et al. 2013; Stratton, 
Campbell, and Futreal 2009). SNVs are annotated based on site and function of mutations 
in classes of noncoding variants (5’/3’ UTR, intron, RNA, and 5’/3’ flanking variants) and 
coding variants (missense, nonsense, nonstop, translation start site, synonymous, and splice 
site variants). The coding variants are annotated based: change of one amino acid to another 
(missense), change of one amino acid codon to another codon of the same amino acid 
(synonymous), change of an existing codon to translation stop codon (Nonsense), change 
of translation start site codon to another codon (Translation start site), and change of 
translation stop codon to another codon (nonstop). Missense and nonsense variants are also 
called non-synonymous. The noncoding and synonymous variants that do not alter amino 
acid sequence are also known as silent mutations (Diederichs et al. 2016). Indels are also 
sub-classified to four classes of variants including insertions and deletions that change the 
reading frame of target genes (frameshift insertions and deletions), and those that do not 
change the reading frame of target genes (in-frame insertions and deletions). All types of 
variants can potentially play roles in the development of cancer. However, the focus of 
cancer research was mostly on CNVs, SVs, and SNVs in exons (missense, nonsense, 
nonstop, translation start site and splice site mutations) (Diederichs et al. 2016). As a result, 
the potential role of silent and noncoding mutations in the biology of cancer remained 
underrepresented (Komar 2007). Findings of recent studies on roles of synonymous and 
noncoding variants in the development of cancer are bringing an increasing attention 
towards these classes of variants (Khurana et al. 2016; Puente et al. 2015).  
Driver genetic and epigenetic mutations target specific genes (oncogenes, tumor 
suppressor genes, housekeeping genes), noncoding RNA (miRNA) and regulatory regions 
that have critical functions in the cell. Genes that are targeted by driver mutations and 
contribute to neoplasticity of the cell are called driver genes (Vogelstein et al. 2013). To 
understand mechanisms of tumorigenesis, it is necessary to identify driver mutations, 
driver genes and their potential functions in the cell. In the present study, we analyzed 
somatic CNVs, SNVs and indels including synonymous and noncoding mutations to 
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identify driver mutations, genes, and pathways that contribute to the development and 
progress of Mantle cell lymphoma (MCL). 
 Role of tumor suppressor genes and oncogenes in cancer 
Malignant transformation of normal cells to tumor cells is the result of genetic and 
epigenetic alterations in series of genes, noncoding RNA, and regulatory regions. 
Oncogenes (OG) and tumor suppressor genes (TSG) are two classes of driver genes that 
contribute to tumorigenesis (Vogelstein et al. 2013). In normal cells, Oncogenes express 
proteins that induce cell proliferation and inhibit cell death. Expressions of these genes are 
carefully regulated in the cell. Some somatic SNVs, indels, copy number gains, and 
amplifications can result in the gain of function or over expression of Oncogenes and 
deregulation of cell proliferation, cell death, and survival leading to tumor development 
and progress (Schwab 1998; Vogelstein et al. 2013). The gain of function mutations in 
Oncogenes have a dominant effect which means one altered allele suffice for activation of 
Oncogenes (E. Y. H. P. Lee and Muller 2010).  
On the other hand, tumor suppressor genes encode proteins that prevent tumor formation 
through different mechanisms such as inhibition of cell proliferation and induction of cell 
death. Some somatic SNVs, indels, heterozygous and homozygous deletions, NLOH and 
epigenetic changes cause truncation, loss-of-function or down-regulation of tumor 
suppressor genes resulting in deregulation of cell proliferation, cell death, and subsequent 
tumor development and progress (Vogelstein et al. 2013).  Since the human genome is 
diploid and has two copies of genes, in most cases alterations of both alleles of tumor 
suppressor genes are required for deactivation of the proteins. It is common in cancers that 
various combination of somatic SNVs, CNVs, LOH and promoter methylations result in 
bi-allelic deactivation, loss of function or silencing of tumor suppressor genes (Balmain, 
Gray, and Ponder 2003). For example, mutation or methylation might happen in one allele 
and LOH in the other allele of a TSG. Inactivation of tumor suppressor genes happens more 
frequently than oncogenes due to the higher chances of truncation rather than activation of 
a gene. Oncogenes and tumor suppressor genes show two distinct patterns of distribution 
of mutations which are used as parameters for distinguishing roles of driver genes in 
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cancer. The gain of function mutations in Oncogenes usually target the same amino acid 
positions, whereas loss-of-function mutations in tumor suppressor genes tend to scatter 
through the length of the genes. That is why hotspot mutations in cancer are frequently 
detected in Oncogenes (Vogelstein et al. 2013). 
Activation of Oncogenes and deactivation of tumor suppressor genes by genetic and 
epigenetic variations are the critical parts of the multistep process of tumorigenesis. Driver 
mutations in the driver genes cause loss of balance in cellular functions, thus leading to 
gain of various advantageous traits that are necessary for the development of cancer 
(Balmain, Gray, and Ponder 2003; Vogelstein et al. 2013). 
1.4. Hallmarks of cancer 
Normal cells have cellular control systems that prevent tumor formation by tight regulation 
of cell functions such as DNA replication. Therefore, normal cells need to escape the cell 
control systems to be able to fully transform into malignant cells, which make 
tumorigenesis a multi-step process that requires a substantial amount of time and 
accumulation of mutations to obtain the beneficial traits necessary for the survival of 
transforming cells. It has been suggested that neoplastic cells develop nine features to 
transform into fully malignant cells (Hanahan and Weinberg 2000, 2011b). The 
advantageous features which are common for most types of cancers have been described 
as the nine hallmarks that contribute to the multistep development of cancer (Hanahan and 
Weinberg 2000, 2011b). The nine hallmarks of cancer are: “self-sufficiency in growth 
signals, insensitivity to growth-inhibitory signals, evasion of programmed cell death, 
limitless replicative potential, sustained angiogenesis, tissue invasion, and metastasis, 
genome instability, reprogramming of energy metabolism, evading immune system and 
supportive tumor microenvironment” (Hanahan and Weinberg 2000, 2011b). 
 Sustained proliferation 
Growth signals induce cell division and proliferation in normal cells, in response to 
signaling molecules and proteins, which are tightly regulated in the cell  (Hanahan and 
 7 
Weinberg 2000, 2011b). Cancer cells gain the capability of constitutive proliferation 
through a number of ways such as independence in the production of growth factors, 
stimulation of neighboring normal cells for production of growth factors, overexpression 
of the related receptors, ligand-independent constitutive activation of the receptors and the 
downstream signaling pathways.  
 Escaping growth inhibitors 
Cell proliferation is negatively regulated in normal cells by suppressive mechanisms that 
get activated in response to extracellular growth-inhibitory signals, intracellular stress 
signals and cell-to-cell contacts (Hanahan and Weinberg 2000, 2011b). Cancer cells evade 
these suppressive operating systems through gain of inactivating mutations, deletions or 
epigenetic mutations in the associated components. 
 Resistance to cell death 
Two main cellular mechanisms maintain regulation of cell death in the cell namely 
apoptosis and autophagy (Hanahan and Weinberg 2000, 2011b). These mechanisms 
promote cell death or cell survival, respectively, in response to intracellular or extracellular 
stress-inducing signals. The death-inducing signals can be triggered when cells are under 
physiologic stress such as DNA damage, oncogenic proliferation, and nutrient deficiency. 
Tumor cells escape apoptosis by increasing survival signals, deactivating the pro-apoptotic 
factors, activating the anti-apoptotic factors and inhibiting regulators of phagocytosis 
(Hanahan and Weinberg 2011b). 
 Immortality 
Non-immortal normal cells can only undergo limited cycles of cell division and growth 
which are determined by the length of telomeres (Hanahan and Weinberg 2000, 2011b). 
Telomeres protect chromosomes ends from degradation and fusion. In non-immortal 
normal cells, telomeres are gradually shortening in every cell division. Subsequently, when 
a cell passes its limited replicative potential, telomere length become critically short. The 
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telomere loss and the possible resulting DNA damages induce two proliferation barrier 
mechanisms: apoptosis and senescence. The former induces cell death and the latter blocks 
cell division and growth to prevent DNA damage and formation of neoplastic cells. In 
immortal cells, an enzyme called telomerase is expressed that add telomere segments to 
the end of telomeres to prevent their shortening. It has been suggested that the initial 
neoplastic cells proliferate exhaustively which result in the chromosomal abnormalities. 
DNA damage triggers the crisis signals leading to activation of apoptosis or senescence. 
Thus, most of the preneoplastic cells get eliminated. However, few of the cells, which may 
carry alterations that cause activation of telomerase or inhibition of apoptosis, can survive. 
The survived cells with activated telomerase reconstruct the telomeres and acquire 
immortality. The chromosomal alterations that raised at the time of telomere-shortening 
promote accumulation of more driver mutations leading to further progress of tumor 
(Hanahan and Weinberg 2000, 2011b).  
 Sustained angiogenesis 
Oxygen and nutrients are delivered to the cells, and wastes and carbon dioxide are removed 
from the cells by blood vessels (Hanahan and Weinberg 2000, 2011b). Neovascularization 
becomes temporary active to contribute to processes such as wound healing. Some ligands 
and receptors regulate angiogenesis in normal cells. In oppose to the normal cells, tumor 
cells carry alterations that inactive negative regulators of angiogenesis therefore new 
vascularization become permanently active in tumor cells (Hanahan and Weinberg 2000, 
2011b).   
 Invasion and metastasis 
More invasive tumors gain the ability to invade and metastasize to other tissues that are 
close or distant from the site of origin (Hanahan and Weinberg 2011b). The metastasized 
tumor cells show dysregulation in the expressions of genes involved in cell-to-cell adhesion 
and cell-to-ECM adhesion processes, which allows detachment of tumor cells. In addition, 
tumor cells release signals that can trigger cells in the tumor microenvironment to secrete 
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the enzymes and molecules that help tumor cells invasion and metastasis (Hanahan and 
Weinberg 2000, 2011b).  
 Enabling hallmarks 
Three additional hallmarks are started to emerge recently, but their roles in tumorigenesis 
remain to be established. These traits are: “reprogramming of energy metabolism”, 
“Escaping from immune surveillance”, and “Tumor microenvironment” (Hanahan and 
Weinberg 2011b).  
Genome Instability and Mutations 
Cancer cells develop the nine hallmarks during tumor development to survive, proliferate 
and spread. The driver mutations that arise in drive genes result in the gain of the hallmarks 
of cancer. Therefore, increase in the mutation rate is a necessary feature that provides more 
opportunities for cancer cells for obtaining the advantageous hallmarks. In the normal cells, 
the genomic maintenance machinery prevents accumulation of mutations by repairing 
DNA damage or inducing cell death and senescence in cells with DNA damage (Hanahan 
and Weinberg 2011b). These mechanisms keep mutation rate of cells at a low level. For 
cancer cells, the alterations in the genomic maintenance machinery are necessary to induce 
genomic instability and increase mutation rate. Therefore, genomic instability is one of the 
enabling hallmarks of cancer which is required for the development of neoplastic traits 
(Hanahan and Weinberg 2011b).  
Tumor-Promoting Inflammation  
A second enabling hallmark of cancer is activation of inflammatory responses. 
Inflammatory cells can induce mutagenesis by releasing reactive oxygen and can support 
tumor development by supplying molecules that induce proliferation, survival, 
angiogenesis, metastasis, invasion, and inflammation such as growth factors, 
proangiogenic factors, chemokines and cytokines (Hanahan and Weinberg 2011b). These 
molecules can also be secreted by other normal cells that are recruited in response to 
inflammation. 
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Tumor Microenvironment 
The normal cells such as inflammatory cells, macrophages, neutrophils that are recruited 
to the tumor site and the surrounding normal stromal cells form microenvironment of the 
tumor. Signaling network between tumor cells and tumor microenvironment (TME) is 
crucial for tumor development and survival (Hanahan and Weinberg 2011b). The cells in 
TME should be supportive and permissive so the cancer cell with neoplastic traits can 
proliferate and survive. It has been proposed that neoplastic cells recruit supportive normal 
stromal cells and continuously interact with and reprogram the surrounding stromal cells 
based on the genetic changes in tumor cells. This signaling network between tumor cells 
and TME is established gradually during development of tumor (Hanahan and Weinberg 
2011b). 
1.5. Resistance to therapy and relapse 
Clonal heterogeneity is the feature underlying tumor evolution, resistance to therapy and 
relapse (McGranahan and Swanton 2016). Genetic heterogeneity provides a diverse 
population of cells with capabilities of adaptation to a variety of environments such as 
different types of therapies. Small populations of cells with specific mutations can adapt to 
the pressure from microenvironment and survive therapies. Therefore, Genetic 
heterogeneity plays a fundamental role in treatment failure and resistance to treatment. 
Ultimately subclone of cells with the selective advantage expand and become dominant 
which can lead to the relapse of the disease. Clonal heterogeneity is a known factor 
associated with resistance to therapies and poor prognosis in cancer patients, and a 
challenge in the way of successful treatments. Understanding evolutionary patterns, 
subclonal dynamics, and evolving mutational processes allow us to identify biological 
mechanisms underlying resistance to treatment. Insights on the subclonal architecture of 
tumors and their role in mechanisms of resistance to therapy are critical steps for prediction 
of risk of relapse, the success of therapies, development of effective treatment and the road 
to personalized treatments (E Sabaawy 2013). 
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1.6. Cancer genomics 
 
Cancer genomics is the field of research for studying genetic alterations in genomes of 
cancer cells. The main goal of research in this area of science is to characterize somatic 
driver mutations, driver genes and pathways in cancers to identify novel biomarkers for 
better stratifications, prognostications, and novel targets for the development of treatment 
strategies. Next-generation sequencing (NGS) is the state of art technology that has 
accelerated the understanding of cancer biology (Chun et al. 2014; Jun Zhang et al. 2011). 
Application of NGS revolutionized our understanding of biological mechanisms in cancers 
by providing large amounts of data on cancer genomes and transcriptomes with high 
sensitivity, resolution, and cost-efficiency (Chun et al. 2014; Jun Zhang et al. 2011). NGS 
platforms produce a considerably larger amount of data in a shorter time with a lower cost 
compared to the previous sequencing methods (Chun et al. 2014; Jun Zhang et al. 2011). 
Two main applications of NGS are whole genome sequencing (WGS) and whole exome 
sequencing (WES). WGS offers a higher resolution for detecting SNVs, indels, and CNVs 
compared to the other methods (Chun et al. 2014; Zhang et al. 2011). However, it is not 
the favorable method because of the high cost, lack of optimal bioinformatics algorithms 
for accurate variant calling and challenges of handling the large amount of data that is 
produced (Chun et al. 2014; Zhang et al. 2011). Resolution of WES, on the other hand, is 
limited to the exonic regions of the genome and therefore only detects genetic variants that 
are within exons or their flanking sites (Chun et al. 2014; Zhang et al. 2011). Thus, 
resolution of WES for detecting any types of variants is lower than WGS and for detecting 
CNVs is lower than array-based techniques (Chun et al. 2014; Zhang et al. 2011). Array-
based technologies, which are the most commonly used method for detection of CNVs, 
have a lower and higher resolution in detection of CNVs compared to WGS and WES 
methods, respectively. Overall, array-based technologies are the optimal methods for 
detection of CNVs. With the current limitations in studying noncoding variants, the 
important role of mutations of coding regions in tumor development and relatively low cost 
of WES, this method is the favorable method for studying SNVs and indels in large sample 
sizes of tumor (Chun et al. 2014; Zhang et al. 2011).  
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A typical workflow of a WES study consists of the initial experimental methods and the 
WES data analysis pipeline (Bao et al. 2014; Ku et al. 2012). The experimental methods 
involve extraction of genomic DNA from tumor biopsies and their matched normal 
samples, genomic library preparation, exome capture and enrichment, and quality control 
of exome libraries. The routine WES data analysis pipeline includes, primary data 
processing (preprocessing of raw sequencing data, mapping reads to the reference genome, 
and post-processing of the aligned sequencing reads), and secondary data processing 
(somatic SNV/CNV calling, annotating effects of somatic SNVs/indels, identifying targets 
of CNVs, significant genes, significant pathways, recurrently mutated genes, and other 
related computational analysis) (Figure 1.1) (Bao et al. 2014; Ku et al. 2012). Some of the 
main steps of the experimental workflow and the bioinformatics pipeline of WES are 
explained in greater details in the next sections. 
 
Figure 1.1. The general framework of a whole exome sequencing study. 
The general workflow of WES including four main steps: Sample preparation and exome capture (red 
outline), sequencing (purple outline), primary data processing (green outline), and secondary data processing 
(blue outline). 
DNA Extraction 
from 
Tumor/Normal 
Samples
Library Prepration, 
Exome Capture and 
Enrichment
Quality Control
Sequencing
Quality Control and 
Pre-processing of Raw 
Sequencing Reads
Maping Reads to 
the Reference 
Genome
Post-processing of 
Sequencing Data
Downstream 
Analysis
 13 
 Exome library preparation and capture 
In the last several years NGS platforms have become a staple in the field of cancer 
genomics. All the platforms follow the main principle of hybridizing exonic regions to 
biotinylated oligonucleotide probes and extracting exons from the rest of DNA fragments 
by pulling down the hybridized probes with magnetic streptavidin beads (Clark et al. 2011). 
Platforms differ in length of probes, coverage of genome and type of molecule 
(DNA/RNA) (Clark et al. 2011). Agilent's SureSelect platform uses RNA probes while the 
two other platforms use DNA probes. Roche/Nimblegen probes overlap at the edges while 
Illumina probes have gaps and Agilent probes are located adjacent to each other (Clark et 
al. 2011). Coverage of the platforms also differs based on the mRNA transcript sequences 
they target. In addition to the coding mRNA, each platform specifically covers some 
additional regions of the genome. For example, Illumina and Nimblegen cover a large 
number of UTR and miRNA, respectively (Clark et al. 2011). Based on needs of the study, 
the platform of interest is selected for generating exome libraries. In this study, we used 
two exome capture platforms for preparing whole exome libraries for MCL samples: 
Illumina's TruSeq Exome Enrichment and Agilent's SureSelect Human All Exon. To 
prepare libraries for MCL, we used Illumina (Illumina's TruSeq Exome Enrichment) and 
Agilent (Agilent's SureSelect Human All Exon) platforms. Finally, whole exome libraries 
are used for sequencing, imaging and base-calling which produce raw sequencing reads 
that are the input for the downstream computational pipeline (J. Li et al. 2015).  
 Computational pipeline 
Mapping sequencing reads 
Sequencing of exome libraries generates raw sequencing reads that need to be mapped to 
the reference genome. Before sequence alignment, some preprocessing steps are done on 
raw sequencing data to remove adapter sequences, low-quality base-calls, and 
contaminations (Bao et al. 2014). Next, the processed reads are aligned to the reference 
genome using the alignment algorithms specific for short reads mapping such as Burrows–
Wheeler Aligner (BWA) (H. Li et al. 2009). Finally, the aligned reads undergo some post-
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processing steps such as removal of PCR duplicated reads and trimming the overlapping 
sequences of read pairs (Bao et al. 2014). The resulted processed and mapped sequencing 
data is used for the downstream analysis including detection of somatic SNVs, indels, 
CNV, LOH and SVs (Bao et al. 2014; Ku et al. 2012).  
One challenge of analyzing NGS data is to distinguish real mutations from artifacts or 
unreal variant calls. False positives can be the result of technical errors that arise during 
PCR amplification, sequencing or alignment, and can be random or systematic. Another 
challenge of working with NGS data is the biological complexities of tumor biopsies such 
as subclonal heterogeneity, variations in DNA copy number, and contamination with 
normal cells. Development of sophisticated computational methods is necessary for 
handling NGS data and overcoming the specific challenges of working with tumor samples. 
In this study, we used algorithms and tools to carry out analyses on SNV/indel, and 
CNV/LOH detected from WES data of a new in-house cohort and two previously published 
cohorts of MCL (Figure 1.1). 
Approaches for detection of somatic SNVs and indels 
NGS methodologies led to significant improvements in understanding cancer drivers, 
tumorigenic mechanisms, evolutionary patterns and mechanisms underlying resistance to 
therapy. A standard practice in cancer genomics studies is to identify somatic SNVs and 
indels by comparing sequencing data from matched normal and tumor samples. Numerous 
bioinformatics tools have been developed for somatic variant calling (Krøigård et al. 2016). 
Variant calling tools differ in levels of sensitivity and specificity, thus report quite different 
numbers of variants using the same input. High sensitivity variant callers detect large 
numbers of variants but with higher numbers of false positive (low specificity) (Krøigård 
et al. 2016). Alternatively, higher specificity variant callers output shorter and more 
confident lists of variants but might miss some of the true variants (low sensitivity). 
Analyzing NGS data and detecting variants in cancers have some challenges such as the 
presence of artifacts in the data and “false positive” variant calls, subclonal heterogeneity 
of some tumors, contamination with normal cells, variations in copy number. Because of 
the technical and biological complexities of WES data from tumor samples, none of the 
current variant callers can detect an entirely complete and real list of variants (Krøigård et 
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al. 2016). However, bioinformatics algorithms are rapidly improving by taking into 
account the technical artifacts, false positives and biological complexities of tumor 
samples. Therefore by using a combination of variant calling tools we can detect lists of 
variants with high confidence and minimal false positives (Krøigård et al. 2016). In this 
study, we used Strelka, which has a high specificity in detecting variants and reliable in 
reporting a low number of false positives (Figure 1.2). Strelka calls SNVs and indels in 
two rounds of analysis and only reports those variants that are detected in both tiers of data 
(i.e., high-confidence and low-confidence). In each round, several filters are applied. In the 
first step, read pairs with low mapping quality or one unmapped read are removed and in 
the second phase, read pairs with low mapping quality are removed (Saunders et al. 2012).  
Approaches for annotation of somatic SNVs and indels 
Cancer cell genomes often are highly mutated and carry a large number of mutations, most 
of which are passengers. Thus, variant callers output long lists of variants in most paired 
tumor/normal analyses of WES and WGS. Large portions of these variants are expected to 
represent passenger mutations and need to be distinguished from drivers. Different 
methods were developed that predict functional effects of variants on proteins. These 
methods predict the impact of variants using different approaches. SIFT (sorting tolerant 
from intolerant) (Ng and Henikoff 2001) and PolyPhen (Polymorphism Phenotyping) 
(Adzhubei et al. 2010) are two algorithms that are often used to inform on the potential 
effect of mutations in cancers (Figure 1.2). These methods differ in their approaches. SIFT 
predicts the effect of non-synonymous mutations based on the conversation of amino acids 
within a protein family. This tool estimates the probability of tolerating amino acid change 
based on its conservation within the protein family. If the probability is lower than a 
threshold (0.05), the amino acid change will be called damaging. PolyPhen, on the other 
hand, predicts effects of nonsynonymous mutations based on conservation of amino acids 
and protein 3D-structure. The Ensembl Variant Effect Predictor (VEP) uses the predictions 
from SIFT and PolyPhen and output this information for all isoforms of a gene. In this 
study, we used a tool called VCF2MAF that uses the predicted outcome by the VEP and 
select isoforms based on transcript biotype, the severity of effect and length of the 
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transcript. This tool increases the accuracy of variant annotation by standardizing selection 
of isoforms (Kandoth 2015). 
Approaches for detection of CNVs 
WGS enhances the resolution of CNV detection to a single base pair (Chun et al. 2014; 
Zhang et al. 2011). However, array based methodologies are still favored for detecting 
CNVs because of the high cost of WGS. Current cancer genomics studies use WES 
commonly for detecting SNVs and indels. Using the same input data for detection of SNVs 
and CNVs can be time and cost-effective (Chun et al. 2014; Zhang et al. 2011). It is possible 
to detect CNVs using WES data. However, because of the targeted capture of exons, it is a 
challenge to identify CNVs accurately using the uneven read coverages of WES data. 
Bioinformatics tools were developed to detect CNVs using WES data (Ha et al. 2014). 
TITAN is one of the CNV/LOH calling tools that can also estimate the cellular prevalence 
of the events (Ha et al. 2014). TITAN is a statistical model that uses common SNPs that 
exist in both matched normal and tumor sample WGS and WES data to predict CNV and 
LOH events (Ha et al. 2014). It estimates the cellular prevalence of CNVs based on the 
BAF of each SNP and their corresponding read depth. TITAN assumes that each SNP 
represents data from three population of cells namely: normal cells, tumor cells with CNV 
and tumor cells without CNV (Ha et al. 2014). In this study, we used TITAN for detecting 
CNV and LOH in the matching normal/tumor sample pairs.  
Variant Allele Fraction 
B-allele frequency (BAF) and variant allele fraction (VAF) are both measures of the 
relative frequencies of two alleles of a given gene (Cibulskis et al. 2013). BAF is a term 
that is commonly used for the allelic frequencies in a gene carrying reference allele or 
single nucleotide polymorphisms (SNP) whereas VAF is the term that describes the allelic 
frequencies of mutated alleles in a gene. Using WES data, we can calculate BAF/VAF by 
dividing the number of reads that support each allele (SNP/reference alleles and 
mutated/wild type alleles) by the total number of reads covering the locus (Cibulskis et al. 
2013). SNPs are point mutations that commonly arise in individuals and are the sources of 
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polymorphisms in populations (Griffith et al. 2017). SNPs are categorized to rare and 
common in human populations. SNPs are rare when present in less than 1% of a population 
(minor allele frequency <0.01) and are common when present in more than 1% of a 
population (minor allele frequency >=0.01) (J. W. Kent 2011). Common SNPs do not have 
any effect on the health but are used as markers for various applications such as detection 
of CNVs from WES and WGS data based on BAF of SNPs (Griffith et al. 2017; J. W. Kent 
2011). Cancer genomics studies calculate BAF for SNPs and VAF for somatic mutations 
using WGS and WES data from normal and tumor sample to estimate respectively, the 
copy number of tumor cells and fractions of cancer cells (CCF) carrying a specific mutation 
(Griffith et al. 2017). For a heterozygous locus in a cell BAF/VAF of 50% is expected. 
However, BAF/VAF can be lower (e.g., 30%) or higher (e.g., 80%) than the normal 
frequency when the copy number state of the locus is not normal (i.e., gain, deletion, LOH). 
Since SNPs uniformly exist in all the cells in the body of an individual including tumor 
cells, SNPs are useful markers to estimate copy number state and detected CNVs/LOH 
(Griffith et al. 2017). Somatic mutations, on the other hand, are only present in the 
progenitor cell and its daughter cells. Therefore, VAFs that are calculated using WES data 
are also affected by the signals from normal cells and genetically distinct subclones of cells 
present in the tumor biopsy (Griffith et al. 2017). The three parameters of intratumor 
heterogeneity, purity, and copy number state need to be considered for estimating the actual 
VAF of mutations in a population of cells (Cancer cell fraction or CCF) (Griffith et al. 
2017). Bioinformatics tools are designed to analyze WES data while taking into 
consideration the complexity of the biological heterogeneity of tumor samples. In this 
study, we used a bioinformatics tool that calculates and compare BAFs for the SNPs that 
are sequenced between normal and tumor samples to detect somatic CNVs. Also, we used 
VAF> 80% as a marker to identify loci harboring bi-allelic mutations. 
Approaches for detection of significant genes and candidate drivers 
Discovering cancer driver genes is a major goal in cancer genomics. The improvements of 
NGS methods, the decrease in the cost of sequencing methods, and development of 
bioinformatics tools have significantly increased the power of detecting driver events. 
Meanwhile, false positives are still a major challenge in cancer genomics. In the last 
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decade, WGS and WES studies identified significant driver genes and the mutation 
landscape of different types of tumor. Comprehensive and large-scale studies such as the 
Cancer Genome Atlas (TCGA) and the International Cancer Genome Consortium (ICGC) 
have been initiated to provide a complete profile of cancer drivers in different types of 
cancer. Results of these studies brought into attention some systematic errors such as 
reporting insignificant genes as candidate drivers because of their high natural mutation 
rate (Lohr et al. 2012; Stransky et al. 2011). Size and conservation of a gene can impact 
natural mutation rate of the gene. Another source of false positives is technical artifacts 
from library preparation steps, sequencing, post processing or alignment of sequencing 
reads. For example, alignment of reads covering a gene with a high number of paralogs 
might result in a large number of mismatches which can be mistaken with real mutations. 
Therefore the biological and technical factors need to be considered to distinguish 
passenger mutations from drivers, and errors from true mutations (Lawrence et al. 2013; 
Shyr et al. 2014; Stamatoyannopoulos et al. 2009). For this purpose, statistical 
bioinformatics algorithms were designed to detect significantly mutated genes based on 
various parameters such as recurrence of mutations, functional impacts of mutations, and 
high frequencies of mutations in a network of genes (pathway) (Lohr et al. 2012; Stransky 
et al. 2011). Some of the available tools such as Mutation Significance with Covariates 
(MutSigCV) also take into account the factors that are associated with a high natural rate 
of mutations or artifacts (Lawrence et al. 2013). MutSigCV is developed to identify 
mutated genes with signatures of selective pressure that are thus more likely to represent 
true drivers (Lawrence et al. 2013). MutSigCV estimates patients’ specific mutation rate 
and gene background mutation rate considering DNA replication time, chromatin state, GC 
content and expression levels of the gene. This tool determines significant levels of its 
results using p-value and q-value measures. Although MutSigCV and similar approaches 
can increase specificity considerably, these methods are limited to the genes with a high 
frequency of mutations. Complementing the recurrence-based approaches, are the methods 
that screen for mutations with high functional impact on the protein. The methods that 
consider both recurrence and functional impacts of mutations enable detection of driver 
genes that are less frequently mutated compared to other driver genes, or genes with a high 
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natural rate of mutations. To complement MutSigCV, we also included Oncodrive-fm in 
our analysis which uses the function-based approach to identify cancer driver genes based 
on the bias toward accumulations of mutations with the high functional impact on the 
proteins (FM bias) (Gonzalez-Perez and Lopez-Bigas 2012). Oncodrive-fm is developed 
based on the rationale that driver genes bear highly damaging mutations as the result of 
positive selection of these mutations which are advantageous for cancer cells. Oncodrive-
fm computes a score (FI=functional impact) for each mutation across tumor samples using 
measures of the impact of mutations on proteins such as SIFT and PolyPhen. This method 
assigns the lowest scores to synonymous/silent mutations, and the highest scores to 
nonsense, missense and frameshift mutations. Then, Oncodrive-fm calculates the average 
of FI score of all the mutations present in each gene across all the patients. Based on this 
approach cancer driver genes show FM bias which means the final FI score of mutations 
in the driver genes is significantly higher than the background. Gonzalez-Perez et al. (2012) 
defines background as “a null distribution of average FIs produced by sampling with 
replacement either from the list of somatic mutations observed in the tumor (internal null 
distribution) or from nsSNVs that appear across human populations in genes within the 
same broad biological process as the one under analysis (external null distribution)” 
(Gonzalez-Perez and Lopez-Bigas 2012). In addition, to determine whether a high average 
FI is statistically significant, a p-value is calculated which is the probability of finding a 
set of three mutations with the same average FI by random (Gonzalez-Perez and Lopez-
Bigas 2012). The statistical significance of the genes with FM bias is tested by random 
sampling of a similar set of mutations from the list of variants for one million times and 
calculating their average FI scores. The ratio of arrays with the same or a higher average 
FI score to the gene of interest is taken as the p-value of the gene. Finally, FDR or 
Bonferroni's approach is used for correction of multiple testing (Gonzalez-Perez and 
Lopez-Bigas 2012). The Genes carrying mutations with significantly higher average FIs 
(FM bias) than the background are selected as potential cancer driver genes. On the other 
hand, the average FI scores of the passenger mutations, which are not subjected to positive 
selection in cancers, are low (Gonzalez-Perez and Lopez-Bigas 2012). Therefore, using 
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this approach, driver genes with rare damaging mutations (minimum of two) can be 
distinguished from the genes with high mutations rate or recurrent passenger mutations.  
Current bioinformatics tools such as MutSigCV and Oncodrive-fm, use statistical tests to 
measure significance of findings and probabilities of false positives. Both tools output list 
of genes that are supported by p-value and q-value, which are statistical measures that are 
commonly used for analysis of large genomic data-sets (Benjamini and Hochberg 1995; 
Storey and Tibshirani 2003). P-value is the probability of getting a significant result when 
the null hypothesize is true (false positives). For example, MutSigCV calculates gene-
specific-p-value to test the hypothesize that mutations in a given gene significantly exceed 
the background mutation rate. Lawrence et al. (2013) included the detailed calculations of 
p-value by MutSigCV in the supplementary file of this paper (Lawrence et al. 2013). q-
value is the probability that a statistically significant result is a false positive (false 
discovery rate) (Benjamini and Hochberg 1995; Storey and Tibshirani 2003).   
Approaches for detection of cancer driver pathways 
Some cancers are genetically heterogeneous, therefore patients with the same type of tumor 
(intertumor heterogeneity) and tumor cells of an individual (intratumor heterogeneity) may 
have distinct genetic variations (Burrell et al. 2013). Identifying driver pathways in a 
specific tumor type is a favorable approach to eliminate the genetic heterogeneity that is 
observed in tumors (Dimitrakopoulos and Beerenwinkel 2017). Genes encode individual 
components of the larger protein networks in the cell which cooperate to regulate specific 
biological processes. Driver mutations that arise in components of pathways cause 
deregulation and malfunction of the cellular processes leading to gain of hallmarks of 
cancer (Hanahan and Weinberg 2011a). Two patterns of mutations are common in 
members of pathways namely, co-occurring mutations and mutual exclusive mutations 
(Dimitrakopoulos and Beerenwinkel 2017). The former occurs when two or more members 
of a pathway need to be mutated to provide a selective advantage for the cell. The latter 
occurs in individual members of a pathway which is enough for the tumor cell to gain a 
selective advantage. In this case, it is unlikely that other members of the same pathway 
would gain mutations in the same cell since they will not provide any additional selective 
advantage for the tumor cell. Moreover, driver mutations might arise frequently in one 
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specific component of a pathway or rarely in the same gene but commonly in multiple 
components of the same pathway. Algorithms were developed that use the mutual 
exclusivity and co-occurrence of mutations in a pathway to determine driver mutations 
(Babur et al. 2015; Dimitrakopoulos and Beerenwinkel 2017). An alternative approach for 
identifying rare cancer driver mutations and the underlying pathogenic mechanisms is 
using the average FI scores and FM bias of mutations (Gonzalez-Perez and Lopez-Bigas 
2012). In this study we used Oncodrive-fm to identify driver pathways involved in 
development and progression of MCL (Gonzalez-Perez and Lopez-Bigas 2012). Compared 
to the other two methods that analyse genes individually, the pathway enrichment approach 
explores impact of mutations on the networks of genes. Oncodrive-fm (pathway) uses the 
gene sets that were defined by MsigDB (Subramanian et al. 2005) and calculates the 
average FI and FM bias for each pathway with minimum of 10 mutations. This method 
compare the average FIs of each pathway with null distributions of average FIs obtained 
from random sampling of arrays of genes and calculate Zscore (Gonzalez-Perez and Lopez-
Bigas 2012). Zscore is a statistical measure for rejection of the null hypothesize. Finally, 
the p-value is calculated by combining the Zscores obtained each method (SIFT and 
PolyPhen) (Gonzalez-Perez and Lopez-Bigas 2012). This approach provides insights into 
the underlying driver mechanisms of cancers by taking into account networks of genes and 
functional impact of rare and recurrent mutations on the proteins.  
Studying overrepresentation of various annotation categories such as gene ontologies and 
pathways, in a given list of genes is another method for the detection of cancer driver 
pathways. DAVID is a web server that uses this approach and the predefined annotations 
in public databases such as KEGG (Kanehisa et al. 2012), to categorize genes into the 
functionally related groups of genes (Huang, Sherman, and Lempicki 2008; Jiao et al. 
2012). Then, this method detects enrichment of gene ontology (GO) terms and pathways 
in the gene list and estimate significance of the associated GO terms and pathways by 
comparing to the random chance. The chance of observing enrichment randomly is 
calculated by dividing the total number of genes in a category or pathway by the total 
number of genes in human genome. DAVID uses Fisher exact test and EASE score to 
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determine the biological significance of the enriched annotations (Hosack et al. 2003; 
Huang et al. 2007).  
The advances in the genomic research have yielded large amount of information on biology 
of cancers. These studies have vastly improved the understanding of biological diversity 
of B-cell lymphomas (Sehn and Gascoyne 2015). Because of the rarity of MCL the 
knowledge on tumorigenic mechanisms driving this type of lymphoma is still limited and 
incomplete. Few WES sequencing studies were performed previously on MCL. These 
studies found several important frequently mutated driver genes and revealed genetic 
heterogeneity of this tumor type. However, their findings were affected by the small sizes 
of the cohorts and the genetic heterogeneity of MCL. In addition, the focus of sequencing 
studies of most types of lymphoma were mainly non-synonymous coding mutations. As a 
result, the role of noncoding and silent mutations on the biology of lymphoma remained 
largely unknown. Therefore, large-scale sequencing studies are necessary to obtain a 
complete understanding of the biology of MCL and to identify the driver genes bearing 
rare, noncoding or silent driver mutations. The objective of this study was to improve the 
understanding of the molecular mechanisms involved in the development of MCL, by 
performing a meta-analysis of WES data from three MCL cohorts using cutting-edge 
bioinformatics tools. The findings of this study possibly have important implications for 
the development of novel therapeutic strategies and introduce new candidate driver genes 
that may have applications for molecular subtype classification, prognosis, and 
stratification of MCL. 
1.7. Mantle Cell Lymphoma 
The focus of my thesis is MCL which is an aggressive type of B-cell Non-Hodgkin 
lymphoma (NHL). Lymphomas are cancers of the immune cells. They form a 
heterogeneous and complex group of cancers driven by the malignant expansion of white 
blood cells. Lymphomas are sub-divided into two classes of NHL and Hodgkin 
Lymphoma. NHL accounts for 90% of lymphomas and 3.4% of cancer-related deaths in 
the US (Bea et al. 2009; James O. Armitage 2009; Swerdlow et al. 2016). About 85-90% 
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of NHLs arise from B-cells while the remaining NHL arise from T-cells or Natural Killer 
cells (Bea et al. 2009; James O. Armitage 2009; Swerdlow et al. 2016). NHL is mostly 
developed in lymph nodes or lymphatic organs such as spleen, tonsils, Waldeyer ring, small 
intestine, and thymus. These are referred to as “nodal” lymphoma. When lymphoma arises 
in the lymphatic tissues but not in lymph nodes are called “extra nodal” but when it arises 
in non-lymphatic tissues, it is called “extra lymphatic” (Bea et al. 2009; James O. Armitage 
2009; Swerdlow et al. 2016). This study is focused on MCL which is a subtype of B-cell 
lymphoma, and therefore the rest of this introductory section is about B-cell NHL. Based 
on clinical course lymphomas can largely be divided into low grade/indolent entities which 
grow over years and aggressive entities which grow over weeks to months (Sammut and 
Arumainathan 2013). B-cell NHLs are a heterogeneous and broad group of diseases which 
are categorized into about 40 entities based on morphologic and clinical features, 
immunophenotypic patterns, a cell of origin and stage of differentiation and finally genetic 
aberrations including chromosomal abnormalities, point mutations, and gene expression 
profile. B-cell NHLs are categorized into precursor lymphoid neoplasms and mature B-cell 
neoplasms. Some subtypes have two solid and leukemic phase that can be present in the 
same patients. B-cell neoplasms are subdivided into several subtypes based on their cell of 
origin and level of differentiation such as MCL, splenic marginal zone lymphoma (SMZL), 
nodal marginal zone lymphoma (NMZL), Waldenström's macroglobulinemia (WM) and 
Chronic lymphocytic leukaemia (CLL) (Bea et al. 2009; James O. Armitage 2009; 
Swerdlow et al. 2016). The focus of the current study is on MCL which is an aggressive 
and incurable type of B-cell lymphoma. In next section, the clinical and molecular features 
of this tumor type are discussed in more details.  
 Clinical Characteristics of MCL 
MCL is a rare lymphoma that accounts for 5-10% of all NHLs. MCL arises from naïve B-
cells in the mantle zone of lymphoid organs (Wickham and Armitage 2013). Based on cell 
morphology MCL is a subtype of small B-cell lymphoma (SLL) which includes 
lymphomas such as CLL and NMZL (Wickham and Armitage 2013). The distinction of 
MCL from other small cell lymphomas is critical as MCL has a more aggressive clinical 
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course (Kimura et al. 2011). MCL is more common in elderly with an average age of 60 
and has a higher incidence in males (3:1) (Wickham and Armitage 2013). MCL is one of 
the most aggressive and incurable NHLs. Patients with MCL have a median survival time 
of 3-4 years and usually, are diagnosed with the advanced-stage disease which develops 
resistance to therapy or relapse shortly and frequently after treatment. The disease generally 
affects lymph nodes but also tends to involve bone marrow, spleen, liver, peripheral blood, 
gastrointestinal tract and Waldeyer’s ring (James O. Armitage 2009, Campo et al. 2011); 
however, a subset of MCL cases have the indolent form of the disease and can survive for 
several years without therapies (Orchard et al. 2003). MCL is morphologically, clinically 
and biologically heterogeneous, and therefore is subcategorized to three variants that have 
distinct clinical course namely: classical variant, blastoid variants (classic blastoid and 
pleomorphic blastoid) and leukemic variant (non-nodal MCL) (Chapman-Fredricks et al. 
2014; Z.-M. Li, Zucca, and Ghielmini 2013) (Figure 1.3). In terms of clinical and biological 
features, the cases of classic variant often have unmutated or minimally mutated IGHV, 
positive expression of SOX11 (a biomarker expressed in a large number of MCL cases), 
condensed chromatin and involvement of lymph nodes and extranodal sites (Swerdlow et 
al. 2016). This variant can transform to the aggressive blastoid or pleomorphic variants 
with gaining secondary driver alterations (Swerdlow et al. 2016). The blastoid and 
pleomorphic variants are the most aggressive variants and have the worse outcome. These 
variants have finely dispersed chromatin, higher cell proliferation, more chromosomal 
imbalances and complex karyotypes (Ott et al. 1997; Weisenburger and Armitage 1996). 
The non-nodal leukemic variant is the indolent form of MCL which includes a small 
proportion of cases (Swerdlow et al. 2016). The leukemic MCL cases arise from B-cells 
that undergone somatic hypermutations of IGHV (Swerdlow et al. 2016). These cases that 
preferentially involve PB, BM, and spleen, have a better prognosis and prolonged survival 
time without therapies, more stable genome, low rate of Ki67 (a biomarker based on mitotic 
activity) and lack of SOX11 expression (Swerdlow et al. 2016). The leukemia cases may 
progress to a very aggressive disease when gaining secondary driver aberrations such as 
alterations of TP53. MCL cells are also categorized into three different classes based on 
growth patterns of MCL cells namely mantle zone, nodular and diffuse (Kauh et al. 2003). 
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Mantle zone pattern is found in about 3%-26% of the cases and represent the initial stages 
of the disease and low-grade MCL (Kauh et al. 2003). This pattern is similar to normal 
nodal architecture with the expansion of neoplastic cells. The nodular pattern is observed 
in about 13-39% of the MCL cases (Kauh et al. 2003). In this pattern, malignant cells form 
abnormal follicle-like nodules and disrupt the normal nodal structure of including germinal 
centers (Kauh et al. 2003). The mantle zone and nodular patterns can eventually lead to the 
diffuse pattern. The diffuse pattern which is detected in 28%-78% of cases is associated 
with loss of nodal architecture and lack of follicles (Kauh et al. 2003).  
Because of the heterogeneity of MCL in clinical outcome, it is critical to distinguish the 
distinct variants of MCL. Biomarkers are used for the stratification and differentiation of 
MCL from less aggressive types of lymphoma (diagnosis biomarkers), for the prediction 
of clinical course and outcome of the disease (prognosis biomarkers), and for the prediction 
of response to treatments (predictive biomarkers) (Inamdar et al. 2016). Identification of 
driver genes and pathways targeted by somatic alterations in cancers is one of the main 
steps in the discovery of novel biomarkers and development of better therapies for patients.  
 
Figure 1.2.  Development of the three variants of MCL: Classical, Blastoid, and 
Leukaemic MCL. 
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 Genomic Alterations in MCL 
The first key event detected in MCL is t(11;14)(q13;q32) translocation that places the 
proto-oncogene CCND1 under the control of immunoglobulin heavy chain (IgH) promoter 
region (Jares, Colomer, and Campo 2012). As the result of this translocation, cyclin D1, 
which is not expressed in normal B-lymphocytes, is overexpressed constitutively and 
therefore deregulates cell cycle at the G1/S phase transition. Translocation of CCND1 is 
known as the first genetic alteration (primary or initiating event) arises in MCL. However, 
it is not enough for development of MCL, and therefore other driver mutations (also 
referred to as secondary events) are necessary for the full malignant transformation of this 
type of lymphoma. Several Secondary events have been detected in MCL by traditional 
cytogenetic methods and array-based methodologies (Allen et al., 2002; Falcieri & Even, 
1998; Thelander et al., 2007; Salaverria et al., 2007; Beà et al., 2008). These studies showed 
that, MCL has the highest level of genomic instability among lymphomas (Beà and Campo 
2008), and resulted in significant improvements in finding targets of recurrent CNVs in 
MCL such as ATM (DNA repair genes) (Schaffner et al., 2000), CDKN2A, CDK4, RB1, 
and TP53 (cell cycle regulators) (Bea et al. 2009; Greiner, Moynihan, and Chan 1996; 
Hernandez, Fest, and Cazorla 1996). High resolution of NGS studies improved 
understanding of MCL biology by identifying driver genes that are frequently mutated in 
MCL such as chromatin modifiers (MLL2, WHSC1, SMARCA1 and MEF2B), the nuclear 
factor kB (NF-kB) pathway regulators (TRAF2, BIRC3 and CARD11), E3 ubiquitin ligase-
encoding gene (UBR5), and apoptosis regulators (NOTCH1, NOTCH2 and BCL2) (Beà et 
al. 2013; Kridel et al. 2011; Jenny Zhang et al. 2014).  
Beà et al. (2013) and Zhang et al. (2014) were the firsts to employ WES on matched 
tumor/normal samples from 29 and 28 MCL patients, respectively to identify the landscape 
of somatic mutations in MCL. Beà et al. (2013) and Zhang et al. (2014) identified 25 and 
37 recurrently mutated genes, respectively. Interestingly, the gene lists of the two studies 
had only eight genes in common namely ATM, CCND1, TP53, MLL2, NOTCH1, WHSC1, 
BIRC3 and UBR5 (Figure 1.3). The low number of genes shared between the two studies 
might be the result of small cohort size or sample selection bias. This nonetheless lends 
uncertainty to the mutational profile of MCL and underlying mechanisms.  
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Figure 1.3.  Venn diagram of genes identified by the two exome studies of MCL.  
Venn diagram shows the counts of recurrently mutated genes and the shared list of genes detected by Bea 
et al. (2013) (yellow plot) and Zhang et al. (2014) (orange plot). 
The findings of CNVs and SNVs had significant implications for understanding the 
mechanisms of tumorigenesis in MCL and predicting the outcome of the disease. Some of 
these alterations affect tumor suppressor genes and Oncogenes and are associated with a 
more aggressive form of the disease with short survival time. Among the genes targeted by 
recurrent chromosomal imbalances and mutations, CDKN2A, TP53, RB1, BMI1, NOTCH1, 
and NOTCH2 are common in the blastoid variant of MCL and associated with poor 
outcome (Bea et al. 2009; Greiner, Moynihan, and Chan 1996; Hernandez, Fest, and 
Cazorla 1996). Array-based and NGS studies expanded our knowledge on driver genes and 
molecular mechanisms involved in the development of MCL. Nevertheless, more NGS 
studies are required to fully understand biology of this tumor type, and to find the driver 
genes that were not detected previously because of a low mutation frequency, small sample 
sizes or other limitations of the previous studies. In addition, targets of some of the 
frequently alerted regions in MCL are still unknown such as the gain of 3q27-q29, losses 
of 1p, 6q and 13q and most regions of LOH. A study reported the high frequency of LOHs 
in MCL, especially in regions of copy number gains (Bea et al. 2009). TP53 is one of the 
targets of LOHs in MCL harboring SNVs in both alleles and total loss of the reference 
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allele. Biallelic mutations, which can be results of mutation of one allele and loss/LOH of 
the reference allele, were also detected in other types of lymphoma such as chronic 
lymphocytic leukemia (CLL) (Bea et al. 2009). CLL shares many clinical and genetic 
features with MCL. The high frequency of LOH in MCL and their presence in several other 
types of lymphoma suggest the potential role of these events in the development of MCL. 
Further work is required to establish targets of LOH in MCL. 
 Clonal Heterogeneity and Resistance to Therapy in MCL 
Resistance to therapy and relapse is a common event in MCL. Our understanding of 
underlying mechanisms of relapse and resistance to therapy in MCL is limited; However, 
improvements in understanding of tumorigenic mechanisms in MCL have led to the 
development of new therapies. B-cell receptor signaling inhibitors such as ibrutinib are one 
of the effective therapies that are being used for MCL. These inhibitors are also used for 
DLBCL and CLL treatment (Young and Staudt 2013).  
Three recent NGS studies (Beà et al. 2013; Rahal et al. 2014; C. Wu et al. 2016) reported 
evidence of subclonal heterogeneity, branched evolutionary pattern and mechanism of 
resistance to BCR inhibitor agents in MCL. Bea et al. (2013) detected mutations in BIRC3 
and NOTCH1 that were specific to relapse or one sequential sample. A recent study 
reported recurrent mutations in CARD11, which is a member of BCR/NF-κB signaling, 
and discussed the possible role of resistance to BCR inhibitors in MCL cases with CARD11 
mutations (C. Wu et al. 2016). The third study by Rahel et al. (2014) investigated the 
mechanism of action of BCR inhibitors in MCL. Interestingly they found that activation of 
alternative (non-canonical) NF-kB signaling pathway as one of the mechanisms of 
resistance to BCR inhibitors. Rahel et al. (2014) detected two groups of MCL cases. The 
first group were sensitive to the therapy because of the activation of canonical NF-kB 
signaling wheeras the second group showed resistance to the therapy because of the 
recurrent mutations in members of alternative (non-canonical) NF-kB signaling pathway 
leading to activation of this signaling pathway (Rahal et al. 2014). Mutations in several 
members of non-canonical NF-kB pathway have been associated with SMZL, CLL and 
Multiple Myeloma (MM) pathogenesis (Annunziata et al. 2007; Quesada et al. 2012; Rossi 
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et al. 2011). Understanding mechanisms of resistance and characterizing the altered genes 
is critical for developing targeted therapies for specific mutations. 
1.8. Hypothesis and Overview of Goals 
The previous array-based studies have detected driver genes that are targets of focal 
amplifications and homozygous deletions or are differentially expressed between normal 
and tumor samples. NGS studies improved the insight on driver genes and molecular 
mechanisms underlying MCL development and progression. However, because of the 
small sample sizes, use of bioinformatics tools, genomics databases and the reference 
genome that are now outdated, and the genetic heterogeneity of this tumor type, it is likely 
that some of the driver genes have remained undetected. Therefore, combining and 
reanalyzing the previously published sequencing data using the state-of-art bioinformatics 
algorithms may result in finding new driver genes and pathways that might have 
applications for development of long-term therapeutic options, and better prognostication 
and stratification of MCL. In this study, we implemented a large-scale meta-analysis on in-
house and published MCL exome sequencing data. The first aim of this study was to 
improve the understanding of somatic driver mutations and pathways in MCL by using the 
most recent bioinformatics tools, developing unified pipelines and integrating results of all 
the employed approaches. We hypothesize that the meta-analysis of MCL WES data using 
a set of unified and cutting-edge bioinformatics tools will reveal additional significantly 
altered driver genes and molecular mechanisms. These alterations may drive development, 
progression, and dissemination of MCL. The new sets of candidate driver genes and 
pathways which result from this study might offer new biomarkers or bring opportunities 
for development of new therapeutic approaches.  
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Chapter 2.  
 
Characterization of Somatic Single Nucleotide Variants 
and Indels in MCL  
The results achieved in chapter 2 are the original and unpublished work by Arezoo 
Mohajeri. I wrote the entire chapter 2, performed all the analysis downstream of variant 
calling, and obtained the results and conclusions. I used the publically available human and 
canine genomics data from previous studies for further analysis of mutations of MAP3K14.  
I generated all the tables and figures in this chapter. For generating figure 2.4, I used and 
modified an R-script written by Marco Albuquerque. Dr. Randy Gascoyne provided the 
Genomic DNAs for the matched tumor/normal samples of a large de-novo cohort of MCL 
cases including the cases of discovery cohort. I performed the initial preparations of DNA 
samples for the available MCL cases of the new cohort. Sarah Arthur and myself performed 
library preparations, and exome captures for the discovery cohort with contribution of 
Miguel Alcaide. Alignments of sequencing reads for 14 cases of the discovery cohort were 
carried out by genome science center (GSC) as a service. Sequencing reads for about ten 
cases of the discovery cohort were aligned by Prasath Pararajalingam. The bam files for 
the two previously published cohorts (cohort-B and cohort-Z) were available from the two 
WES studies of MCL (Beà et al. 2013; Zhang et al. 2014). Bruno Grande prepared VCF 
files for cohort-B and cohort-Z and MAF files for cohort-B. I prepared MAF files for 
cohort-Z and VCF files and MAF files for discovery cohort. The VCF files for canine data 
was generated by Bruno Grande or were previously published by (Elvers et al. 2015). 
Variants for the canine samples were annotated by Elvers et al. (2015) or myself. For the 
discovery cohort, I performed the post modifications of sequencing reads (ClipOverlap), 
calculated the total read coverage of the cases, detected and annotated the somatic 
SNVs/indels (Strelka, VCF2MAF), extracted the read coverage for each variant 
(Augmented MAF). Finally, I performed all the downstream analyses (except the 
previously published data) for chapter 2, including analysis of VAF distributions, filtering 
of variants based on VAF distribution and IGV validations, detecting significantly mutated 
 31 
genes using MutsigCV and Oncodrive-fm, identifying recurrently mutated noncoding and 
silent mutations, and identifying candidate driver genes with potential role in pathogenesis 
of MCL and several types of lymphoma.
2.1. Introduction 
MCL is an aggressive and clinically heterogeneous lymphoid malignancy. A high number 
of chromosomal imbalances is a characteristic of MCL and is associated with poor 
prognosis and more aggressive clinical behavior. Numerous studies have attempted to 
identify pathogenesis and prognostic biomarkers in MCL by detecting recurrent 
chromosomal imbalances and rearrangements using cytogenetics and array-based 
methodologies (Ahmed et al. 2016; Hartmann et al. 2010; Inamdar et al. 2016; Jares, 
Colomer, and Campo 2012; Swerdlow et al. 2016). Recently two sequencing-based studies 
focused on the mutational landscape of MCL and reported lists of significant genes. 
Although both studies improved our understanding of the mutational landscape of MCL, 
there were discrepancies between the reported lists of significantly altered genes. Much 
uncertainty still exists about the driver mutations in MCL, and this encouraged us to 
conduct a meta-analysis study using the WES data from Bea et al. (2013), Zhang et al. 
(2014) and a new in-house cohort. By reducing the issue of sample size and sampling bias 
here, we report several novel potentials drivers of MCL targeted by recurrent mutations 
such as HNRNPH1, SP140, PTPRD, S1PR1, MAP3K14, DST, LRP1B, FAT1.  
2.2. Materials and Methods 
 Sample Cohorts 
In this study, we analyzed WES data from three cohorts consisting diagnosis biopsies from 
a total of 67 MCL patients (cases). Two of the cohorts were composed of the previously 
published WES data from the two MCL studies (Beà et al. 2013; Jenny Zhang et al. 2014). 
In the current study, the WES data from Bea et al. (2013) and Zhang et al. (2014) were 
referred to as Cohort-B and Cohort-Z, respectively. The third cohort (was called Discovery 
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cohort) contained unpublished in-house WES data. Cohort-B, Cohort-Z and discovery 
cohort consisted of WES data for 25, 17 and 37 matched tumor/normal samples from 26, 
17 and 24 MCL cases, respectively. For several cases, more than one sample was available 
including, six cases of Cohort-B with synchronizing samples from two different 
topographic sites (PB/LN or PB/Spleen), and three cases of Cohort-B and discovery cohort 
with sequential samples from two different time points (diagnosis and progression/relapse) 
(Table 2.1). The data included a total of 73 primary tumor samples and six relapse samples. 
The focus of this study was on primary/diagnosis MCL samples. Therefore, only the WES 
data from 67 MCL cases (73 samples) were analyzed (Table 2.1). Some of the clinical 
information for the cases of the three cohorts were missing such as “tumor site”, “subtype” 
and “IGHV mutations status” for the discovery, “sampling time”, “subtype” and “IGHV 
mutations status” for Cohort-Z, and “sex” for Cohort-B (Table 2.2). 
Table 2.1.  Sample size details for the three MCL cohorts that were included in 
the current study.  
Cohort 
Total Count 
Samples 
(Cases) per 
Cohort 
Diagnosis Relapse or Progression 
Single 
Samples 
Synchronic Samples from Two 
Topographic Sites 
Sequential 
Samples from Two 
Time Points 
Single 
Samples 
Discovery 
Cohort 25 (24) 23 - 
- 1 1 - 
Cohort-Z 17 (17) 17 - - - - - 
Cohort-B 37 (29) 18 6 6 2 2 3 
Total 79 (70) 73 (67) 6 (6) 
PB: Peripheral Blood; LN: Lymph Node. Counts of cases: numbers in the parentheses; Counts of 
samples: any number that is not in parentheses. Darkest gray: the main headings of the table; 
Light gray: sub-categories of the “Diagnosis” and “Relapse or Progression” headings.  
Table 2.2. The clinical information that was available for each cohort. 
Case_ID Time of Sampling 
Se
x 
SOX11 
expression 
IGHV 
mutation 
state 
Tumor-Site Subtype Histology 
109 Diagnosis F - H Not LN C Z 
122 Diagnosis M - L - C NL 
126 Diagnosis M - L - - D 
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128 Diagnosis F - L - - NL 
13 Diagnosis M - L - - - 
13 Relapse M - L - - - 
138 Diagnosis M - H - - NL 
14 Diagnosis F - H - - Z 
146 Diagnosis M - H - - D 
24 Diagnosis M - H - C NL 
25 Diagnosis F - L Not LN C D 
28 Diagnosis F - H - C D 
33 Diagnosis M - M - C D 
35 Diagnosis F - H - - D 
38 Diagnosis F - L - - Z 
39 Diagnosis M - H - C Z 
40 Diagnosis M - H - C NL 
42 Diagnosis M - L - C NL 
45 Diagnosis M - M - C NL 
46 Diagnosis F - H - - D 
47 Diagnosis F - M - - D 
61 Diagnosis F - L - - Z 
71 Diagnosis F - M - C NL 
75 Diagnosis M - M - C Z 
98 Diagnosis M - L - C NL 
M004 Diagnosis - N M PB C - 
M007 Diagnosis - P U Colon C - 
M008 Pre_tr - P U PB C - 
M011 Diagnosis - P U LN C - 
M012 Diagnosis - P M LN C - 
M013 Diagnosis - P U LN C - 
M014 Diagnosis - P U LN C - 
M015 Untreated - N M PB SC - 
M019 Diagnosis - P U PB B - 
M020 Diagnosis - P U PB C - 
M021 Untreated - N M PB SC - 
M024 Diagnosis - P M LN B - 
M025 Untreated - P L LN C - 
M027 Untreated - N M PB SC - 
M028 Diagnosis - P U PB C - 
M029 Diagnosis - P U PB B - 
M030 Diagnosis - P U PB C - 
M001 Diagnosis - P U LN C - 
M001 Diagnosis - - - PB - - 
M010 Diagnosis - P U LN C - 
M010 Diagnosis - - - PB - - 
M016 Pre_tr - - - PB - - 
M016 Untreated - N M Spleen SC - 
M023 Diagnosis - P U LN C - 
M023 Diagnosis - P U PB C - 
M026 Diagnosis - P M LN C - 
M026 Diagnosis - - - PB - - 
M031 Diagnosis - P U LN B - 
M031 Diagnosis - - - PB - - 
M002 Diagnosis - P U Tonsil B - 
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M002 Post_tr - - - PB - - 
M003 Diagnosis - N M PB SC - 
M003 Pre_tr - - - PB - - 
M009 Post_tr - N - PB SC - 
M018 Post_tr - P M PB C - 
M022 Post_tr - P U LN B - 
MCL.1177 - F - L LN - - 
MCL.1180 - M - L LN - - 
MCL.1183 - M - L LN - - 
MCL.1184 - - - L LN - - 
MCL.1498 - - - L LN - - 
MCL.1499 - - - L LN - - 
MCL.1500 - - - H Spleen - - 
MCL.1501 - - - L Stomach - - 
MCL.1502 - - - L LN - - 
MCL.1504 - - - H LN - - 
MCL.1505 - - - L Inguinal mass - - 
MCL.1802 - F - H LN - - 
MCL.1803 - M - H LN - - 
MCL.1807 - M - H LN - - 
MCL.1808 - M - L LN - - 
MCL.1810 - F - L LN - - 
MCL.1813 - M - L LN - - 
Abbreviations: Female (F); Male (M); Not available (-); Negative (N); Positive (P); 
Immunoglobulin heavy chain gene (IGHV); Hyper mutated IGHV (M); Unmutated IGHV (U); 
IGHV status was not available and there were no or very few somatic mutations in IG genes (L); 
IGHV status was not available but there were recurrent somatic mutations in IG genes (H); Lymph 
node (LN); Peripheral blood (PB); Classic variant (C); Blastoid variant (B); Small cell variant (SC); 
Mantle zone pattern (Z); Nodular pattern (NL); Diffuse pattern (D); Post_tr (Post-treatment); Pre_tr 
(Pre-treatment). 
 Exome capture, library preparation, and sequencing of MCL 
For discovery cohort, 24 biopsies were collected at the time of diagnosis and in one case, 
a second biopsy was taken at the time of relapse. Blood from each patient was also collected 
to provide a source of normal (germline) DNA. Informed consent for participating in the 
study was obtained prior to the sample collection. Genomic DNAs, which were extracted 
from tumor biopsies and buffy coat using the All-Prep RNA/DNA kit (Qiagen) by our 
collaborators, were provided to us for further analysis. For exome library preparation, first 
50 ng and 100 ng of genomic DNA were sheared to 200-300 bp fragments using Covaris 
M220 for KAPA library and SureSelectXT2 Target Enrichment System Illumina VD.1 and 
VD.2 protocols, respectively. The quality and size of fragmented DNA were confirmed 
using the Agilent 2100 Bioanalyzer instrument. Libraries were barcoded, amplified and 
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captured using KAPA library and SureSelectXT2 Target Enrichment System Illumina 
VD.1 and VD.2. Exome libraries from two normal samples and two tumor samples were 
pulled together. Concentrations of tumor exome libraries were two times higher than 
normal libraries to achieve a higher coverage for tumor samples. Each pool of four libraries 
was sequenced in a single sequencing lane using HiSeq 2000 platform (Illumina, CA) to 
generate 300-400 bps paired reads.  
 Detecting and annotating somatic SNVs and indels 
The WES data for cohort-B and cohort-Z were previously mapped to hg19 and hg18, 
respectively by the previous studies. WES data for discovery cohort was aligned to the 
human reference genome hg19 using BWA aligner. The alignment for 14 cases of 
discovery cohort was done by Canada's Michael Smith Genome Sciences Centre (GSC), 
and for the remaining ten cases was performed using BWA-MEM aligner. The depth of 
coverage for each exome was calculated using Samtools (H. Li et al. 2009). BamUtil 
clipOverlap tool was used to clip overlapping read pairs in all the three cohorts. Removing 
the overlapping regions of read pairs will reduce false positive variant calls in the libraries 
with a high number of overlapping reads. The clipped normal/tumor bam files were used 
as input for Strelka (Saunders et al. 2012) to detect somatic SNVs and indels. The detected 
somatic SNVs and indels were annotated using VCF2MAF (Kandoth 2015) and VEP. Read 
coverage for two alleles of every mutated site were extracted from bam files using an in-
house tool (Augmented MAF).  
 Filtering the false positives in the list of somatic variants 
Several samples of cohort-Z (three samples) and discovery cohort (ten samples) had large 
numbers of technical artifacts which resulted in a higher number of false indels calls for 
the three samples of cohort-Z and false SNVs calls for the ten samples of discovery cohort 
(Supplementary Table 2.1). The mismatches of the cases of discovery cohort can be 
because of the higher sensitivity of the Burrows-Wheeler Aligner-MEM (BWA-MEM) that 
results in more mismatches than the other version of BWA. It is unclear why there is a 
greater proportion of indels in the cohort-Z, but this may reflect raw data quality. To 
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eliminate the noise from these technical artifacts, the VAF of 0.05 was determined as the 
cut-off for including the variants in the downstream analysis. We further verified recurrent 
mutations using IGV by comparing the data for each variant in several tumors and normal 
samples at once.  
 Detecting significantly mutated candidate driver genes 
We used MutSigCV (Lawrence et al. 2013) and Oncodrive-fm (Gonzalez-Perez and 
Lopez-Bigas 2012) to identify candidate driver genes that were mutated significantly above 
the natural mutation rate or showed a significant bias toward accumulations of mutations 
with high functional impact. Genes with FDR (q-value) =< 0.2 were considered statistically 
significant. Somatic SNV and indel calls from 67 diagnostic MCL cases were merged to 
detect significantly mutated genes and candidate drivers in MCL. Oncodrive-fm and 
MutSigCV considerably increase the specificity of significant genes discovery, but these 
tools undermine rare mutations, noncoding and synonymous variants. Indeed, except few 
studies, the focus of cancer genomic research was truncating coding variants. However, 
synonymous and noncoding mutations can impact protein in regulatory sites such as 
transcription factors binding sites, and post-transcriptional and post-translational 
modification sites (Khurana et al. 2016). Therefore, important cancer driver mutations 
might remain unnoticed. Owing to this, we also analyzed all the real mutations that were 
recurrent in three or more patients and were targeting genes that were functionally relevant 
to the biology of lymphoma. 
 Detecting candidate driver mutations using an alternative approach 
We extracted the genes that were mutated in at least two patients. The second layer of 
filtering removed low confidence variants using visual inspection in IGV. Because of the 
high numbers of the mismatches in ten of the cases, a third filter has removed the variants 
with VAF of lower than 0.05 (Supplementary Table 2.1). Combination of all the analyses 
aims to exhaustively screen the full list of variants for possible drivers of MCL. The high 
confidence and validated list of genes from each analysis were compared and merged to 
obtain the optimal results.  
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2.3. Results 
 Landscape of somatic mutations in MCL 
The mean depth of coverage for cohort-Z and cohort-B were 79.6 ×	and 10 ×, respectively. 
The average depth of sequencing reads for discovery cohort’s tumor, and normal exomes 
were 91×	and	47.7×, respectively. SNVs and indels were detected and compared before 
and after excluding overlapping read pairs in discovery cohort to ensure accurate 
estimation of variant allele fraction for SNVs. For some samples, the number of variants 
did not change considerably, but in other samples, there was a considerable decrease in the 
number of variants after filtering overlapping read pairs (Supplementary Table 2.2). Two 
cases of cohort-B (M006 and M021) and one case of cohort-Z (MCL.1808) were excluded 
from the analysis of this section of study due to the extraordinarily high number of SNVs 
(14000, 1793 and 1249) in these samples (Supplementary Table 2.3). The large numbers 
of somatic mutations in these samples can be the result of technical artifacts, chemotherapy 
or biological mechanisms such as AID/APOBEC activation (Rebhandl et al. 2015). In fact, 
MCL.1808 had mutations in APOBEC3F, but the mutational signature of MCL.1808 only 
showed a signature associated with age (C>T) (Figure 2.1). The same signiture was also 
present in most of the cases of MCL. 
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Figure 2.1.  The mutational signature associated with age in case MCL.1808.  
Y-axis: Counts of 96 nucleotide substitution categories extracted from the list of somatic variants of 
MCL.1808. X-axis: Colors represent six classes of base substitution (C>A, C>G, C>T, T>A, T>C, 
T>G) each has 16 categories based on the flanking bases of the mutated site. Because of lack of space, 
the labels only show four of 16 categories. 
About 11144 somatic SNVs/indels including 800 indels and 10343 SNVs were detected in 
73 primary tumor samples (Supplementary Table 2.3 and 2.4). Cases of discovery cohort 
and cohort-Z were harboring 2-3 times higher number of somatic SNVs and 3-10 times 
higher number of indels than cohort-B (Supplementary Table 2.3). The mean values for 
SNVs were 93.5 (42-337), 206.7 (47-1101) and 302.5 (range 57-981), and for indels were 
3.81 (range 0-12), 34.37 (range 0-382), 8.25 (range 0-32), for cases of cohort-B, cohort-Z 
and discovery cohort, respectively. The higher number of SNVs in discovery cohort and 
indels in cohort-B were mainly because of the higher number of technical artifacts (Figure 
2.2). After filtering out the variants with VAF < 0.05, the remainder consisted of 8210 
somatic variants including 6941 (84%) noncoding and 1269 (16%) coding mutations. The 
SNVs and indels were targeting a total of 5495 genes, 44% of which were the coding class 
(Figure 2.2). The significantly higher number of noncoding mutations was expected as 98% 
of the genome is composed of noncoding sequences. 
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Figure 2.2. Classifications of somatic variants detected in the three MCL cohorts. 
The bar plot shows different classes of somatic variants which were detected in cases of the three MCL 
cohorts. The numbers demonstrate the percentage of each class of variants per cohort. Other truncating 
mutations includes categories of nonsense, nonstop, splice site, translation start site and targeted region 
variants. The unfiltered list of variants was used for generating this bar plot.  
After filtering out the variants with VAF < 0.05, the remainder consisted of 8210 somatic 
variants including 6941 (84%) noncoding and 1269 (16%) coding mutations. The somatic 
SNVs and indels were targeting a total of 5495 genes, 44% of which were in coding regions 
of the genes (Figure 2.2).  
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Distributions of variant classes were uniform across individual cohorts except for the 3’ 
UTR variants and indels, which were substantially higher in discovery cohort and cohort-
Z, respectively (Figure 2.2). The great rate of 3’ UTR variants can be because of the high 
coverage of these regions by the particular exome capture kits used for this cohort. Also, 
cohort-B had a greater sequencing depth and less technical errors compared to cohort-Z 
and discovery cohort (Supplementary Figure 2.1 and Supplementary Table 2.1). Overall, 
this result reflects the quality of WES data of the three cohorts which were the highest for 
cohort-B and lower for cohort-Z and discovery cohort. The understanding of data quality 
improves the downstream analysis and generation of more accurate results with less false 
positives. 
In the next section, we performed statistical analysis on the list of somatic mutations 
in the three MCL cohorts using Oncodrive-fm and MutSigCV. These analyses resulted in 
the identification of 22 significant genes that were recurrently mutated in the 67 MCL cases 
of this study. Because of the large number of false positives, the technical noise and 
limitations of these tools in detecting noncoding and non-truncating driver mutations, the 
results of Oncodrive-fm and MutSigCV were missing some potential driver genes that were 
recurrently mutated in our dataset. Therefore, we also extracted the list of genes harboring 
somatic mutations in three or more patients. We excluded false positives that were results 
of alignment artifacts (low VAF and recurrent in a specific set of samples including normal 
samples) or high background mutation rate using IGV visual assessment. After validating 
the list of recurrently mutated genes using IGV, we studied in more depth several of the 
most certain mutations that were targeting genes with biologically relevant functions to 
lymphoma. This analysis resulted in detection of 13 candidate driver genes which were 
recurrently mutated and have pathogenic roles in other types of lymphoma.    
 Driver genes harboring recurrent coding mutations in MCL 
Using the statistical approaches, MutSigCV and Oncodrive-fm, we identified 15 and 37 
significant candidate genes which were harboring recurrent mutations or damaging 
mutations, with q-value of <0.2, respectively (Supplementary Tables 2.5 and 2.6). After 
visual assessment and necessary curations, we identified 22 significantly mutated genes 
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with a total of 215 SNVs and indels in 61 patients (Figure 2.3, Figure 2.4, and Table 2.3). 
Among our list of significant genes were the following nine genes which were previously 
identified in MCL and their functional roles have been studied: ATM (43%), TP53 (19 %), 
BIRC3 (9 %), MEF2B (6 %), WHSC1 (16 %), MLL2 (13 %), CCND1 (28 %), RB1 (4 %), 
and CARD11 (7 %) (Beà et al. 2013; Kridel et al. 2011; Jenny Zhang et al. 2014) (Table 
2.3). ATM, TP53, CCND1, MLL2, and WHSC1 were the most commonly mutated genes in 
the three cohorts (Figure 2.3). Mutations of the known drivers of MCL were detected in 
the three cohorts except for mutations of TP53 which were present only in a single case of 
discovery cohort. Furthermore, we identified 11 novel candidate drivers namely DST (10.3 
%), SYNE1 (10.3 %), LRP1B (10.3 %), CSMD2 (8.8 %), SP140 (7.3 %), DNAH9 (5.9 %), 
S1PR1 (5.9 %), PTPRD (5.9 %), FAT1 (5.9 %), DPYD (4.4 %), ADAM30 (4.4 %), and 
PCSK2 (4.4 %), for which no pathogenic roles in MCL have been established previously 
(Figure 2.4). Most of these genes have pathogenic roles in cancer. However, we will only 
discuss in a greater detail few of these genes that have known or related roles in the biology 
and pathogenesis of lymphoma.  
Table 2.3. The significant genes recurrently mutated in MCL were detected 
using Oncodrive-fm and MutsigCV.  
Gene p-value q-value % of Patients 
Number of 
Patients 
Number of 
Cohorts Methods 
BIRC3 3.77E-15 2.13E-13 8.96 6 3 Both 
WHSC1 3.77E-15 2.13E-13 16.42 11 3 Both 
TP53 3.77E-15 2.13E-13 19.40 13 3 Both 
ATM 3.77E-15 2.13E-13 43.28 29 3 Both 
MEF2B 2.17E-09 8.18E-08 5.97 4 2 Both 
TTN 1.83E-07 5.92E-06 20.90 14 3 Oncodrive-fm 
RB1 4.65E-04 0.01 4.48 3 1 Both 
LRP1B 5.85E-04 0.01 10.45 7 3 Both 
FAT4 8.44E-04 0.02 5.97 4 2 Both 
PTPRD 0.001 0.03 5.97 4 1 Oncodrive-fm 
DST 0.002 0.03 11.94 8 3 Both 
CARD11 0.003 0.04 5.97 4 2 Oncodrive-fm 
MLL2 0.003 0.04 13.43 9 3 Both 
CCND1 0.003 0.04 28.36 19 3 Oncodrive-fm 
S1PR1 0.008 0.08 5.97 4 3 Both 
PCSK2 1.06E-02 0.09 4.48 3 2 Oncodrive-fm 
SP140 0.015 0.12 7.46 5 3 Oncodrive-fm 
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CSMD2 1.85E-02 0.14 8.96 6 3 Oncodrive-fm 
FAT1 0.026 0.17 5.97 4 3 Oncodrive-fm 
DNAH9 0.024 0.17 5.97 4 3 Oncodrive-fm 
SYNE1 0.028 0.18 11.94 8 3 Oncodrive-fm 
DPYD 0.028 0.18 4.48 3 3 Oncodrive-fm 
Abbreviations: Y=Previously known driver, Novel=novel candidate driver genes identified by our 
study, U=detected in MCL previously but the function is unknown, FP=False positives that did 
pass the IGV validation). 
 
Figure 2.3.  The prevalence of mutations in the 22 significant genes in the three 
MCL cohort.
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Figure 2.4. Mutations plot for the recurrent mutations of the candidate drivers in the cases of MCL.  
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S1PR1 
We identified a significant frequency of mutations in Sphingosine-1-Phosphate Receptor1 
(S1PR1) in 5.9% of the MCL cases. We detected two frameshift indels (p.V6Gfs*30 and 
p.V126Cfs*16), one in frame insertion (p.G122_S123insN) and one missense mutation 
(p.M80V) in four of the MCL patients with VAFs of 0.53, 0.41, 0.19 and 0.22, respectively 
(Table 2.4, Figure 2.4, Figure 2.5). All the mutations were monoallelic, and two of the 
mutations were subclonal. All the mutated cases had un-mutated IGHV status or low 
number of somatic mutations in IGHV genes. Two of the cases were extracted from LN 
biopsies.  
Table 2.4. Recurrent mutations of S1PR1 in MCL.  
Chr Start End 
Variant 
Type 
Nu 
Change 
Sample 
ID 
cDNA 
position 
A.A. 
Change 
VAF 
1 101704912 101704913 FS_Ins -/T 122_T1 c.375dupT 
p.V126 
Cfs*16 
0.41 
1 101704778 101704778 Missense A/G 138_T1 c.238A>G p.M80V 0.22 
1 101704906 101704907 Inf_Ins -/AAT M014 
c.367_ 
368insATA 
p.G122_ 
S123insN 
0.19 
1 101704557 101704559 FS_Del TCC/GG MCL.1808 
c.17_19del 
TCCinsGG 
p.V6 
Gfs*30 
0.53 
Abbreviations: FS_Ins=Frameshift insertion; FS_Del = Frameshift deletion; Inf_Ins= Inframe 
insertion. 
The inframe insertion (G122_S123insN) add an amino acid (asparagine) between residues 
G122 and S123 without changing the translation frameshift whereas the V6Gfs*30 and 
V126Cfs*16 change the frameshift starting from residues V6 and V126 and change the 
30th and 16th downstream residues to a stop codon, respectively. The predicted functional 
impact of the frameshift indels and missense mutation on the protein were deleterious, and 
mutations were targeting amino acids that are conserved in orthologous genes in 
vertebrates and some species of chordates. 
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Figure 2.5. Lollipop plot and UCSC view of recurrent mutations of S1PR1. 
The lollipop plot on top illustrates the four recurrent mutations of S1PR1 mapped to amino acid 
sequence and the targeted domains. The UCSC diagrams show conservation of mutated residues 
among 17 primates and 100 vertebrates. Colors: Red=Inframe insertion; Black: Frameshift indels; 
Blue: Missense mutation. 
S1PR1 encodes a G-coupled protein receptor (S1P1) with numerous regulatory roles in the 
cell such as cell migration, immune inflammatory response, vascularization, epithelial cell 
integrity and circadian clocks control of adaptive immune response (Druzd et al. 2017; 
Liang et al. 2013; Lo et al. 2005; O’Sullivan and Dev 2013). This receptor is activated 
upon interactions with its ligand, Sphingosine-1-Phosphate (S1P). Deregulation of S1P1 
was associated with invasion and progression of various tumor types. For example, deletion 
or down regulation of S1P1 results in retention of lymphocytes in lymphoid tissues, and 
overexpression of S1P1 promotes tumor growth and metastasis by activation of STAT3 and 
excessive migration of lymphocytes into the lymph and blood (H. Lee et al. 2010; 
Thangada et al. 2010; Wallington-Beddoe, Bradstock, and Bendall 2013). Furthermore, 
mutations of S1PR1 were reported recently in two new cases of MCL and several cases of 
ATL (Kataoka et al. 2015; C. Wu et al. 2016). S1PR1 resides within a region (1p21) which 
was recurrently deleted in 50% of the MCL cases of our study. Interestingly, cases with 
mutations and copy number variants were mutually exclusive. One of the cases (M014) 
with subclonal SNV in S1PR1 (VAF of 0.19) was carrying a deletion of 1p21 in another 
subclone. This sample was collected from a lymph node. In overall, our results in addition 
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to the pathogenic role of S1PR1 in cancers suggest that this gene is possibly a driver gene 
in MCL and might play a major role in development and progression of MCL.  
PTPRD 
Protein tyrosine phosphatase (PTPRD) was one of the candidate driver genes mutated in 
5.9 % of the MCL cases (Figure 2.4, Figure 2.6, and Table 2.5). We identified four somatic 
SNVs in PTPRD, including two missenses (p.V1848I and p.G1817R), one nonsense 
(p.R427*) and one intron mutation. Mutations were in exons 41, 42, 18 and intron 12 
(Table 2.5 and Figure 2.6). The missense (p.G1817R) and the nonsense variants (p.R427*) 
were also detected by 1000 genome project in the normal European population with minor 
allele frequencies of 0.0002 and 0.001, respectively (T. 1000 G. P. Consortium 2015). The 
two variants were recorded as rare SNPs in dbSNP (Repository for SNPs and short 
sequence variation) with the following rs identifiers: rs147793450 and rs533774328. The 
three coding mutations were changing the highly conserved amino acids among vertebrates 
and were predicted to have damaging impacts on the protein. The two missense mutations 
were clustered in the tyrosine phosphatase domain of PTPRD, and the truncating nonsense 
mutation was introducing a stop codon within the Fibronectin type-III domain. The intron 
variant might impact splicing motifs. In addition, in chapter we identified large deletions 
harboring PTPRD locus. Overall, 19% of the MCL cases had SNVs or CNVs in this gene. 
The deletions of 9p, were either heterozygous and spanned both PTPRD and CDKN2A loci, 
or homozygous and harbored CDKN2A locus and few surrounding loci. The four cases 
with small homozygous deletion specific in CDKN2A locus were blastoid sub type of MCL 
(Figure 2.7).  PTPRD is a member of protein tyrosine phosphatases (PTPs) and a negative 
regulator of STAT3 signaling. Deactivation of PTPRD results in constitutive 
phosphorylation and activation of STAT3 which subsequently lead to activation of 
chemokine signaling (Peyser et al. 2015). PTPRD functions is a TSG in various types of 
cancer (Solomon et al. 2008; Stallings et al. 2006; I Vater et al. 2015). Alterations of PTP 
family are also involved in the pathogenesis of lymphoma. For example, recent studies 
reported frequent mutations of PTP family in lymphomas such as CNS lymphoma 
(PCNSL) (I Vater et al. 2015), Follicular lymphoma (Cheung et al. 2010) and NMZL 
(Spina et al. 2016). 
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Table 2.5.  The recurrent mutations of PTPRD in four MCL patients.  
Gene 
ID Chr Position 
Variant 
Type 
Nu 
Change 
Sample 
ID 
cDNA 
position 
A.A. 
Change VAF 
PTPRD 9 8528361 Intron A/C 128_T1 c.541+230T>G n/a 0.47 
PTPRD 9 8319959 Missense C/T 39_T1 c.5542T>A p.V1848I 0.19 
PTPRD 9 8331667 Missense C/T 40_T1 c.5449G>A p.G1817R 0.33 
PTPRD 9 8518112 Nonsense G/A 45_T1 c.1279A>T p.R427* 0.21 
  
Figure 2.6. Lollipop plot of the recurrent mutations of PTPRD in MCL. 
 
Figure 2.7. The heat map of clinical data and PTPRD mutations. 
The heat map at the left shows clinical information of the MCL cases harboring mutations of 
PTPRD (MS=Missense, NNS=Nonsense, Int=Intron) or deletions of PTPRD and CDKN2A. The 
heat map at the right shows the most frequently gained and deleted regions in MCL that is present 
in the PTPRD/CDKN2A-altered cases. (Blue and green: Heterozygous loss, Red, and purple: Gain, 
Navy blue: Homozygous loss, Purple: Uncertain deletion supported by less than 3 SNPs). 
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SP140 
Lymphoid-Specific SP100 Homolog (SP140) was one of the most recurrently mutated 
candidate driver genes detected in our study. SP140, SP100, and SP140L loci were mutated 
in 14% of MCL patients (Table 2.6). We identified seven novel somatic mutations in SP140 
including two frameshifts (N147Kfs*6, S434Ffs*2), one nonsense mutation (Q144*), one 
missense (E164K), one silent mutation (P321P) in five of the MCL patients and two intron 
mutations in SP100 and SP140L (Figure 2.7).  
Table 2.6. Recurrent mutations of SP140 in five MCL patients. 
Gene 
ID Chr Start-End 
Variant 
Type 
Nu 
Change 
Sample 
ID 
cDNA 
position 
A.A. 
Change VAF 
SP140 2 231106150-231106154 FS_Del TAATG/- 122_T1 
441_445de 
lTGTAA 
N147K 
fs*6 0.47 
SP140 2 231155240-231155240 Missense G/T 122_T1 1786G>T G596W 0.04 
SP140 2 231134304-231134305 FS_Ins -/T 38_T1 1300dupT 
S434F 
fs*2 0.41 
SP140 2 231106202-231106202 Missense G/A 46_T1 490G>A E164K 0.2 
SP140 2 231106142-231106142 Nonsense C/T M028 430G>T Q144* 0.39 
SP140 2 231110780-231110780 Intron T/C MCL.1501 
742+125 
T>C - 0.04 
SP140 2 231113670-231113670 Silent A/C MCL.1501 963A>C P321P 0.33 
SP140L 2 231235578-231235579 Intron -/A MCL.1499 
524-44 
dupA - 0.11 
SP100 2 231372654- 231372655 Intron CT/- MCL.1498 
2014-53_ 
2014-52delTC - 0.13 
Abbreviations: FS_Ins=Frameshift insertion; FS_Del = Frameshift deletion; Inf_Ins= Inframe 
insertion. 
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Figure 2.8. Recurrent mutations of SP140 in MCL mapped to the protein 
structure.  
Five of mutations were clonal including three mutations (N147Kfs*6, Q144*, E164K) 
clustered at exon 4, one silent mutation at exon 9 (P321P) and one at exon 13 (S434Ffs*2) 
of transcript ENST00000392045. POLYPHEN and SIFT predictions for the impact of 
frameshift and nonsense mutations (N147Kfs*6, Q144*, S434Ffs*2) were highly 
deleterious, whereas the predictions were low and moderate for the silent and missense 
mutations (P321P, E164K). The nonsense and frameshift mutations are frequent in tumor 
suppressor genes. The missense mutation (E164K) was within the canonical splicing motif, 
and the silent mutation was about 15 bp downstream of the splicing site. We used splicing 
prediction to test both mutations for alternative splicing. The results showed that the 
missense mutation is affecting splicing of the mRNA by removing a wild type donor 
splicing site. The predictions for the silent mutations showed several potential variations 
in the splicing regulatory motifs such as disruption of the hnRNP A1 motif (data not 
shown). Therefore, both mutations have the potential to damage protein by silencing the 
mRNA splicing or removing the functional part of the protein through abnormal splicing. 
Moreover, two of the patients (MCL.1505 and 122_T1) were harboring two mutations 
each. The estimated VAF for each of the mutations indicated that one of the two mutations 
in each patient was clonal and the other was sub-clonal (a missense and an intron mutation). 
The sub clonal mutations were supported by four and nine reads and had VAF lower than 
0.05, and therefore were among the variants which were filtered out. However, the 
incidence of bi-allelic mutations in SP140 is not unexpected since this locus is also targets 
of homozygous deletions in MCL which will be discussed in chapter 3. Overall, this results 
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suggest that SP140 is a TSG in MCL and the recurrent mutations of this gene in MCL 
possibly have a deleterious impact on the protein. SP140 is a nuclear lymphocyte-specific 
protein specifically expressed in lymphocytes. It is a member of SP100 family of proteins 
and located as a cluster with two other members of this family (SP100 and SP140L) at 
2q37.1. This region is recurrently deleted in MCL cases of our study which is also reported 
previously (Beà et al. 2009). Alterations of SP140 were also prevalent in some other types 
of lymphoma and leukemia such as MM, AML and CLL (Bolli et al. 2014; Sille et al. 2012; 
Yamazaki et al. 2016). The function and mechanism of pathogenesis of SP140 are 
unknown. Studies suggested some rules for SP140 in antiviral immunity, chromatin-
mediated transcription regulation and autoimmunity (Madani et al. 2002; Regad and 
Chelbi-Alix 2001).  
 Driver genes harboring recurrent noncoding and synonymous 
mutations in MCL 
MutSigCV and Oncodrive-fm identify significantly mutated genes based on the recurrence 
of mutations and functional impact of mutations on the protein. However, these methods 
oversimplify functional impact of mutations and overlook effects of synonymous and 
noncoding mutations on regulatory elements such as post transcriptional and translational 
modification sites, enhancers, silencers, promoters, splicing motifs, miRNA binding sites 
and transcription binding site (Diederichs et al. 2016). Thus, in next section, we analyzed 
the list of somatic variants based on the recurrence of mutations and their relevance to the 
biology of lymphoma. We selected genes that were mutated in a minimum of two cohorts 
and two patients to remove the false positives that were specific to a single cohort. This 
analysis resulted in a list of 684 genes which were mutated in a minimum of two patients. 
Many of the genes had relevant roles in the biology of lymphomas such as SAMHD1, 
USH2A, PCDH11X, NFKBIE, JAKMIP1, FHIT, IGLL5, MAP3K14, HNRNPH1, and 
HNRNPA2B1. In addition, we detected non-random clustering of mutations in several 
genes, among which MAP3K14 and HNRNPH1 showed the clearest pattern of clustering 
of mutations in the first exon and flanking regions of exon-5, respectively (Figure 2.4). The 
 51 
specific patterns of mutations in these two genes encouraged us to study their mutations in 
more depth.
HNRNPH1 
We detected recurrent noncoding mutations in Heterogeneous Nuclear Ribonucleoprotein 
H1 (HNRNPH1) (Table 2.7 and Figure 2.8). HNRNPH1 was harboring four intron 
mutations including three variants flanking exon four and one variant in the middle of 
intron five. The latter had a low VAF (0.03) and were supported by six reads. Notably, all 
the three variants flanking exon-4 of the gene were within the splice regions. In addition to 
HNRNPH1, we also detected rare mutations in other members of splicing machinery such 
as HNRNPA2B1 and RBM25. 
Table 2.7. The recurrent mutations of HNRNPH1 in four of the cases of MCL. 
Gene 
ID Chr Start 
Variant 
Type 
Sample 
ID 
cDNA 
position 
A.A. 
Ch. VAF 
HNRNPH1 5 179045097 Intron 122_T1 c.716-36G>T - 0.03 
HNRNPH1 5 179046415 Intron 126_T1 c.398-7G>T - 0.45 
HNRNPH1 5 179046416 Intron M022 c.398-8G>C - 0.37 
HNRNPH1 5 179046264 Intron MCL.1180 c.536+6G>T - 0.4 
HNRNPA2B1 7 26233080 Intron 71_T1 c.878-87T>C - 0.52 
HNRNPA2B1 7 26233262 Silent MCL.1501 c.810T>A p.G270G 0.27 
HNRNPA2B1 7 26233263 Missense MCL.1501 c.809G>C p.G270A 0.25 
 
 
Figure 2.9. UCSC view showing the recurrent mutations of HNRNPH1 mapped 
to the reference gene.  
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A low functional impact was predicted for mutations of HNRNPH1 and HNRNPA2B1. 
However, because of the non-random distribution of mutations in the intronic sequences 
near the splicing regions, we studied impacts of mutations of HNRNPH1 on splicing of 
pre-mRNA using human splicing finder tool (Desmet et al. 2009). The human splicing 
finder tool predicted several potential variations including disruption of splicing enhancers, 
silencers, and addition or disruption of donor site (data not shown). One of the consistent 
predictions among the three mutations was disruption of a splicing silencer motif 
([T/G]G[T/A]GGGG) from Sironi et al. (Sironi et al. 2004). Interestingly, the three 
mutations flanking exon-4 of HNRNPH1 were targeting two G-rich splicing silencer motifs 
namely “UAGG and GGGG” and the “GGG” motifs (Caputi and Zahler 2001; Engelbrecht, 
Knudsen, and Brunak 1992; Han et al. 2005; McCullough and Berget 1997) (Figure 2.9). 
One of the mutations (c.536+6G>T), which was located at the 5’ end of intron-5, was 
changing the GGGG motif to GGGT. The other two mutations (c.398-7G>T, c.398-8G>C) 
which were located at the 3’ end of intron-4, both were targeting the same splicing motif 
and change the GGG wild type sequence to GGT and GCG, respectively. Splicing factors 
bind to the G-rich motifs and regulate splice-site selection, intron splicing and exon 
inclusion/exclusion (Caputi and Zahler 2001; Han et al. 2005). Therefore, the results of our 
analysis strongly suggest that recurrent non-coding mutations of HNRNPH1 in MCL 
impact splicing of exon-5 during pre-mRNA processing. 
 
Figure 2.10. The mutated splicing motifs of HNRNPH1 in MCL.  
The diagram shows part of the DNA sequences of exon-5 and adjacent introns of HNRNPH1 
containing splicing regulatory motifs. 
 
5’.....gtccttgggttgaag 
 
gtggggatggat..... 3’ 
 UAGG Motif 
Exon 5 
GGGG Motif 
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GGG Motif 
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G......AAGAATAGGGCACAG 
 53 
Recurrent silent mutations in MAP3K14 
In this section of study, we discovered hotspot mutations in MAP3K14 in MCL. We further 
found records of the same clusters of mutations in five other types of human B-cell 
lymphoma/leukemia and in canine B-cell lymphoma. 
G33G and G53G are two novel mutation hotspots in MAP3K14 in MCL 
In this study, we identified recurrent mutations in Mitogen-Activated Protein Kinase 
Kinase Kinase 14 (MAP3K14) in 10% (6 of 66) of MCL patients. The recurrent mutations 
of MAP3K14 were not detected by Oncodrive-fm and MutSigCV approaches because of 
the RNA (noncoding) annotation of these variants. Notably, the initial annotation of the 
mutations of MAP3K14 was “RNA” according to the incomplete information about this 
gene in the older release of Ensembl. In Ensembl 75, which features GRCh37 human 
assembly, MAP3K14’s transcripts have been recorded as non-active and non-coding RNAs 
(also called “Processed transcript”). VEP uses information in Ensembl genome databases 
to annotated the variants (Flicek et al. 2012). We re-annotated the variants by converting 
GRCh37 coordinates to GRCh38 using UCSC liftover tool and running VEP on the 
mutations using the new release of Ensembl. The corrected annotations of the mutations 
were silent and missense. The results presented in this section are based on the corrected 
annotations.  
We detected eight silent and missense mutations in MAP3K14, which importantly were 
clustered at the first exon of this gene including a silent mutation (p.G33G) in two samples 
from two cases (M016 and PT9), a silent mutation (p.G53G) in four samples from three 
cases (M016, 71_T1, and M011), and finally two missense mutations (A67G and K54N) 
in two samples from two cases (M015 and MCL.1500) (Table 2.8 and Figure 2.10). PT9 
was one of the cases of an additional cohort in our lab from a recently published WES data 
of MCL (C. Wu et al. 2016). PT9 was one of the few cases of the additional cohort which 
was harboring mutations in MAP3K14; Thus the mutational data from the three samples 
(diagnostic, relapse1, and relapse 2) of this case was included only in this section of study.  
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Table 2.8. Mutation hotspots in MAP3K14 in 10% of MCL patients. 
Gene ID Chr: Position VEP Annotation Sample ID 
Subtype/ 
Tumor site 
cDNA 
position 
aa 
chang
e 
VAF 
MAP3K14 17:43367912 Missense M015-PB SC/PB c.200C>G A67G 0.29 
MAP3K14 17:43368013 Silent PT9-R2 - c.99G>T G33G - 
MAP3K14 17:43368013 Silent M016-PB -/PB c.99G>T G33G 0.10 
MAP3K14 17:43367953 Silent M016-PB -/PB c.159A>T G53G 0.38 
MAP3K14 17:43367953 Silent M016-Sp SC/Sp c.159A>T G53G 0.26 
MAP3K14 17:43367953 Silent M011-LN C/PB c.159A>T G53G 0.31 
MAP3K14 17:43367953 Silent MC-071 C/N c.159A>T G53G 0.28 
MAP3K14 17:43367950 Missense MCL.1500-Sp -/Sp c.162A>T K54N 0.32 
 
 
Figure 2.11. Lollipop plot of recurrent mutations of MAP3K14 in MCL that were 
detected by our study. 
Importantly, the G33G mutation were present in only one of the two samples (PB and 
spleen) of M016 and one of the three sample (Diagostic, Relapse 1 and Relapse 2) of PT9, 
which suggest the clonal expansion of this mutation in both cases. The G33G mutation was 
only detected in the PB sample of case M016, whereas the G53G mutation were present in 
both PB and spleen samples, respectively. The spleen biopsy was taken from an untreated 
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patient, and the PB sample was taken before treatment of patient. In addition, G33G in PB 
sample had VAF of 0.10 which was considerably lower than VAF of G53G (0.38) in the 
same sample and VAF of G53G (0.26) in spleen sample. It is important to note that, a 
single sequencing read from M016-PB, which was covering both genomic coordinates of 
chr17:43368013 and chr17:43367953, supported the G33G mutation and the reference 
allele of the latter coordinate, which indicates that the two mutations are either in two 
different alleles of the gene or in two different subclones. G33G mutation was only 
observed in the first relapse sample of PT9 with VAF of 0.38 and was absent from the 
matched diagnostic and second relapse tumor samples.   
 
 
Figure 2.12. The biallelic mutations of MAP3K14 in a single case in MCL. 
This figure shows the sequencing reads supporting two of the mutated sites of exon-1 of MAP3K14 
which was harboring two mutations: G53G (red box) and G33G (blue box). The three panels show 
the WES data for three samples: PB (panel on top), Spleen (panel in the middle) and normal (panel 
at the bottom) belong to a single patient (M016). The red arrow shows the sequencing read that was 
covering one of the mutations (G33G) in one site (the black arrow on the right) and the reference 
allele in the other site (the black arrow on the left). The single read shows that the two mutations 
are not in the same allele of the gene or are not in the same subclone of the cells.  
G33G G53G 
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The figure illustrates WES from three MCL samples using alignment and coverage tracks in IGV 
(Robinson et al. 2011). Each gray bar represents a single mapped read. The bar charts on top of 
each locus show the depth of coverage supporting each allele. The color of the bar charts is gray 
when both alleles are a reference, and in other colors when at least one of two alleles are mutated. 
Proportions of colors in the mutated sites show the number of reads covering each base (A, B, C, 
D).  
K54N was a novel mutation, whereas A67G missense mutation had an associated COSMIC 
and SNP identifier (rs569647218) with MAF of 0.0002, and was detected previously in 
some types of lymphoid malignancies namely: MCL, CLL, and SMZL (Beà et al. 2013; 
Landau et al. 2013; Parry et al. 2013, 2015). However, its function on the protein has not 
been studied. The records of G33G and G53G mutations were also available in COSMIC 
which were deposited by a study on CLL (Landau et al. 2013). However, because of the 
lack of functional annotations of the silent mutations, the potential significance of the 
recurrence of these mutations and their driver role remained unnoticed (Landau et al. 2013). 
MAP3K14 is a proto-oncogene encoding the NF-κB-inducing kinase (NIK) protein. NIK 
plays key roles in the regulation of a variety of cellular processes, and the understanding 
of its functions and important roles in normal and tumor cells is rapidly growing (Cildir, 
Low, and Tergaonkar 2016; Jung et al. 2016). The best known and the key functions of 
NIK are positive regulations of non-canonical and canonical NF-kB signaling which are 
the central pathways regulating inflammatory and immune responses (G. Xiao and Fu 
2011). The knowledge about the function, regulation, and mutations of NIK is still limited, 
and despite the critical role of this protein in lymphoma, there is insufficient information 
on somatic driver SNVs targeting this gene. Hence, systematic studies on the mutations of 
MAP3K14 and their impact on the protein offers great potential for a better understanding 
of the regulatory and tumorigenic mechanisms of functions of NIK. Here, we performed a 
computational analysis of mutations targeting the first exon and intron of NIK in human 
B-cell lymphoma. We collected the previously detected mutations in MAP3K14 which 
were available in COSMIC (Forbes et al. 2001), TumorPortal (Lawrence et al. 2014) and 
TCGA databases.  
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Five hotspot residues were detected in MAP3K14 in six lymphoid malignancies 
Initially, we collected a list of mutations (N=30) of MAP3K14 detected in lymphoma by 
searching the databases of genomic variants. Mutations of MAP3K14 showed a pattern of 
distribution that was specific to lymphomas.  
 
Figure 2.13. The lollipop plot of somatic mutations of MAP3K14, that were 
available in COSMIC. 
I generated the lollipop plots using the data available in COSMIC and cBioPortal MutationMapper 
(v1.0.1). The panel on top shows mutations detected in non-lymphoid malignancies and the panel 
at the bottom shows mutations which were detected in lymphoid malignancies namely: MCL, CLL, 
SMZL, MM, and WM. Mutations of MAP3K14 in lymphoma were clustered at exon 1 and exons 
11-13.  
 
Mutations were mainly clustered between residues 33-84 (exon-1) or between residues 
765-863 (exons 11-13) (Figure 2.12). About 70% of the mutations were in the first exon of 
MAP3K14. Notably, we found more cases of lymphoma carrying mutations of the first 
exon of MAP3K14 by searching the lists of mutations included in the related literatures. 
These variants were missing from the databases that were used in this study. Overall, we 
collected a total of 28 mutations including those indeitifed by out study, in the first exon 
of MAP3K14 in the following types of B-cell lymphoma/leukaemia: MCL (C. Wu et al. 
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2016), CLL (Bolli et al. 2014; Landau et al. 2013), NMZL (Spina et al. 2016), SMZL 
(Martinez et al. 2014; Parry et al. 2013, 2015), MM (Chapman et al. 2011; Lawrence et al. 
2014), and WM (Treon et al. 2012). In addition, a single mutation in the splicing motif of 
the first intron of this gene was reported previously in AML, which might impact the 
splicing of pre-mRNA. Importantly, we identified four clusters of mutations in the first 
exon of MAP3K14 in the following residues: G33 (five samples), G53-54 (five samples), 
A67 (9 samples), and I80-A84 (five samples) (Figure 2.13 and Table 2.9). About 71 % (20 
of 28) of the mutations of exon-1 of MAP3K14 were the three types of variants, which were 
detected in this study in MCL, namely: G33G, G53G, and A67G. The hotspot pattern of 
mutations in the first exon of MAP3K14 indicates that these mutations possibly provide 
selective advantages for the tumor cells of the specific types of lymphoma. In addition, our 
analysis showed that in some cases of CLL, MCL, MM, and SMZL the three hotspot 
mutations were only in the relapse samples, which further support the potential role of these 
mutations in development and progress of lymphoma and leukemia (Bolli et al. 2014). 
I80 and A84 hotspot residues were common between canine and human lymphoma 
In addition to the cases of human lymphomas with MAP3K14 mutations, some cases of 
canine B-cell lymphoma were also carrying mutations in the first exon of MAP3K14. A 
recent study reported frequent mutations of MAP3K14 in 28% cases of canine B-cell 
lymphoma (Elvers et al. 2015). Because of the similarities between genetic alterations of 
human lymphoma and canine lymphoma (Bushell et al. 2015), we also included and 
analyzed mutations of MAP3K14 in canine lymphoma by using the previously published 
(Bushell et al. 2015; Elvers et al. 2015) and in-house exome sequencing and RNA-Seq data 
(Bushell et al. 2015). A total of 13 SNVs and indels were detected in the first exon of 
MAP3K14 in 13 cases of canine lymphoma including, six missense mutations (A84V, 
T66A, I80T, A84G, I80N, G65D), two indels (IAQA81-84T, I80_A84del), one translation 
start site variant, and one intron indel (c.256+18_256+43del) (Table 2.9 and Figure 2.13).  
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Figure 2.14. The lollipop plot mapping recurrent mutations of MAP3K14 on 
protein sequence.  
The Lollipops on top shows recurrent mutations of MAP3K14 in human lymphoid malignancies 
(MCL, CLL, MM, WM, NMZL, and SMZL), and the bottom plot shows mutations of MAP3K14 
in cases of canine lymphoma. The numbers in parentheses are the counts of MAP3K14 mutations 
which were detected by the current study.  
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Table 2.9. The recurrent mutations of the first of MAP3K14 in human and 
canine lymphoma. 
AA 
Ch. 
Tumor 
Type 
Var 
* 
Coding 
Sequence 
Position 
at chr17 
Time 
point VAF Sample ID Reference 
- AML IN c.257-11A>G 43366682 NA NA AML1 (Welch et al. 2012) 
A84G MM MS c.251C>G 43367861 R1 0.16 MM-0318 (Chapman et al. 2011; Lawrence et al. 2014) 
A84G MCL MS c.251C>G 43367861 T1 0.24 P-13P (Wu et al. 2016) 
A84G SMZL MS c.251C>G 43367861 NA 0.27 29 (Parry et al. 2015) 
I80_del WM IFD c.238-240del 43367871 NA NA WM10 (Treon et al. 2012) 
I80T SMZL MS c.239T>C 43367873 NA 0.37 94 (Parry et al. 2015) 
A67G CLL MS c.200C>G 43367912 NA NA CW56-pre (Lawrence et al. 2014) 
A67G CLL MS c.200C>G 43367912 
D, 
R1, 
R2 
0.11 CLL019 (Landau et al. 2013; L. Wang et al. 2011) 
A67G NMZL MS c.200C>G 43367912 NA 0.30 21T (Spina et al. 2016) 
A67G SMZL MS c.200C>G 43367912 D 0.15 4 (Parry et al. 2013) 
A67G SMZL MS c.200C>G 43367912 D 0.26 5 (Parry et al. 2013) 
A67G SMZL MS c.200C>G 43367912 NA 0.21 160 (Parry et al. 2015) 
A67G SMZL MS c.200C>G 43367912 NA 0.16 172 (Parry et al. 2015) 
A67G SMZL MS c.200C>G 43367912 NA 0.35 173 (Parry et al. 2015) 
A67G MCL MS c.200C>G 43367912 Un-tr 0.29 M015 Current study 
K54N MCL MS c.162A>T 43367950 D 0.32 MCL.1500 Current study 
G53G CLL SL c.159A>T 43367953 NA NA CLL_89 (Lawrence et al. 2014) 
G53G CLL SL c.159A>T 43367953 D 0.18 CLL033 (Landau et al. 2013) 
G53G MCL SL c.159A>T 43367953 D 0.31 M011 Current study 
G53G MCL SL c.159A>T 43367953 P-tr 0.38 M016-PB Current study 
G53G MCL SL c.159A>T 43367953 Un-tr 0.26 M016-Sp Current study 
G53G MCL SL c.159A>T 43367953 D 0.28 MC071 Current study 
Q36* SMZL NS c.106C>T 43368006 NA 0.13 28 (Parry et al. 2015) 
G33G SMZL SL c.99G>T 43368013 D 0.14 P14 (Martinez et al. 2014) 
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G33G CLL SL c.99G>T 43368013 D 0.37 CLL008 (Landau et al. 2013) 
G33G CLL SL c.99G>T 43368013 D 0.08 CLL025 (Landau et al. 2013) 
G33G MM SL c.99G>T 43368013 R1 0.16 PD4300 (Bolli et al. 2014) 
G33G MCL SL c.99G>T 43368013 P-tr 0.10 M016-PB Current study 
G33G MCL SL c.99G>T 43368013 R1 0.36 PT9-R2 Current study 
G65S Dog-BL MS c.193G>A 43367918 NA NA ccb020009 (Elvers et al. 2015) 
T66A Dog-BL MS c.196A>G 43367916 NA NA ccb060135 (Elvers et al. 2015); Current study 
IIAQA
80_A8
4del 
Dog-BL IFD c.236-250del 43367862 NA NA ccb030021 
(Elvers et al. 2015); 
Current study 
I80N Dog-BL MS c.239T>A 43367873 NA NA ccb010010 (Elvers et al. 2015); Current study 
I80T Dog-BL MS c.239T>C 43367873 NA NA CHIMUN (Elvers et al. 2015); Current study 
IAQA8
1 
_84Tde
l 
Dog-BL IFD c.242-250del 43367862 NA NA ccb010338 
(Elvers et al. 2015); 
Current study 
A84G Dog-L MS c.251C>G 43367861 NA NA ccb040032 (Elvers et al. 2015); Current study 
A84G Dog-BL MS c.251C>G 43367861 NA NA ccb060052 (Elvers et al. 2015); Current study 
A84V Dog-L MS c.251C>T 43367861 NA NA ccb060042 (Elvers et al. 2015); Current study 
A84V Dog-BL MS c.251C>T 43367861 NA NA ccb060047 (Elvers et al. 2015); Current study 
A84V Dog-BL MS c.251C>T 43367861 NA NA MB2C13 (Elvers et al. 2015); Current study 
IN Dog-BL IN 
c.256+18_ 
256+43del 
43367816 NA NA MBGRF16 (Elvers et al. 2015); Current study 
M1K Dog-BL TS c.2T>A 43368110 NA NA MADGUS (Elvers et al. 2015); Current study 
Abbreviations: Intron (IN); Missense (MS); Silent (SL); In-frame deletion (IFD); Not available (NA); 
Diagnostic biopsy (D); Relapse biopsy (R); Untreated biopsy (Un-tr); Pre-treatment biopsy (P-tr); 
Variant type (*). 
Overall, we collected 41 somatic SNVs and indels in the first exon of MAP3K14 including 
those detected by our study, in 25 cases of human lymphomas and 13 cases of canine B-
cell lymphoma (Table 2.9, Figure 2.13). We identified four clusters of mutations in the first 
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exon of MAP3K14, namely mutations of residues 33-36 (six samples), residues 53-54 
(seven samples), residues 65-67 (ten samples) and residues 80-84 (13 samples). Mutations 
of residues 65-67 and 80-84 were shared between human and canine lymphomas. The 
enrichment of mutations in the specific sites and types of lymphoma and conservation of 
mutations between human and dog suggest that these mutations including the G33G and 
G53G silent variants possibly have important roles in the biology of lymphoma (Figure 
2.14). 
 
Figure 2.15. Recurrent mutations in the exon-1 of MAP3K14 mapped to cDNA 
sequence from human and dog. 
G33G and G53G mutations induce alternative splicing of pre-mRNA and stability of 
NIK 
Hotspot somatic mutations might be the result of strong selective pressure providing 
advantages for growth and survival of tumor cells. The sites of hot spots denote 
functionally critical amino acid residues. The mutated residues targeted by hotspot 
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mutations of MAP3K14 possibly are crucial for normal function, regulation or structure of 
the protein. To understand functions of mutations of MAP3K14 specifically the G33G and 
G53G silent mutations in lymphoma we studied the potential impact of mutations on the 
protein using computational tools and databases.   
Except for the synonymous mutations of G33G and G53G, other mutations were predicted 
to have a damaging function on the protein. The G33G and G53G mutations were predicted 
to have no impact on the protein (silent mutation). While silent mutations do not change 
amino acids, they might still interfere with different stages of protein expression, 
modification, and regulation. For example, silent mutations can alter a protein expression, 
function, and structure by introducing or removing canonical splicing donor or acceptor 
sites and other splicing elements, disrupting miRNA binding sites and regulatory elements 
such as enhancers or transcription factor binding sites. Because the two clusters of silent 
mutations were upstream of the other mutation clusters, we hypothesized that the silent 
mutations might impact splicing of pre-mRNA by introducing a new donor or acceptor site. 
To evaluate our hypothesis, we used multiple splice prediction tools including human 
splicing finder (Desmet et al. 2009) and MaxEntScan (Yeo and Burge 2004). These tools 
predict splicing sites by comparing the input nucleotide sequence to the consensus splicing 
sequences. For input sequences, we used both wild type and mutant nucleotide sequences 
which are flanking the mutated sites (G33G, G53G). Then we compared the splice 
predictions between wild-type and mutant sequences. In addition, we did the same analysis 
for several MAP3K14 mutations of exon-1 detected in other tumor types. Interestingly, the 
results of all the methods supported our hypothesis by showing the addition of a cryptic 
donor site in both mutant sequences (G33G and G53G) in exon-1 of MAP3K14, whereas 
no donor site was detected in the region of interest for the un-mutated wild-type sequence 
or other mutations of exon-1 (Table 2.10 and Figure 2.15).  
Table 2.10. Splicing predictions for G33G and G53G mutants and wild type 
MAP3K14.  
Donor site predictions for wt exon-1 Donor site predictions for G33G(c.99G>T) 
Start End Score Exon   Intron Start End Score Exon   Intron 
22 36 0.46 tgcccaggtgcccct 22 36 0.46 tgcccaggtgcccct 
- - - - 91 105 0.99 ccactgggtaagaaa* 
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Donor site predictions for wt exon-1 Donor site predictions for G53G(c.159A>T) 
Start End Score Exon   Intron Start End Score Exon   Intron 
22 36 0.46 tgcccaggtgcccct 22 36 0.46 tgcccaggtgcccct 
- - - - 151 165 1 ttctgcggtaagtgg* 
Results of splicing site predictions using Genie (Reese et al. 1997) in exon-1 of MAP3K14 for the 
wild type and mutant cDNA. 
 
Figure 2.16. The potential impact of recurrent mutations of MAP3K14 on splicing. 
Both the novel donor sites are stronger than the canonical donor sites. Therefore, the 
splicing event may occur preferentially between the cryptic donor sites at residues 33 and 
53 and the canonical acceptor site at the end of intron-1. These results strongly support our 
hypothesis that silent mutations of G33G and G53G impact MAP3K14 by inducing 
aberrant splicing. Alternative splicing induced by G33G and G53G possibly lead to 
deletions of the regions downstream of the mutated sites in the first exon of MAP3K14. 
 65 
The abnormal mRNAs may produce proteins with partial in-frame deletions of 
G33_C86delinsG and G53_C86delinsG (Figure 2.15). Since these deletions overlap with 
the commonly altered region of the fourth cluster (SNVs or deletion of residues I80-A84 
in 14 cases), it is likely that all the mutations of residues G33, G53, and I80-A84, impact 
the same site and have the same downstream effect on the protein.Therefore it is tempting 
to speculate that the third cluster of mutations (residues 65-67) also have a similar 
downstream effect on splicing of pre-mRNA. In fact, the result of running Human Splicing 
Finder (Desmet et al. 2009) predicted that the three mutations of residues 65-67 impact 
splicing enhancers or silencers. However, the impact of mutations on splicing needs to be 
analyzed in more depth and be evaluated by functional studies.  
Two protein binding motifs were identified in NIK, namely IAP-binding motif (IBM) 
resides at A2-V3 (S. Lee et al. 2014) and TRAF3 binding site (T3BD) resides at 78-
ISIIAQA-84 (Liao et al. 2004) (Figure 2.13 and Figure 2.15). IBM and T3FB motifs are 
two DNA elements that are necessary for ubiquitin-mediated degradation and regulation 
of NIK (Liao et al. 2004). In addition, based on the available data in PhosphoSite, three 
PTM sites were predicted in the first exon of MAP3K14 (Dinkel et al. 2016; Hornbeck et 
al. 2012). The three predicted PTM sites were namely two phosphorylation sites: Y40 and 
K48 (J. Jin et al. 2012; K. Xiao et al. 2010) and one ubiquitination site: K64 (Udeshi et al. 
2013). PhosphoSite is a database with a collection of information about PTM sites which 
were observed in proteins by experimental studies (Dinkel et al. 2016; Hornbeck et al. 
2012). Predictions of these sites are based on observations of single studies, and their 
function in the regulation of NIK have not been studied experimentally. Our findings 
strongly indicated that mutations of the second, third clusters (G33G and G53G) and fourth 
cluster (I80N, I80T, A84G, A84V, A84G and indels I80_A84del, IAQA81-84T) induce 
partial deletion of exon-1 or missense mutations that both target the core motif of T3BD 
(78-ISIIAQA-84). Among the list of mutations, M1K was the only mutation that was 
targeting IBM directly by removing the initial methionine and shifting the translation start 
site to the next methionine (M4) in the amino-acid chain which might result in loss of IBM 
at residues 2-3. Together these results suggest that mutations of MAP3K14 including G33G 
and G53G disrupt the regulatory motifs and possibly some unknown DNA elements that 
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are necessary for negative regulation of NIK, which enhance the stability of the protein 
leading to constitutive activation of NF-kB signaling. Constitutive activation of NF-kB 
signaling is one of the key mechanisms involved in the development of most types of 
lymphoma such as  MM, MZL, CLL, ABC-DLBCL, and MCL (Thu and Richmond 2010). 
Clinical presentations of MCL cases with mutations of MAP3K14 
Table 2.11 shows the clinical properties of the MCL cases which were carrying the 
recurrent mutations of MAP3K14 including the six cases of this study and the data for a 
single MCL case with A84G mutation that was reported previously (C. Wu et al. 2016). 
Based on the available clinical information, the cases with mutations in MAP3K14, could 
be segregated to two groups. The first group consisted of four sample and had the features 
of the leukemic or non-nodal subtype of MCL such as high numbers of somatic mutations 
in IGHV, negative expression of SOX11, splenomegaly or peripheral blood presentation, 
and the small cell classification (Del Giudice et al. 2012). The second group consisted of 3 
samples and had features of the nodal variant of MCL such as unmuted IGHV, positive 
expression of SOX11, and nodal presentation (Del Giudice et al. 2012). Interestingly, 
except two cases (MCL.1500 and 71_Tumor1), the rest of the cases of the two groups had 
two features in common, namely the low number of CNVs (genome stability), and lack of 
SNVs and CNVs in TP53 and ATM. Both features are common in the leukemic variant of 
MCL (Del Giudice et al. 2012). Based on predicted function of the recurrent mutations of 
MAP3K14 and their recurrence in several types of lymphoma, the emergence of the 
recurrent mutations of MAP3K14 in relapse samples, involvement of both nodal and non-
nodal variants of MCL, and the two common features of the mutated cases, we propose 
that the clusters of mutations of MAP3K14 might have application as novel prognostic 
biomarkers for distinguishing a third group of MCL cases with risk of relapse and 
progression of the disease among the leukemic,  non-nodal, and nodal variants. 
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Table 2.11. The clinical presentations of the MCL cases with the recurrent 
mutations of MAP3K14. 
 
 
Case_ID
MAP3K14 
mutations
N    
CNVs
N 
SNVs/indels
Sex SOX11
IGHV 
Status
Tumor-
Site
Cytology
P13-P A84G M P - LN C
PT9-R2 G33G M P U LN C
M011_LN G53G 4 45 - P U LN C
71_Tumor1 G53G 33 354 F - M - C
M016_PB G53G, G33G 0 58 - - - PB -
M015_PB A67G 1 68 - N M PB SC
M016_Spleen G53G 0 48 - N M Spl SC
MCL.1500 K54N - 114 - - H Spl -
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2.4. Discussion 
This chapter aimed to identify driver genes and driver somatic SNVs/indels involved in the 
biology of MCL that may have applications for development of novel biomarkers and 
targets of therapies. In this section of the study, we employed two statistical approaches 
and one custom approach to analyze the list of somatic SNVs and indels generated from 
WES data of 67 MCL cases.  We identified novel candidate driver genes which were targets 
of recurrent coding and noncoding sequence SNVs and indels in this tumor type. Using 
OncodirveFM and MutsigCV, we identified several known drivers of MCL, such as 
CCND1, BIRC3, ATM and TP53, and several novel candidate driver genes with no 
previously established roles in the biology of MCL, such as S1PR1, SP140, PTPRD, 
ADAM30, LRP1B, FAT1, FAT4, DST, SYNE1, and DNAH9. Using the custom approach, 
we identified 684 genes harboring mutations in the minimum of two patients. Some of 
these genes were harboring recurrent non-coding mutations but were highly relevant to the 
biology of lymphoma. The most important findings of our custom approach were hotspot 
silent and missense mutations of MAP3K14 and recurrent non-coding mutations of 
HNRNPH1. Further analysis of these mutations showed that the silent and intron mutations 
of MAP3K14 and HNRNPH1 likely impact pre-mRNA splicing and induce stability of the 
proteins. The G33G and G53G mutations of MAP3K14 were recurrent in a minimum of 
10% of the MCL case, 28% of SMZL (2 of 7 cases) and 5 % of CLL. The recurrent non-
coding mutations of MAP3K14 and HNRNPH1, are two examples of the driver genes that 
are being overlooked because of lack of functional annotations by the studies and 
bioinformatics tools that are focused on coding mutations with impact on amino acids. This 
shows the need for the development of proper computational tools, and a complete 
collection of all the somatic mutations detected in cancers regardless of their annotations.  
Because of the limited scope of this study, we only analyzed mutations of five genes, 
namely, PTPRD, S1PR1, SP140, HNRNPH1, and MAP3K14. In the following sections, we 
discussed the potential driver role of recurrent mutations of the five genes in the 
development or progression of MCL.  
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 Deactivating mutations of PTPRD 
We are reporting recurrent mutations of PTPRD for the first time MCL. PTPRD is a 
haploinsufficient TSG which is commonly mutated, deleted or methylated in various types 
of cancer, such as adult acute lymphoblastic leukaemia, MM and NMZLs (van den Brand 
et al. 2017; Lohr et al. 2014; Okamoto et al. 2010; Spina et al. 2016; Inga Vater et al. 2009). 
PTPRD is a tyrosine phosphatase that regulates cell signaling, cell proliferation, migration, 
cell-cell adhesion and angiogenesis in coordination with tyrosine kinase (Du and Grandis 
2015). One of the functions of PTPRD is dephosphorylation and deactivation of STAT3, a 
transcription factor and a member of JAK/STAT signaling pathway (Peyser and Grandis 
2013). Deactivation of this protease triggers phosphorylation and activation of STAT3 
which induces production of cytokines and induction of an IL6-STAT3 positive feedback 
loop (Ortiz, Fabius, et al. 2014; Veeriah et al. 2009). Constitutive activation of STAT3 is 
common in cancers and induces production of proinflammatory cytokines, and 
proliferation and survival of tumor cells (H. Yu and Jove 2004). Constitutive activation of 
STAT3 was previously detected in 50 % of the cases of MCL by gene expression studies 
(L. Zhang et al. 2012) which show the important role of this pathway and suggest the 
potential driver role of mutations of PTPRD in the biology of MCL. The detected mutations 
in our study including nonsense, missense and intron variants were distributed at the same 
sites on the protein as mutations of PTPRD in NMZL (Spina et al. 2016) (Figure 2.17). 
Mutations of PTPRD are recurrent in 20% of NMZL. The similarity between mutated sites 
suggests that mutations of PTPRD in MCL and NMZL might share the same function. 
Spina et al. (2016) studied the role of PTPRD mutations in NMZL and reported the loss of 
phosphatase activity in the mutated cases which were associated with deregulation of cell 
cycle program (Spina et al. 2016). However, they did not detect deregulation of cytokines 
in the mutated cases of NMZL which suggest that mutations of PTPRD in MCL might also 
impact regulation of cycle in MCL. Moreover, studies showed that homozygous and 
heterozygous deletions of PTPRD cooperate with recurrent homozygous deletions of 
CDKN2A, to promote tumor growth (Veeriah et al. 2009). Deletions and mutations of 
PTPRD are associated with shorter survival when accompanied with deletions of CDKN2A 
which are also recurrent in MCL (Ortiz, White, et al. 2014). In the cases of MCL, we 
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identified differences in the clinical representation of PTPRD/CDKN2A deleted cases (six 
cases) with PTPRD mutated cases (four cases). The main difference of the PTPRD-mutated 
and deleted cases were their IGHV mutation state. The deleted cases had un-mutated IGHV 
with positive SOX11 expression, whereas the mutated cases had a high number of somatic 
mutations except for one case with intron mutation of PTPRD (128_T). In addition, all the 
deleted cases had recurrent deletions of 1p21, whereas only one of the four PTPRD mutant 
cases was harboring the 1p21 deletion. The cases with homozygous deletions of CDKN2A 
loci had the blastoid sub type of MCL irrespective of co-occurrence with PTPRD deletions. 
This pattern confirms the association of homozygous deletions of CDKN2A with poor 
outcome in MCL but also indicate that CDKN2A is the main target of 9p deletions in MCL. 
In conclusion, mutations of PTPRD might have a role in activation of STAT3 signaling 
which disagrees with the reports about functions of these mutations in NMZL or might 
have a role in cell adhesion. A larger set of MCL cases with complete clinical information 
and function studies of PTPRD alterations are necessary to confirm the stratification value 
of PTPRD mutations and their functional role in the pathogenesis of MCL. Experimental 
studies are necessary to understand the role of PTPRD and its mutations in the biology of 
MCL.  
  
Figure 2.17. Lollipop plots of PTPRD mutations in MCL and NMZL. 
Black font: The mutations detected by our study in MCL; Red font: The mutations detected in NMZL cases 
(Spina et al. 2016). 
 Potential role of mutations of S1PR1 in motility of MCL cells 
We identified recurrent missense, in frame and frameshift indels in S1PR1 in 6% of the 
cases of MCL. A very recent study reported a missense and a frameshift indel in S1PR1 in 
two other cases of MCL (C. Wu et al. 2016). Mutations of S1PR1 are also recurrent in adult 
T cell leukemia/lymphoma (ATL) (Kataoka et al. 2015) (Table 2.12).  
 71 
Table 2.12. The recurrent mutations of S1PR1 in MCL and ATL.  
Gene Sample ID Type 
cDNA 
position 
A.A. 
Change 
Tumor 
type/site/ VAF Source 
S1PR1 122_T1 FSI c.375dupT V126Cfs*16 MCL 0.41 Present Study 
S1PR1 138_T1 MS c.238A>G M80V MCL 0.22 Present Study 
S1PR1 M014 INI c.367_368 insATA G122_S123insN MCL/LN 0.19 Present Study 
S1PR1 MCL. 1808 FSD 
c.17_19del 
TCCinsGG V6Gfs*30 MCL/LN 0.53 Present Study 
S1PR1 M006 MS - R324L MCL - Present Study 
S1PR1 P9-D FSI c.364dupG E121fs MCL/LN 0.33 (C. Wu et al. 2016) 
S1PR1 P9-R1 FSI c.364dupG E121fs MCL/LN 0.48 (C. Wu et al. 2016) 
S1PR1 P9-R2 FSI c.364dupG E121fs MCL /SB 0.31 (C. Wu et al. 2016) 
S1PR1 p6-D MS c.T209G I70S MCL/LN 0.21 (C. Wu et al. 2016) 
S1PR1 p6-R MS c.T209G I70S MCL/INT 0 (C. Wu et al. 2016) 
S1PR1 ATL007 NS c.G351A W117* MCL/LN 0.38 (Kataoka et al. 2015) 
S1PR1 ATL074 MS c.G240T M80I ATL/Acute 0.32 (Kataoka et al. 2015) 
S1PR1 ATL074 NS c.C663G Y221* ATL/Acute 0.29 (Kataoka et al. 2015) 
S1PR1 ATL012 NS c.C1024T R342* ATL/Acute 0.34 (Kataoka et al. 2015) 
S1PR1 ATL211 NS c.C1024T R342* ATL 0.46 (Kataoka et al. 2015) 
S1PR1 ATL103 NS c.C1024T R342* ATL 0.04 (Kataoka et al. 2015) 
S1PR1 ATL426 NS c.C993A C331* ATL 0.26 (Kataoka et al. 2015) 
S1PR1 ATL169 FSI c.165_167del 55_56del ATL 0.24 (Kataoka et al. 2015) 
S1PR1 ATL281 NS c.C1024T R342* ATL 0.48 (Kataoka et al. 2015) 
S1PR1 YUKLAB MS c.238A>T M80L ML/T2 - 
(Krauthammer et al. 
2012) 
 
S1PR1 encodes a G-protein coupled receptor (S1P1) with seven transmembrane helices 
(TMs) linked by alternating extracellular and intracellular loops (Hanson et al. 2012). S1P1 
functions via interactions with its ligand, S1P, which is the key regulator of many cellular 
processes, such as angiogenesis, vascular maturations, cytoskeletal rearrangements, 
lymphocytes differentiation and trafficking (Hait et al. 2009; Spiegel and Milstien 2003; 
Visentin et al. 2006). One of the key regulatory functions of S1P1 and S1P is regulation of 
adaptive immune system and angiogenesis. This mechanism, which is named inside-out 
signaling, depends on the levels of S1P inside and outside of the cell. S1P is formed in 
response to various stimuli such as growth factors and cytokines leading to elevation of 
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extracellular S1P concertation. The Intracellular S1P gets degraded by a specific enzyme 
or transport out of the cell by S1P2 and ATP-binding cassette family of transporters (ABC 
transporters). High levels of S1P stimulates S1P1 and migration of lymphocytes toward 
S1P chemoattractant. Interaction of S1P1 with its ligand causes temporary internalization 
of S1P1(Takabe et al. 2008).  
Activation and internalization of S1P1, activate two G-proteins (GNAI2 and GNAI3) 
which trigger activation of the downstream signaling pathways (Takabe et al. 2008). S1P1 
is expressed at various levels based on the role it plays in the cell. For example, studies 
showed that S1P1 is expressed in high levels in normal mantle cells (Nishimura et al. 2010) 
and in low levels in GC B-cells to ensure sufficient time for the clonal expansion of Ag-
induced B-cells. Nishimura et al. studied the expression of S1PR1 in lymph nodes and 
multiple types of lymphoma using Immunohistochemistry. All cases of nodal, extranodal 
and cycling D1- MCL showed strong signals for S1PR1 except one aggressive case of 
MCL. Extranodal MCL including gastrointestinal tract and bone marrow had less 
consistent signals compared to the nodal MCL. Their study also suggested that S1PR1 
might have a role in the migration of MCL cells to the bone marrow and gastrointestinal 
(Nishimura et al. 2010). Moreover, a very recent study found a rhythmic pattern in the 
expression of S1PR1 lymphocytes (Druzd et al. 2017). They also found that mono allelic 
deletion of S1P1, which is the key regulator of the cyclic trafficking of lymphocytes, results 
in disruption of this mechanism (Druzd et al. 2017). Because of the importance of S1P1 
levels in the regulation of lymphocytes trafficking and B-cell differentiation, alterations 
that lead to reduction or accumulation of S1P1 levels might have tumorigenic 
consequences on the cell. In fact, it was shown previously that overexpression of S1PR1 
promote tumor cells migrations, invasion, and metastasis (L. Jin et al. 2016), and is 
associated with worse prognosis in DLBCL and classical Hodgkin lymphoma (Kluk et al. 
2013; Paik et al. 2014). One the other hand, down regulation of this protein is associated 
with survival of leukemic CLL cells in the supportive niche of the secondary lymphoid 
organs (Capitani et al. 2012) and the progression of T-lymphoblastic lymphoma (T-LBL) 
to acute T-lymphoblastic leukemia (T-ALL) (Feng et al. 2010).  
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The recurrent mutations of MCL and ATL, which were shown in Table 2.12, were mainly 
truncating variants such as frameshift indels and nonsense mutations. Mutations of MCL 
were clustered at two regions: missense mutations between residues 70-80 and indels 
between residues 121-126. Interestingly, residue M80 was mutated in three types of tumor, 
namely ATL (M80I) (Kataoka et al. 2015), MCL (M80V) (current study), and melanoma 
(M80L) (Krauthammer et al. 2012). ATL and melanoma share a similar driver pathway 
which is Rho/Rac signaling which suggests that missense mutations of M80 might impact 
this signaling pathway. It is important to note that, all the three mutations of residue M80 
are covered mutations changing methionine to valine, leucine, and isoleucine. Therefore, 
it is unlikely that the conserved mutations of amino acid have any impact on the protein. 
However, these mutations might impact regulatory elements. M80 is a conserved residue 
and part of a motif (78RPMYY) in the protein that is necessary for interactions with the 
receptor with FTY720P, which is an inhibitor of S1P1 that has therapeutic applications by 
inducing internalization, ubiquitination and degradation of S1P1 (Kataoka et al. 2015; 
Valentine et al. 2011). Mutations of residues 121-126 were close to the S1P core binding 
pocket (residues 120-121) and upstream of the residues necessary for interactions of S1P1 
and CD69 (Bankovich, Shiow, and Cyster 2010) which is necessary for internalization and 
inhibition of the receptor (Bankovich, Shiow, and Cyster 2010). More importantly, all the 
mutations targeting residues 121-126 in MCL were the frameshift/inframe insertion types. 
Overall, based on the patterns of mutations of S1PR1 in MCL and the potentially damaging 
impact of frameshift mutations and premature stop codon of the protein, it is likely that 
mutations of S1PR1 in MCL have a damaging impact on the protein and inhibit Rho/Rac 
mediated migration of cells. Mutations of S1PR1 possibly inhibit egress of lymphocytes 
from lymphoid organs and might inhibit movement of B-cell within lymph node 
compartments which is necessary for B-cell differentiation. Deactivation and deletions of 
S1PR1 can also disrupt the normal structure of lymph nodes (Rivera and Chun 2007) which 
is one of the features of diffuse and nodular subtypes. Notably, these subtypes were 
abundant in the cases with deletions of 1p21 (Figure 2.18). Nevertheless, experimental 
validations are necessary to overrule a potential activating impact of these mutations on the 
proteins. 
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Figure 2.18. Recurrent deletions of 1p21 in MCL harboring S1PR1 locus 
 The tumor suppressive role of SP140 in MCL 
SP140 was one of the significantly mutated genes in MCL which was harboring recurrent 
nonsense, frameshift indels, and silent mutations. The bias in accumulation of nonsense 
and frameshift indels in this gene indicate that SP140 function as a tumor suppressor gene 
in MCL. The homozygous deletions and rare mutations in SP140 were previously reported 
in MCL (Bea et al. 2009; Beà et al. 2013) and were also detected in the present study. The 
0 62 124 186 249
126_Tumor1
122_Tumor1
128_Tumor1
138_Tumor1
14_Tumor1
146_Tumor1
24_Tumor1
25_Tumor1
28_Tumor1
33_Tumor1
35_Tumor1
38_Tumor1
39_Tumor1
40_Tumor1
42_Tumor1
45_Tumor1
46_Tumor1
47_Tumor1
61_Tumor1
71_Tumor1
98_Tumor1
M001_PB
M002_PB2
M002_Tonsil
M003_PB
M003_PB2
M004_PB
M006_PB
M007_Colon
M008_PB
M010_PB
M011_LN
M012_LN
M013_LN
M014_LN
M015_PB
M018_PB
M019_PB
M020_PB
M021_PB
M022_LN
M023_LN
M023_PB
M024_LN
M025_LN
M026_PB
M027_PB
M028_PB
M029_PB
M030_PB
M031_PB
PT013_T1
PT013_T2
Gain
Scores
LOH_A
Scores
Loss_Heterozygo
Scores
LOH_N
Scores
S1PR1
Gain
0 6
LOH_A
0 6
Loss_Heterozygous
0 21
LOH_N
0 6
p3
6.1
3
p3
6.1
1
p3
4.3
p3
4.2 p3
3
p3
2.3
p3
1.3
p3
1.1
p2
1.3
p2
1.1
p1
3.3
p1
3.2 q1
2
q2
1.1
q2
1.3
q2
3.3
q2
5.2
q2
5.3
q3
1.1
q3
1.3
q3
2.1
q3
2.2 q4
1
q4
2.2 q4
3
q4
4
Score
Chromosome 1
Location (Mb)
merged-bea-morin-input.xls
0 62 124 186 249
126_Tumor1
122_Tumor1
128_Tumor1
138_Tumor1
14_Tumor1
146_Tumor1
24_Tumor1
25_Tumor1
28_Tumor1
33_Tumor1
35_Tumor1
38_Tumor1
39_Tumor1
40_Tumor1
42_Tumor1
45_Tumor1
46_Tumor1
47_Tumor1
61
71_Tumor1
98 r
M001_PB
M002_PB2
M002_Tonsil
M003_PB
M003_PB2
M 04_PB
M006_PB
M007_Colon
M008_PB
M010_PB
M011_LN
M012_LN
13 LN
14 LN
15 PB
M018_PB
M019_PB
M020_PB
M021_PB
22 LN
23 LN
23 PB
024_L
M025_LN
M026_PB
M027_PB
028_PB
9
30
31 PB
PT013_T1
PT013_T2
Gain
Scores
LOH_A
Scores
Loss_Heterozygo
Scores
LOH_N
Scores
S1PR1
Gain
0 6
LOH_A
0 6
Loss_Heterozygous
0 21
LOH_N
0 6
p3
6.1
3
p3
6.1
1
p3
4.3
p3
4.2 p3
3
p3
2.3
p3
1.3
p3
1.1
p2
1.3
p2
1.1
p1
3.3
p1
3.2 q1
2
q2
1.1
q2
1.3
q2
3.3
q2
5.2
q2
5.3
q3
1.1
q3
1.3
q3
2.1
q3
2.2 q4
1
q4
2.2 q4
3
q4
4
Score
Chromosome 1
Location (Mb)
merged-bea-morin-input.xls
 75 
pathogenic role of SP140 has been previously implicated in several other types of 
lymphoma namely DLBCL, CLL, MM and AML. Deleterious somatic SNVs and indels of 
SP140 are also recurrent in MM and are associated with the higher risk of relapse (Bolli et 
al. 2014) (Figure 2.19). This result is in line with association of mutations of SP140 with 
poor prognosis in MM and CLL (Bolli et al. 2014). 
 
Figure 2.19. The distribution of recurrent somatic mutations and germline 
variants in MCL, CLL, and MM.  
In addition, several germline variants in SP140 were identified in CLL that were associated 
with the lower expression of the protein and the higher risk of relapse (Di Bernardo et al. 
2008; Sille et al. 2012). Another study investigated the impact of one of the CLL risk alleles 
(rs10201872) which was carrying a silent mutation in exon-7. The results of this study 
confirmed the damaging impact of the risk allele on the protein causing partial deletion of 
exon-7 by alternative splicing (Zhao et al. 2013). Notably, three of the MCL cases with 
SP140 mutations had the blastoid or diffuse subtype of the disease. This might indicate 
that, SP140 mutations are associated with a poor prognosis in MCL as well. The pathogenic 
chr2 (q37.1) 21 12 3435
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function and mechanisms of SP140 are still unclear. However, two roles have been 
suggested for this gene namely, regulation of antiviral immune response (Madani et al. 
2002), and regulation of transcription (Zucchelli et al. 2014). Importantly, it has been 
hypothesized that SP140 might have a role in mechanisms involving immune self-tolerance 
(Matesanz et al. 2015) because of the association of this genes with multiple immune-
mediated diseases such as multiple sclerosis (MS), inflammatory bowel disease 
(IBD)(Peloquin et al. 2016), autoimmune thyroid diseases (AITD) (Hasham et al. 2013).  
Based on the significant frequency of deleterious mutations of SP140 in MCL, and the 
pathogenic role of this gene in CLL and MM, we suggest that SP140 is a driver TSG in 
MCL with a potential role in regulation of transcription and autoimmune responses. 
Furthermore, our findings suggest that mutations of SP140 might have application for 
prediction of poor outcome in MCL. Experimental studies are necessary to validate this 
hypothesize and explore the role of mutations of SP140 in the biology of MCL and its 
association with the more aggressive type of the disease.  In addition, the clusters of 
mutations detected in our study can be used for mutagenesis studies to develop a better 
understanding of SP140 mechanism of function. 
 Impact of the non-coding mutations of HNRNPH1 on exon inclusion 
and protein stability  
In this study, we identified recurrent splicing mutations in HNRNPH1 and HNRNPA2B1. 
Mutations target two G-rich splicing motifs namely “UAGG and GGGG” motif and the 
“GGG” motif (Caputi and Zahler 2001; Engelbrecht, Knudsen, and Brunak 1992; Han et 
al. 2005; McCullough and Berget 1997). The “UAGG and GGGG” motif is a rare silencer 
motif composed of two smaller elements including the UAGG motif that can be found 
anywhere in the exon and the GGGG motif that can be found within the first 3–10 bases of 
introns (Han et al. 2005). The “GGG” motif is usually located within the first or last 3–10 
bases of introns (Martinez-Contreras et al. 2006). G-rich motifs are recognized and bound 
by hnRNP A/B and F/H splicing factors to regulate splicing (Caputi and Zahler 2001; 
Engelbrecht, Knudsen, and Brunak 1992; McCullough and Berget 1997). Some of the 
splicing factors have these motifs in their DNA sequence. Thus they can also interact with 
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each other and regulate splicing in one another (Cartegni et al. 1996; Han et al. 2005; 
Martinez-Contreras et al. 2006). Studies showed that change of a single base pair in these 
motifs is enough to inhibit binding of the splicing factors to these sequences (Martinez-
Contreras et al. 2006). Han et al. (2005) performed site-directed mutagenesis on these 
motifs and found that mutants have a significant increase of exon inclusion (Han et al. 
2005). More importantly, the G-rich motifs have a specific role in the regulation of hnRNP 
H expression. This mechanism of autoregulation of hnRNP H involves exclusion of exon 
5 (Han et al. 2005). Studies demonstrated that the “UAGG and GGGG” motifs in 
HNRNPH1, induces exon-5 exclusion (Han et al. 2005). Exclusion of exon-5 introduces a 
shift in the reading frame, and an early stop codon which results in a truncated protein or 
removal of the truncated mRNA by nonsense-mediated mRNA decay and subsequent down 
regulation of hnRNP H. Mechanisms of exon silencing in HNRNPH1 is not well defined 
(Han et al. 2005). However, a cooperative role for hnRNP A1 and hnRNP H was detected. 
The former, functions as an inducer of exon exclusion whereas the latter functions as an 
inhibitor of this mechanism (Han et al. 2005). In conclusion, our findings suggest that 
recurrent mutations of HNRNPH1 induce exon inclusion leading to overexpression of 
hnRNP H. 
 Impact of hotspot mutations of NIK on protein stability and 
constitutive activation of NF-kB signaling 
MAP3K14 consists of 15 exons, which codes a 947 amino-acids protein (NIK). NIK is 
constitutively expressed and degraded in unstimulated cells, which keeps the level of the 
protein extremely low in these cells (Liu et al. 2012). Several mechanisms have been 
suggested for the negative regulation of NIK. The most important mechanism is ubiquitin-
mediated degradation of NIK that is regulated by a complex of ubiquitin enzymes namely, 
TRAF2, TRAF3, BIRC2 (IAP-1) and BIRC3 (IAP-2) (Vallabhapurapu et al. 2008). The 
first exon of NIK which is composed of 84 amino acid codons, plays the main role in this 
mechanism. In this exon, residues A2-V3 are the binding motif (IBM) for BIRC2 and 
BIRC3 (S. Lee et al. 2014), and residues 78-ISIIAQA-84 are the binding motif (T3BD) for 
TRAF3 (Liao et al. 2004). Binding of the TRAF3/TRAF2/IAP-1/2 complex to IBM and 
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T3FB are crucial for the successful regulation of NIK. TRAF3 brings members of the 
complex in close contact with NIK by interacting with T3BD and recruiting TRAF2-
BIRC2/3 (cIAP1/2) complex. BIRC2/3 binds to IBM and catalyzes ubiquitination and 
degradation of NIK (S. Lee et al. 2014; Liao et al. 2004; Vallabhapurapu et al. 2008). Two 
other mechanisms that regulate levels of NIK are the negative feedback mechanisms 
involving NIK-dependant transcriptional activation of TRAF2 and elevation of TRAF3 
expression (Sasaki et al. 2008), and IKKA-mediated phosphorylation of NIK. In contrast 
to the TRAF3-mediated negative regulation of NIK that is active in unstimulated 
conditions, Nuclear Factor NF-Kappa-B Inhibitor Kinase Alpha (IKKA) negatively 
regulates levels of NIK in stimulated conditions to prevent uncontrolled elevation of NIK 
(Razani et al. 2010). Several residues involved in this mechanism were identified including 
residue 247 at C-terminal of the protein, which is essential for the interaction of NIK with 
IKKA, and residues S809, S812 and S815 that are targets of phosphorylation by IKKA 
(Razani et al. 2010).  
The knowledge on mechanisms of regulation of NIK is incomplete; Thus, more interacting 
partners, and regulatory elements might be involved in these mechanisms. For example, 
lysine residue that is the target of ubiquitination and subsequent degradation of NIK by 
TRAF3/TRAF2/IAP-1/2 complex is still unknown. In this section of study, we found driver 
mutations in the known and potential novel regulatory sites of NIK. The findings of this 
section, can offer new ideas for the functional studies of regulatory mechanisms of NIK. 
Our results revealed recurrent driver mutations in the first exon of MAP3K14 in about 10% 
of the cases of MCL and several other hematopoietic malignancies, namely CLL, SMZL, 
NMZL, MM, and WM. Our analysis showed that the recurrent mutations of the first exon 
of MAP3K14 were targeting the conserved negative regulatory elements namely, T3BD, 
IBM, and a potential ubiquitination site (K68). Therefore, these mutations, which were 
present in the six types of lymphoma and leukemia, play an oncogenic role in these tumors 
by inducing the stability of NIK and constitutive activation of NF-kB signaling. We found 
four clusters of mutations in this exon, and a single mutation (M1K) in IBM. M1K 
mutation, which was in a single case of canine lymphoma, was changing the translation 
start codon, and likely results in a shirt in the translation start site to the next methionine at 
 79 
residue 4 (M4). The change in the translation start site that is caused by M1K, likely results 
in an inframe deletion of the first three amino acids including IBM (A2-V3). M1K was the 
only mutation that was affecting IBM. On the other hand, mutations were recurrent in 
T3BD in both human and canine lymphoma. Mutations were mostly targeting residues I80 
and A84 of T3BD (I80N, I80T, A84G, A84V, A84G and indels I80_A84del, IAQA81-
84T). The bias in the accumulation of mutations in the two residues I80 and A84, suggests 
that these residues possibly are the core residues of T3BD. The two highly mutated residues 
were also part of the splicing motif and therefore mutations in these sites might also impact 
the splicing of the mRNA. As the result, deletion or change of I80 and A84 possibly have 
significant impact on the protein via disruption of T3BD that is necessary for the interaction 
of TRAF3 and NIK. Moreover, we showed that a potential ubiquitination site (K68) and a 
potential splicing regulatory motif might be the targets of the recurrent missense mutations 
(G65D, T66A, A67G) in canine and human lymphoma. Mutations that were surrounding 
the predicted ubiquitination sites, might be causing changes to the physiochemical 
properties of residues that are essential for the ubiquitination process (Narayan, Bader, and 
Reimand 2016; Sadowski and Sarcevic 2010). Another potential impact of these mutations 
is disruption of a splicing regulatory motif that can result in partial deletion of the 
downstream sequences or total exclusion of exon-1. It was predicted previously that K68 
might be involved in ubiquitination process (Udeshi et al. 2013). Based on the previous 
validation of a ubiquitination site in a residue close to the recurrent mutations of NIK, the 
suited position of the lysine residue between T3BD and IBM, and the enrichment of 
mutations in amino acids next to the lysine residue suggest that K68 might be the 
ubiquitination site involved in NIK regulation. This further suggests that the recurrent 
mutations of the third cluster (G65D, T66A, A67G) in canine and human lymphoma 
possibly impact ubiquitin degradation of NIK. Experimental validations are necessary to 
evaluate this hypothesis and confirm the impact of the missense mutations of the third 
cluster on splicing and ubiquitination of NIK in the living cells. Finally, we found three 
novel mutations in MAP3K14 in MCL namely, G33G, G53G, and K54N. The silent 
mutations (G33G and G53G), were recurrent and were specific to three types of human 
lymphoma namely, CLL, MCL, and MM. Our computational-based analysis revealed that 
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the two silent annotated mutations, G33G and G53G, activate a cryptic donor site that is 
stronger than the canonical splice donor. Our results strongly suggest that activation of the 
cryptic donor sites possibly results in the abnormal splicing of pre-mRNA and in-frame 
partial deletions the first exon of NIK. Based on this observation, the mutated mRNAs 
produce two mutated oncoproteins with in-frame deletions of residues G33_C86delinsG 
and G53_C86delinsG that are missing the T3BD and the potential ubiquitination site 
(K68).  
Collectively our findings indicate that the recurrent mutations of the first exon of NIK 
inhibit ubiquitin-mediated degradation of NIK which elevates the stability and levels of the 
protein in unstimulated cells. Stability of NIK subsequently leads to constitutive activation 
of NF-kB signaling. Constitutive activation of NF-kB signaling plays a major role in the 
pathogenesis of many types of lymphoma (Annunziata et al. 2007; Davis et al. 2001). The 
most frequent alterations that target negative regulation of NIK in lymphoma are deletions 
and mutations of TRAF2, TRAF3, BIRC2, and BIRC3 (van den Brand et al. 2017; Rossi 
et al. 2011). In comparison, reports of alterations that directly target NIK are uncommon. 
Amplifications and translocations of NIK were detected in classical Hodgkin lymphoma, 
CLL, SMZL, and MM (Annunziata et al. 2007; Otto et al. 2012; Parry et al. 2013; Rossi et 
al. 2011). Only two studies detected and reported recurrence of SNVs in the first exon of 
NIK including one study that detected recurrent A67G in SMZL (Parry et al. 2015) and 
another study reported recurrent mutations in T3BD in canine B-cell lymphoma (Elvers et 
al. 2015). Therefore, to the best of our knowledge, the present study is the first to report 
the significance of the recurrent mutations in the first exon of NIK, and the potential 
function of the mutations on the protein, and their pathogenic role in the cell. Studies 
showed that amplification of NIK and deletions of TRAF2 and TRAF3 cause over 
expression and stability of NIK respectively, which result in BAFF-dependant activation 
of alternative NF-kB signaling and strong increase in numbers of peripheral B-cells (Sasaki 
et al. 2008). On the other hand, deletion of T3BD has a more severe impact by stabilizing 
the protein and disrupting the NIK-dependant negative feedback mechanisms which results 
in BAFF-independent activation of NF-kB signaling leading to survival and dramatic 
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expansion of mature B cells in secondary lymphoid organs and disruption of lymphoid 
organs’ structure (Sasaki et al. 2008).  
The distribution of the recurrent mutations of MAP3K14 among cases of human and 
canine lymphoma. 
Our results showed that the recurrent mutations of MAP3K14 were not distributed evenly 
between human and canine lymphoma, and among the six lymphoma subtypes. For 
example, all the mutated cases of canine lymphoma were harboring mutations of cluster 
four (80-84) except three cases with mutations close to K68 and IBM whereas, cases of 
human lymphoma were mostly carrying G33G and G53G mutations, which were unique 
to human lymphoma. The specificity of the G33G and G53G to human lymphoma and the 
higher prevalence of mutations of I80-A84 in dogs suggest that MAP3K14 might have 
additional regulatory elements, splicing motifs, and functions in human that are absent in 
dogs. We also observed specific distribution of mutations among cases of human 
lymphoma. Our analysis showed that the activating mutations of MAP3K14 were specific 
to six types of lymphoma namely, MCL, CLL, SMZL, WM, MM, and NMZL. The six 
lymphoma subtypes originate from post-germinal center B cells or antigen-naïve B-cells 
and share some similarities in their biology including constitutive activation of NF-kB 
signaling which is a key feature of these lymphoma types. Moreover, distribution of the 
recurrent mutations of the first exon of MAP3K14 varied among the six types of 
lymphomas. For example, G33G and G53G were more common in cases of MCL and CLL 
whereas A67G was more common in cases of SMZL. The difference in the prevalence of 
the recurrent mutations of MAP3K14 among lymphoma subtypes might be because of the 
bias of the previous research towards reporting non-synonymous mutations and against the 
synonymous mutations. We only found a small number of studies on these types of 
lymphoma that included a full list of variants including synonymous and non-synonymous 
mutations. Supporting this observation, are two of the NGS studies in SMZL that detected 
the A67G mutations but were excluded the synonymous variants (Parry et al. 2013, 2015), 
and a single study on SMZL that reported their full list of variants which also included the 
G33G mutation in a single case of SMZL (Martinez et al. 2014). Another noticeable pattern 
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in the mutations of MAP3K14 in human lymphoma were the clonal expansion of mutations 
in relapse or progressed tumor biopsies, which is discussed in the next section.  
Potential association of MAP3K14 hotspot mutations with the higher risk of relapse 
Our results showed evidence of clonal expansion of G33G mutation in two cases of MCL. 
We found the G33G mutations in two cases of MCL. Interestingly, we detected this 
mutation in only one of the samples of each patient, namely the first relapse sample from 
PT9 and the PB sample from M016. This mutation was only in the first relapse sample of 
PT9, but were absent from the diagnostic and the second relapse of this case. The 
sequencing data from PT9 was previously studied by Wu et al. (2016) who reported the 
branched clonal evolution of the three samples of this case. Accordingly, the branched 
evolution of the three samples explains the unique presence of G33G in the first relapse 
sample. Furthermore, G33G mutation was specific to the PB sample from M016 but was 
absent from the matched synchronized spleen sample. This mutation had VAF of 0.10 in 
the PB sample, which was considerably lower than VAF of G53G (0.38) in the same 
sample and VAF of G53G (0.26) in the spleen sample. The purity of two samples of M016 
were close (97% for PB versus 89% for spleen), therefore it cannot explain the difference 
between the VAFs. The low VAF of G33G and the single read that was discussed in the 
results section suggest that a small fraction of cells is carrying this mutation in M016-PB 
sample that was either linearly evolved from the subclone with G53G mutation, or was 
evolved through the branched evolutionary model from an ancestor cell. The scenario with 
the linear evolution of G33G is less likely to be correct since findings of the previous 
studies demonstrated a pattern of mutual exclusivity between mutations of NF-kB pathway 
(Rahal et al. 2014). Mutations of the members of NF-kB signaling were also mutually 
exclusive in the two relapse cases of PT9, including a single mutation in CARD11 in PT9-
R2 (C. Wu et al. 2016) and the G33G mutation of MAP3K14 in PT9-R1.  We found the 
same pattern of mutual exclusivity of mutations in 14 cases of MCL. The only two 
exceptions were two mutations of MAP3K14 (G33G and G53G) in M016-PB and two 
mutations of MAP3K14 (K54N) and BIRC3 in MCL.1500. Collectively, these 
observations suggest that G33G is in a subclone of cells that became distinct from the 
G53G-subclone via the branched evolutionary model. In this scenario, K54N is likely a 
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passenger mutation. M016 and PT9 were not the only cases of lymphoma with the 
emergence of the recurrent mutations of MAP3K14 at relapse. Two cases of MM harbored 
the G33G and A84G mutations only in the relapse samples (Bolli et al. 2014; Chapman et 
al. 2011). These results suggest a potential role for the recurrent mutations of MAP3K14 
in progression and relapse of the disease. Analysing the clinical data from the MAP3K14-
mutated cases showed that, both nodal and non-nodal variants of MCL were harboring 
these mutations. However, about 75% of the samples shared two features of the low CNV 
count and lack of alterations in TP53 and ATM, which are common in the leukemic or non-
nodal variants of MCL. It was suggested that the leukemic or non-nodal variants of MCL 
often have an indolent course of the disease with features such as mutated IGHV, negative 
expression of SOX11, genome stability, and lack of mutations in TP53 and ATM. 
However, this suggestion is still a matter for debate because of the contradictory results of 
the previous studies (Fernandez et al. 2010; Parry-Jones et al. 2007). Based on the current 
understanding, the leukemic cases of MCL, which often have the indolent course of the 
disease, might transform to the aggressive variant of MCL by gaining genetic alterations 
in driver genes. Therefore, detection of novel molecular biomarkers is necessary to achieve 
a better stratification of the variants of MCL. Studies showed that NIK stability induces 
signal-independent constitutive activation of both non-canonical NF-kB pathway and 
canonical NF-kB pathway, which subsequently promote autonomous proliferation and 
survival of tumor cells (Sasaki et al. 2008). Moreover, new insights about functions of NIK 
are emerging that further supports the key role of this proto-oncogene in the biology of 
cancers such as activation of invasion in tumor cells (Duran et al. 2016; Jung et al. 2016). 
Collectively, these results suggest that the recurrent mutations in the first exon of 
MAP3K14 likely play important roles in development, progression, and relapse of the six 
type of lymphoma. Based on what we discussed in this chapter about MAP3K14, we 
propose the four clusters of mutations in the first exon of MAP3K14 as potential biomarkers 
for stratification and prognosis of the aggressive types of nodal and non-nodal MCL.  
In summary, we discovered recurrent somatic mutations in several candidate driver 
genes S1PR1, SP140, PTPRD, ADAM30, LRP1B, FAT1, FAT4, DST, SYNE1, and DNAH9. 
We further analyzed the impact of mutations on five of the most biologically relevant 
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candidate genes, S1PR1, SP140, PTPRD, MAP3K14, and HNRNPH1. The results of our 
analysis suggest that SP140, S1PR1, and PTPRD are targeted by damaging and deleterious 
mutations and function as driver tumor suppressor genes in MCL. Furthermore, we 
discovered recurrent activating mutations in two potential driver oncogenes, MAP3K14 
and HNRNPH1. Mutations of MAP3K14 have potential applications in stratification and 
prognosis of the aggressive form of the non-nodal variants of MCL. Overall, our five 
candidate driver genes might offer novel targets for the development of suitable treatments.   
Recurrent SNVs/indels are not the only players of tumorigenesis. Copy number variants 
and rare somatic SNVs also have equally important roles in cancers. To complement the 
analysis of this chapter and identify the mechanisms underlying development and 
progression of MCL, in the next chapter we analyzed somatic copy number variations and 
their target driver genes in MCL. 
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Chapter 3.  
 
Landscape of copy number variants in MCL 
I wrote the entire chapter 3. I prepared all the images. Figure 3.2 was prepared by myself 
with the contribution of Martin Krzywinski. The analysis of this chapter was designed by 
myself, and Dr. Morin. I used the CNV data detected by Bea et al. (2013) and previously 
published in the supplementary file of this study (Beà et al. 2013). I detected somatic CNVs 
for all the cases of the discovery cohort. I performed the entire downstream analyses of 
chapter3, obtained the results and made the conclusions.  
3.1. Introduction 
Chromosomal alterations are frequent in many types of cancers and induce genomic 
instability which is one of the enabling hallmarks of cancer (Hanahan and Weinberg 
2011a). CNVs and SVs also have a prominent role in the biology of MCL as it has one of 
the highest numbers of chromosomal alterations among lymphomas (Beà and Campo 
2008). CNVs and SVs can contribute to process of tumorigenesis by increasing expression 
levels of Oncogenes, decreasing expression of tumor suppressor genes and introducing 
novel fusion genes. CNVs and even the MCRs of the recurrent CNVs are often large and 
overlap with loci of tens to hundreds of genes. Thus, it is challenging to identify the driver 
genes targeted by CNVs in cancers. Integrating CNVs data with whole genome expression 
data is a commonly used method that facilitates detection of the driver genes targeted by 
CNVs. Chromosomal anomalies of MCL and the associated gene expression profile have 
been studied extensively by array-based and cytogenetics methods (Hartmann et al. 2010). 
These studies identified several secondary driver genes and targets of CNVs that cooperate 
with overexpression of CCND1 to develop this malignancy, such as deletion of tumor 
suppressor genes: ATM and TP53, and amplification of oncogenes such as BMI1. These 
studies improved knowledge of the field on targets of somatic CNVs and their roles in the 
development of MCL. By contrast, there was only one sequencing study that analyzed 
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CNVs in MCL. Although exome sequencing is not the optimal method for detecting copy 
number variation, it allows for detection of small coding CNVs, and integrated analysis of 
somatic CNV and SNV generated from the same source of data. It is common that 
oncogenes and tumor suppressor genes are respectively, targets of gain-of-function 
SNVs/indels or copy number gains, and targets of loss-of-function SNVs/indels or copy 
number losses/LOH in cancers. Therefore, the intersection between the list of genes 
harboring somatic SNVs/indels and the list of genes located in the MCRs can help to 
differentiate the targets of CNVs among the large list of genes located in MCRs. Because 
whole genome expression data was not available for the present study, we performed an 
integrated analysis of CNVs and SNVs to identify novel targets of recurrent CNVs in MCL. 
In this chapter, we identified the potential targets of some of the recurrent somatic in MCL 
by integrating somatic CNVs and SNVs. This chapters resulted in detection of a long list 
of gene including the following potential drivers: TERT, PTPRD, SP140, DOCK8, LAMA2, 
ITGB1, DLC1, MYLK, ROBO2, PAK2, PIP4K2A, SPATA13, PREX2, RACGAP1, AVEP1, 
ORAV1, ARHGAP29, RAP2A, ARHGAP30, FHIT, and PEAK1. In addition, we discovered 
two novel translocations between ORAOV1 and MLLT10, and ORAOV1 and RP11-
141M1.3. ORAOV1 and MLLT10 are two oncogenes that play roles in various types of 
cancer (Burillo-Sanz et al. 2017).  
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3.2. Materials and Methods 
 Cohorts 
In this section of the study, we investigated the copy number profile of primary MCL using 
WES data from 24 cases of discovery cohort. Because of the modest sample size of the 
discovery cohort, we merged our list of CNVs with the previously published CNV data 
from 26 cases (34 primaries) cases of cohort-B which was publically available in the 
supplementary file of the original study (Beà et al. 2013). The CNV analysis of the cases 
of cohort-Z was beyond the scope of the project. A total number of 50 MCL cases (58 
primary samples) included in the analyses of this chapter. 
 Detection of somatic CNVs 
We used TITAN for detecting somatic CNVs and LOH from the trimmed tumor/normal 
bam files for 24 cases of the discovery cohort (Ha, Roth, and Khattra 2014). It was 
mentioned in the previous chapter that ten of the cases of discovery cohort had large 
numbers of mismatches and false positives. The CNV calls for two cases (75_T1 and 
109_T1) with the highest number of alignment artifacts were negatively affected. 
Therefore, the data from these cases were removed from the downstream analyses of this 
chapter. This left a total of 48 MCL cases (56 diagnostic samples) for studying targets of 
CNVs. The landscape of somatic CNVs/LOH was visualized using Circus and Genomic 
Recurrent Event ViEwer (GREVE) plots (Cazier, Holmes, and Broxholme 2012; 
Krzywinski et al. 2009). 
 Identification of recurrent CNVs and their target genes in MCL 
Identifying the key targets of CNVs is challenging because of the large size of copy number 
alterations and a large number of genes residing in the altered regions. To find the driver 
oncogenes, tumor suppressor genes and key targets of CNVs in MCL, we analyzed the 
genes residing in recurrent CNVs in 48 MCL cases of cohort-B and discovery cohort, 
combined with the genes harboring SNVs/indels in 67 MCL cases of the three cohorts. We 
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detected and studied the following lists of genes: (i) the genes were residing in the MCRs 
of recurrent CNVs; (ii) the genes which were frequently mutated in the three cohorts (SNVs 
and CNVs); (iii) the genes were harboring homozygous mutations (two mutated alleles or 
one mutated and one deleted alleles). By integrating the results from analyses of CNVs and 
SNVs, we identified driver oncogenes and tumor suppressor genes that were targeted by 
SNVs and CNVs or recurrent CNVs in MCL.  
The copy number segments and their rate of recurrence were obtained using GREVE 
(Cazier, Holmes, and Broxholme 2012). GREVE detects the overlapping segments of the 
recurrent CNVs and uses the Poisson binomial distribution P-value to test the probability 
of an event happening in the same region based on the individual frequency on a 
chromosome (C_P) and genome-wide (GW_P). In addition, GREVE assigns scores for the 
matching regions by dividing the number of samples with the alteration by the total number 
of samples (Cazier, Holmes, and Broxholme 2012). Using the results obtained by running 
GREVE, the events which were recurrent in a minimum of five patients were selected. 
Then, we used UCSC table browser (W. J. Kent et al. 2002) to extract the genes reside in 
the regions of recurrent CNVs. To narrow the search to the most relevant regions and the 
potential targets of CNVs, we computed the intersections between the two list of genes 
detected in this study and were harboring recurrent SNVs and CNVs in 48 and 67 cases of 
MCL, respectively. Furthermore, we detected and studied genes which harboring focal 
amplifications, ALOH, NLOH, homozygous deletions, and biallelic mutations to identify 
oncogenes and tumor suppressor genes in MCL. Biallelic mutations were defined as 
mutations of both alleles of a gene and total loss of the reference allele. We used VAF 
measures of the somatic SNVs/indels and extracted biallelic variants based on a certain cut 
off (VAF>0.70). Variants with VAF>0.70 can be results of the following events: (i) 
mutations in single X chromosome of males, (ii) two alleles harboring SNVs/indels, (iii) 
one allele harboring SNVs/indels and the second allele harboring a homozygous deletion, 
heterozygous deletion, or LOH, and (iv) Copy number gain of the mutated allele (3n 
mutated allele: 1n reference allele).  
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 Filtering of the overlapping indels and CNVs 
Because we used exome sequencing data for the detection of both CNVs, SNVs, and indels, 
it is possible to have overlaps between the detected lists of indels and CNVs. These 
overlaps can be the source of false discoveries when detecting the potential driver genes 
based on a combined analysis of CNVs and SNVs/indels. About 71% of the detected indels 
were in cases of cohort-Z which was not included in analyses of this chapter. To eliminate 
the potential false discoveries that may be caused by the rest of the overlapping indels, we 
removed the CNV/LOH calls which were based on single SNPs. The remainder was a list 
of 131 indels with the largest size of 43 nt. We used this list of indels to check the potential 
overlapping events in the final list of candidate genes.  
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3.3. Results 
 Landscape of somatic copy number variants in MCL 
Expectedly, we observed unstable genomes associated with high numbers of CNVs in most 
cases of MCL. The previously published cohort harbored CNVs in 92% (24 of 26) of the 
cases (Beà et al. 2013). The number of CNVs in cases of discovery cohort was larger than 
cohort-B possibly because of the differences between the quality of the data and the 
methodologies that were used (SNP array and exome sequencing for cohort-B, and exome 
sequencing for discovery cohort). The WES data mostly covers exon sequences and 
therefore, the CNV calls from WES data contain more break points, and a higher number 
of CNVs compared to the CNV calls from SNP array. In addition, low tumor purity and 
high technical noise can also increase the number of false positives. Overall, 48 cases of 
MCL were harboring 792 alterations including 466 alterations with a mean value of 22.2 
per patient for the 22 cases of discovery cohort and 326 alterations with a mean value of 
12 for the 24 cases of cohort-B (Figure 3.1). Chromosomal gains and losses were equally 
common (n=136 and 159 in 20/21 and 22/21). Alterations of chromosomes 2, 6, 14 and 22 
were higher in the discovery cohort compared to cohort-B because of the large numbers of 
CNVs detected in the immunoglobulin (IG) loci. Overall, except the higher rate of 
alterations in the cases of discovery cohort, we did not detect any major disagreement 
between the data of the two cohorts. (Beà et al. 2013). 
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Figure 3.1. The numbers of copy number alterations in each chromosome.   
The rest of alterations were included 106 neutral copy number LOH (NLOH), 34 amplified 
copy number LOH (ALOH), 13 homozygous loss, and 19 amplifications. The size 
distribution of CNVs was between 1bp to the length of the entire chromosome, whereas 
size distribution of ALOH, amplifications and homozygous deletions were towards the 
minimum range. The most frequent copy number gains and losses in cases of both cohorts 
were following the same typical patterns as detected previously by array-based studies of 
MCL. Frequent segmental gains and losses were detected in chromosomes 1, 3, 5, 6, 7, 8, 
9, 10, 11, 12, 13, 17, 18 and 22 (Figures 3.1 and 3.2). The most frequently altered regions 
of the 48 cases of MCL were namely, losses of 1p13.3-22.3 (49%), 13q14.2-34 (35%), 
11q22.1-23.2 (33%), 17p13.1-.3 (22%), 6q (20%), 9p21.3 (20%), 12p13 (18%), 10p13-15 
(18%), 9p (16%), 1q22 (15%), 1p36.12 (13%) and gains of 3q21.3-29 (47%), and 8q22.2-
24.3 (27%), 7p15-22 (20%), 18q (22%), 10p12.1 (20%), 5p15 (16%) and 12q14-21(16%) 
(Table 3.1, Figures 3.2 and 3.3).  
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Figure 3.2. Circos plot of the CNVs and LOH events in 48 cases of MCL. 
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 Integrated analysis of recurrent somatic CNVs and SNVs of MCL 
We detected about 330 regions (140 MCRs) harboring recurrent copy number gains and 
deletions in the minimum of five patients. We extracted 9243 genes and noncoding RNA 
which was in the recurrently gained and deleted regions, and we analyzed only the genes 
located in MCRs. Then we obtained the intersect of genes residing in the regions of 
recurrent CNVs (N=9243) and genes harboring somatic SNVs. We identified a total of 
2288 genes including known and the novel candidate driver genes of chapter 2 which were 
targets of both SNVs and CNVs in the MCL cohorts. Supplementary Table 3.1 shows some 
of these genes. Table 3.1 shows regions of recurrent CNVs in the two MCL cohorts and 
the genes located in these regions. For each region, two additional lists of genes were 
included. Namely, genes harboring coding variants, and genes harboring non-coding 
variants. A combined analysis of gene expression data is necessary to support the 
phenotypic effect of CNVs on these genes, explore their roles in the development of MCL. 
Table 3.1. Somatic CNVs that were recurrent in minimum of five patients in 48 
cases of MCL. 
See “Metadata_AMohajeri.” 
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Figure 3.3. Venn diagram shows the intersection of somatic CNVs and SNVs in 
cases of MCL. 
The results of MCR and combined analysis were comparable with the findings of the SNP 
array and gene expression studies of MCL. For example, our results showed focal gains 
and deletions harboring the known drivers of MCL such as deletions of SP100 (2q37.1), 
CDKN2A (9p21), CDKN1B (12p13.1) and gains of TNFAIP3, BMI-1 (10p120), and TERT 
(5p) (Supplementary Table 3.1 and Table 3.1). The combined analysis also resulted in 
identification of the known drivers of MCL, such as ATM, MLL2, BIRC3, TP53, RB1, 
which  were enriched in both CNVs and SNVs (Hartmann et al. 2010; Salaverria et al. 
2007; Thelander et al. 2008; X. Wang, Ding, and Meng 2015; W. Yu et al. 2003). 
Moreover, we identified several novel targets of recurrent CNVs and candidate drivers of 
MCL, including (i) the significantly mutated genes reported in the previous section of our 
study (S1PR1, PTPRD, SYNE1, SP140, DPYD, HNRNPA2B1), (ii) genes that are involved 
in pathogenesis of other types of lymphoma such as PRDM1, HACE1, TNFRSF11A, 
PIK3C2G, SAMHD1, HDAC1) or reported by previous studies that are differentially 
6955 5829 
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expressed in MCL or other types of B-cell lymphoma (IL6, CARD11, TERT, ROBO2, 
DGKG, ARHGAP29, and SLC5A1, PIP4K2A) (Appe et al. 2016; Hartmann et al. 2010; 
Nishiu et al. 2004; Salaverria et al. 2007; Thelander et al. 2008; X. Wang, Ding, and Meng 
2015; W. Yu et al. 2003) and (iv) genes without any established relevance to the biology 
of lymphoma (such as CACNA1B, CACNA2D3 and SVEP1). We identified amplification 
and SNVs in the following genes: TERT (5p15.33), PIP4K2A (10p12.2), CARD11 
(7p22.2), TNFRSF11A (18q21.33), and PARD3 (10p11.21), PIK3C2G (12p12.3), PDE3A 
(12p12.2), EPS8 or PTPRO (12p12.3), PEAK1 (15q24.3), SP1 (12q13.13), IL6R and 
PI3KCA (Supplementary Table 3.1). Additionally, we identified focal deletions of several 
potential TSG such as SVIL, SMARCB1, MEF2B, ETV6, NOTCH4, HLA-DQA1, PRDM1, 
SP140, HACE, SF3B5, HDAC2, BCLAF1, IFNGR1, CD58, SKA3, HNRNPA2B1 (Table 
3.1). 
Biallelic alterations in MCL 
We found 275 biallelic mutations with VAF of >0.7 in 206 genes and 56 patients excluding 
the IG loci that are highly polymorphic. Chromosomes X, 22, 1, 2, 14, 6 and nine were 
harboring the highest number of homozygous mutations. 56 of 206 genes were recurrently 
mutated in the cases of MCL such as LOXL2, LAMA2, PCDH11X, ROBO2, OPHN1, 
DNAH9, and LUZP4. The genes, DNAH9 and LUZP4 were two of the significant genes 
identified in the previous section. Among 56 genes, there were the known targets of 
mutations in MCL, namely ATM, TP53, BIRC3, and SMARCA4, harboring biallelic and 
recurrent mutations. Deactivating mutations of both alleles of ATM, TP53, and BIRC3 are 
common in MCL (Bea et al. 2009; Lozano-Santos et al. 2017). We also found few 
mitochondrial genes and miRNA such as MT-CO1 and MIR3648 with biallelic and 
recurrent mutations. Supplementary Table 3.2 shows a list of recurrently mutated genes 
with biallelic mutations. Functional annotation clustering using DAVID clustered 184 of 
206 genes. Importantly, we found enrichment of six cellular functions including 1- immune 
response, 2- Extracellular matrix organization, ECM-receptor interactions, focal adhesion 
and PI3K-Akt pathway, 3-regulation of transcription, 4- protein phosphorylation, 5- cell 
cycle and 6- regulation of GTPase mediated signal transduction.  
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Recurrent Breakpoints flanking CNVs in MCL  
The integrated analysis of CNVs and SNVs lead to the detection of two translocations 
involving 10p12.31, 13q13.1, and 11q13.3. Recurrent amplifications are common in part 
of chromosome 10 in MCL. We also found focal amplification of 10p12.31 in 12% of the 
cases of MCL (Table 3.2 and Figure 3.4). Combining results of SNVs and CNVs, we found 
five genes (NEBL, MLLT10, PIP4K2A, KIAA1217, and ARHGAP21), which were 
located in the region of focal amplifications and were harboring SNVs in the three cohorts. 
MLLT10 (myeloid/lymphoid or mixed-lineage leukemia) was located at the recurrent 
breakpoints of amplifications. MLLT10 is an oncogene and frequent target of 
translocations in hematopoietic malignancies (Bond et al. 2016; Burillo-Sanz et al. 2017; 
Othman et al. 2014; Othman, Vujić, et al. 2015). Translocations of MLLT10 involve 
various fusion partners and give rise to fusion oncogenes that are associated with poor 
outcome of cancers (Bond et al. 2016; Brandimarte et al. 2013; Burillo-Sanz et al. 2015; 
Lo Nigro et al. 2013; Othman, Melo, et al. 2015). Focal amplifications are sometimes 
indirect evidence for the presence of translocations and fusion oncogenes. To test if the 
focal amplifications of 10p12.31 are results of translocations or giving rise to fusion 
oncogenes involving MLLT10, we analyzed sequencing reads covering the breakpoints of 
this region in one of the cases of discovery cohort. We searched for potential chimeric reads 
mapped to MLLT10 locus (21,863,580-22,072,560). Chimeric reads are a group of 
sequencing reads that are mapped to distinct regions of the genome and are indicative of 
SVs. Importantly, we detected two clusters of chimeric read pairs that were mapped to 
chr10-MLLT10 and chr11-ORAOV1 loci (Supplementary Table 3.3). The first set of reads 
were mapped to the forward strand at MLLT10 locus and revered strand at ORAOV1 locus 
whereas the second cluster of reads was mapped to the reverse strand at MLLT10 locus 
and forward strand at ORAOV1 locus. The positive orientation mapping of the chimeric 
read pairs indicates a complex chromosomal rearrangement including inversion of one of 
the two affected regions (MLLT10 and ORAOV1). Notably, MLLT10 and ORAOV1 are 
oriented in the opposite directions of the genome and are transcribed from the forward and 
reverse strands of the genome, respectively. Thus, an inversion is necessary for a functional 
fusion gene involving MLLT10-ORAOV1. Both clusters of reads supported the same 
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breakpoints at intron-11 of MLLT10 (21969608) and the first intron of ORAOV1 
(69489601) fusing the 5’ start of ORAOV1 to the 3’ end of MLLT10 (Figure 3.5 and 3.6, 
and Supplementary Table 3.3). Interestingly, we found third and fourth clusters of chimeric 
reads in the same patient which were mapped close to the first two clusters of reads. The 
third and fourth clusters were mapped to intron-1 of ORAOV1 and intron-4 of STARD13 
(based on GRCh37) or RP11-141M1.3 (based on GRCh38) at chr13 indicating a 
translocation affecting these regions (Figure 3.5 and 3.6). The third cluster of reads was 
aligned to the forward strand in both target sites whereas the fourth cluster was aligned to 
the reverse strand in both sites. Therefore, the second fusion event was also in agreement 
with the orientation of transcription which was the same for both genes. The reads of both 
clusters consistently supported two break points at genomic coordinates of chr11:69489527 
and chr13:34026947 fusing the 5’ start of RP11-141M1.3 to the 3’ end of ORAOV1. The 
breakpoint of the two translocations in ORAOV1 was only 74 nucleotides apart. We did 
not find any chimeric read pair that supports translocation between chr10 and chr13. This 
indicates that the two rearrangements are two separate events and possibly occur in separate 
chromosomes and or in different subclones. 
The focus of this study was analyzing somatic SNVs, indels, CNVs, and pathways. 
Nevertheless, SVs (structural variants) also play important roles in the development of 
cancers such as MC. MCL has often had an unstable genome and one of the highest levels 
of chromosomal imbalances among lymphomas. In addition, the key event of this type of 
lymphoma involves translocation of CCND1 (Ott et al. 1997). There is a lack of sequencing 
studies with a focus on SVs in MCL. Therefore, it is likely that using sequencing studies 
on MCL for detecting SVs reveals driver genes and alterations that were not detectable by 
the previous methods. 
 
Table 3.2.  The CNVs with recurrent breakpoints at 10p12. 
Chromosome Start End Case ID Type of event 
chr10 21828550 23356686 M020-PB Gain 
chr10 22045497 22045497 40_T1 LOH 
chr10 22193422 25755866 138_T1 Gain 
chr10 22602820 22705943 M001-PB Gain 
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chr10 22635442 23408139 39_T1 Amp 
chr10 21061431 25691351 M010-PB Amp 
 
 
Figure 3.4.  The breakpoint of the recurrent deletions of 10p12.31. 
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Figure 3.5. IGV view of the chimeric reads at the breakpoint of MLLT10 and ORAOV1.
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Figure 3.6. Inversion and fusion involving ORAOV1 and MLLT10, and 
translocation involving ORAOV1 and chr13  in one case of MCL    
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3.4. Discussion 
In this chapter, we analyzed CNV data from 48 MCL cases to identify targets of the 
recurrent events that are still unknown. Integrating copy number data and expression data 
is a commonly used method for CNV analysis. However, this approach was beyond the 
scope of this study. Therefore, we limited our analysis to the genes in the focal deleted and 
amplified regions and, for the larger commonly altered regions, we combined the SNV and 
CNV data to identify key targets of recurrent CNVs that contribute to the development of 
MCL. Remarkably, integrating the somatic CNV and SNV data improved detection of the 
target genes and narrowed down the long lists of genes residing in MCRs. First, we found 
that several of the recurrently mutated candidate drivers that were detected in chapter 2, 
were also located in the regions of recurrent CNVs in MCL. These genes were namely, 
S1PR1, PTPRD, SYNE1, SP140, DPYD, and HNRNPA2B1. In addition, we found bi allelic 
mutations in genes with roles in cell adhesion, extracellular matrix organization, cell 
motility and migration, such as COL4A6, LAMA2, PCDH11X, ROBO2, OPHN1 and 
DNAH9 (Supplementary Table 3.2). We also identified several novel potential oncogenes 
and TSG, and novel targets of losses, gain, and amplification in MCL, which were residing 
in MCRs of recurrent gains and deletions. Several members of these pathways were 
harboring SNVs and CNVs such as ROBO2, S1PR1, PTPRD, PARD3, CXCR5, ADCY2, 
IFNGR1 and IL6. S1PR1 and PTPRD are regulators of IL6-STAT3 (JAK-STAT signaling 
and cytokine-cytokine interactions). Nevertheless, it is necessary to confirm the differential 
expression of these genes in MCL. Overall, by using an integrative analysis of SNVs and 
CNVs, we narrowed the large list of genes in the MCRs. However, because of the large 
size of MCRs and large number of SNVs, the final list of genes was long and could still 
contain many false positives. Therefore, we integrated the results of chapter 1 and 2, with 
chapter three, to distinguish the driver genes from false positives and passenger events by 
looking at the most affected gene ontologies and pathways.  
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Chapter 4.  
 
Pathways targeted by SNVs and CNVs in MCL 
I wrote the entire chapter 4, prepared all the figure and tables, performed all the analysis 
and obtained the results for this chapter. The analysis of this chapter was designed by 
myself, Dr. Steidl, and Dr. Morin. I used the list of somatic SNVs/indels and CNVs as the 
input for the downstream analyses of this chapter.  
4.1. Introduction 
In the previous sections, we studied somatic SNVs and CNVs in cases of MCL and 
identified several novel candidate drivers. Using the previous approaches, we identified 
several novel candidate drivers that had mutations with patterns specific to tumor 
suppressors and oncogenes. We also identified two lists of genes which were harboring 
rare mutations, recurrent non-coding/non-truncating or both SNVs/indels and CNVs. 
Because of the limitations of VEP annotations, and a large number of genes residing in the 
CNVs, it was impossible to distinguish the drivers in the two list of genes. In this chapter, 
we used a third approach to complement the results of the previous chapters and detect the 
key targets of somatic alterations in MCL in a global view of gene networks and molecular 
pathways. We studied over representation of members of pathways and gene ontology in 
the list of somatic SNVs in 67 cases of MCL and the list of genes residing in the regions 
of recurrent gains and deletions in 48 cases of MCL. Somatic driver SNVs and CNVs 
induce hallmarks of cancer by causing alterations in protein function, expression, and 
interactions which lead to dysregulation of the associated cellular processes. Identifying 
the affected pathways can offer novel targets for therapeutic approaches.  
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4.2. Materials and Methods 
 Identification of driver pathways in MCL 
Pathway enrichment analysis was performed to identify altered driver pathways that are 
targets of rare and recurrent somatic SNVs and recurrent somatic CNVs. Detecting the 
significantly mutated pathways can lead us to a better understanding of the mechanism of 
MCL development. The pathway analysis was performed separately for each list of genes 
(genes with SNVs and genes with CNVs) as mentioned below.   
 Pathways enrichment analysis in list of somatic SNVs 
The list of Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways was used for 
this analysis  (Kanehisa et al. 2012). The list of pathways included four of five KEGG 
molecular networks including pathways in “Metabolism,” “Genetic Information 
Processing,” “Environmental Information Processing,” “Cellular Processes,” “Organismal 
Systems,” and “Human Diseases.” The list of KEGG pathways consisted 26187 
interactions between 7076 genes and 306 pathways. Significant pathways were determined 
by Oncodrive-fm pathway FM-biased analysis with a threshold of 10 mutations per 
pathway. Using an in-house Perl script, VEP annotations, and SIFT and PolyPhen scores, 
the highest FI score was assigned to missense, nonsense, frame shift, translation start site 
and splice site variants, and the lowest FI score to the rest of mutations. FDR =< 0.06 was 
determined as the cut off for selection of significant pathways. Using the list of somatic 
SNVs/indels from chapter 2 and the list of pathways from this chapter, we detected the 
mutated genes for each pathway. The rationale for including all the highly mutated 
pathways in the downstream analysis, regardless of their FM-bias and significance, was 
Oncodrive-fm detects pathways based on the functional impact of mutations on the proteins 
using the variants affect prediction tools. Using tools and databases that predict functional 
impact of variants on the protein solely based on the amino acid changes such as SIFT and 
PolyPhen, down-weight significance of the driver mutations that function through other 
mechanisms. Therefore, it is likely that some of the driver pathways did not reach the level 
of significance. Finally, we extracted the recurrently mutated genes (Number of cases>=2) 
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with relevant functions to mechanisms of metastasis, dissemination, and invasion by using 
VarElect (Stelzer et al. 2016). The VarElect algorithm facilitates using the wealth of 
information available on genes in GeneCards and 120 gene-centric databases. This tool 
identifies the genes that directly and indirectly match user’s keywords of interests and 
calculate a score based on the overlaps between the phenotype keywords and each gene. 
Stelzer et al. (2016) described in details how the score of genes are calculated. Using this 
tool, we can distinguish potential driver genes that are harboring causal mutations among 
long lists of genes.  
 Gene ontology and pathway enrichment analysis in list of somatic 
CNVs 
We used the list of genes extracted from MCRs for this analysis. We performed pathway 
and gene ontology enrichment analysis using DAVID (Huang, Sherman, and Lempicki 
2008, 2009) to identify the significantly enriched pathways in the regions of recurrent 
CNVs.  
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4.3. Results 
 Pathways targeted by somatic SNVs/indels in MCL 
Results of Oncodrive-fm revealed 92 significant FM-biased pathways (FDR <0.06). We 
extracted the mutated genes for all the pathways included in this analysis. Supplementary 
Table 4.1 shows the list of significant pathways and their mutated (only non-synonymous 
coding) genes and the rest of the pathways that had a minimum of ten mutations but did 
not pass the statistical significance. A large number of significant pathways was due to the 
redundancies and overlaps between the four networks of KEGG pathways and among the 
pathways of each category. For example, 35% of the significant pathways were disease 
associated maps which had overlapping genes with each other and with cellular pathways 
such as “melanoma,” “breast cancer,” “colorectal cancer,” and “pathways in cancer.” Table 
4.1 shows a list of the most relevant and the least redundant candidate pathways after 
excluding disease associated or overlapping pathways. Expectedly, among the list of 
significantly mutated pathways were those with the established roles in pathogenesis of 
MCL, such as “cell cycle” (72% of cases), “apoptosis” (66%), “NF-kB signaling” (62%), 
“Transcriptional misregulation in cancer” (72 %) (Figure 4.1). The known frequently 
mutated drivers of MCL such as TP53, ATM, MLL2, and CCND1 are members of these 
pathways. We also identified significant pathways for which abnormal activations have 
been reported previously in MCL, but their underlying genetic alterations are unknown, 
such as “MAPK signaling”, “JAK-STAT signaling”, “ECM- receptor interaction”, “focal 
adhesion”, “Wnt signaling”, and “PI3K-Akt signaling” (Table 4.1, Supplementary table 
4.1 and Figure 4.1). Moreover, we found novel candidate driver pathways that have no 
established roles in the biology of MCL, such as “sphingolipid signaling,” “endocytosis,” 
“phosphatidylinositol signaling,” and “cAMP signaling.” Several of the candidate drivers, 
detected in the second chapter were involved in regulations of the significant candidate 
pathways such as S1PR1 (JAK-STAT and sphingolipid signaling), PTPRD (JAK-STAT 
signaling), MAP3K14 (NF-kB and JAK-STAT signaling), HNRNPH1 and SP140 
(regulation of transcription and translation), FAT1 (Wnt signaling), LRP1B, TTN, DST, 
LRP1B, ADAM30 and DNAH9 (cell adhesion and ECM-receptor interactions). Overall, the 
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significantly mutated pathways had roles in regulation of four main cellular functions, 
namely cell cycle, cell death, cell survival, inflammatory responses, immune surveillance, 
cell interactions with TME, focal adhesion, cytoskeleton rearrangements, cell migration, 
and regulation of transcription and translation (Table 4.1, Supplementary table 4.1 and 
Figure 4.1). Importantly, about 50% of the significant pathways had roles in signal 
transduction and interactions of cells with the environment. We analyzed the FM-biased 
signaling pathways further by extracting the intersection between the list of SNVs/indels 
and the mutated pathways. Mutations were recurrent in various components of signal 
transduction such as first messengers (ligands), signal transducers (cell surface receptors), 
primary effectors, and secondary effectors. For example, several of the significant 
pathways were harboring mutations in the genes encoding receptors such as “endocytosis,” 
“chemokine-chemokine interactions,” “ABC transporters,” “neuroactive ligand receptor,” 
“focal adhesion,” and “ECM-receptor interactions.” Various types of cell surface receptors 
were recurrently mutated in the cases of MCL, such as receptor tyrosine kinases (RTKs: 
PTPRD, PTPRN2, FGFR2, EPS8, EPHA4, EPHA3, ALK, TGFBR1); G protein-coupled 
receptors (GPCRs: S1PR1, GRM7, GRM8); cytokine receptors (TNFRSF11A, CXCR5, 
CD44, CD74); glutamate-gated ion channel (GRIN2A); axon guidance receptor (ROBO1, 
ROBO2); adhesion molecules (FLRT2, CADM2, NCAM2, FAT1); integrin receptors 
(ITGA1, ITGA8, VWF), and lipoprotein receptors (LRP1B) (Table 4.1). Cell surface 
receptors bind to specific ligands and transfer signals into the cell and induce activation of 
downstream signaling pathways which eventually result in activation of cellular responses 
such as cell proliferation, cell survival, cell death, production of signaling molecules, 
inflammatory responses, cell adhesion, cell migrations, and invasion. In addition to the 
receptors, the genes encoding the downstream intracellular signaling and effectors proteins 
were also recurrently mutations in the cases of MCL. These genes were members of the 
significant signaling pathways, such as “proteoglycans in cancer”, “focal adhesion”, 
“ECM-receptor interactions”, “endocytosis”, “sphingolipid signaling”, “GnRH signaling”, 
“calcium signaling”, “cAMP signaling”, “cGMP-PKG signaling”, “phosphatidylinositol 
signaling”, “JAK-STAT signaling”, “MAPK signaling”, “PI3K-Akt signaling”, “Rap1 
signaling”, “Ras signaling”. Also, five of the pathways, namely “cytokine-cytokine 
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receptor interaction,” “axon guidance,” “regulation of actin cytoskeleton,” “Adherens 
junction,” and “Gap junction” were frequently mutated in the three MCL cohorts but failed 
the statistical significance tests. Remarkably, the mutated signaling pathways were part of 
a large interacting network that regulates mechanisms of cell migration. We used VarElect 
on the list of recurrent mutations that was obtained in chapter 2 to identify genes with roles 
in mechanisms of cell migration. The results showed that about 50% of the recurrently 
mutated genes were associated with the terms related to the mechanisms of cell migration 
(Supplementary Table 4.2). Overall, the results of pathway analysis of SNVs/indels for the 
cases of MCL showed significant bias towards the accumulation of high functional impact 
mutations in genes that regulate cell interactions, adhesion, and migration.  
Table 4.1. The list of the candidate driver pathways significantly mutated in the cases 
of MCL (q-value <0.06). 
Pathway q-value N patients % genes 
N  
SNVs/ 
indels 
% patients 
Apoptosis 1.14E-40 9 0.049 9 0.13 
Transcriptional misregulation 5.47E-31 8 0.045 8 0.12 
NF kappa B signaling 9.48E-30 9 0.076 9 0.13 
Cell cycle 2.07E-28 10 0.073 12 0.15 
Homologous recombination 1.20E-17 5 0.122 5 0.07 
TNF signaling 2.74E-13 8 0.053 8 0.12 
Thyroid hormone signaling 1.86E-12 14 0.107 14 0.21 
Sphingolipid signaling 2.21E-08 12 0.074 14 0.18 
Lysine degradation 2.71E-08 7 0.136 11 0.10 
Wnt signaling 2.71E-08 5 0.035 10 0.07 
MAPK signaling 1.72E-07 19 0.090 25 0.28 
B cell receptor signaling 8.19E-07 10 0.108 11 0.15 
Proteoglycans in cancer 1.32E-06 13 0.067 14 0.19 
NOD like receptor signaling 2.65E-05 9 0.103 12 0.13 
Phospholipase D signaling 3.86E-05 14 0.090 16 0.21 
Adipocytokine signaling 4.51E-05 12 0.155 13 0.18 
PI3KAkt signaling 6.91E-05 26 0.090 39 0.38 
Oxytocin signaling 0.0002 18 0.113 21 0.26 
ABC transporters 0.0004 10 0.227 12 0.15 
Focal adhesion 0.0005 15 0.087 21 0.22 
Jak-STAT signaling 0.0007 8 0.050 8 0.12 
Hedgehog signaling 0.0015 8 0.174 8 0.12 
Circadian entrainment 0.0015 19 0.177 21 0.28 
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Ubiquitin mediated proteolysis 0.0021 9 0.080 14 0.13 
Phosphatidylinositol signaling  0.0025 14 0.137 15 0.21 
Insulin secretion 0.0030 13 0.126 15 0.19 
Chemokine signaling 0.0054 10 0.053 14 0.15 
Estrogen signaling 0.0085 12 0.118 17 0.18 
AMPK signaling 0.0097 13 0.104 16 0.19 
cAMP signaling 0.0155 20 0.094 22 0.29 
Inositol phosphate metabolism 0.0207 11 0.153 12 0.16 
GnRH signaling 0.0207 10 0.098 10 0.15 
Endocytosis 0.0218 18 0.073 25 0.26 
Notch signaling 0.0255 9 0.188 14 0.13 
Glucagon signaling 0.0274 14 0.126 15 0.21 
Prolactin signaling 0.0277 4 0.054 4 0.06 
ECM receptor interaction 0.0480 13 0.169 17 0.19 
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Figure 4.1. The signaling pathways with roles in cell migration were mutated in the 
cases of MCL.   
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Figure 4.2. List of pathways significantly enriched in somatic SNVs detected in 67 
MCL patients. 
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89 12 M002_Tonsil ..;TP53CCND1;..MLL3;MLL2.. .. .. .. ..IL13RA2.. .. ..;HGS;HLA-C*.. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. ..
153 0 M009 BRCA1BIRC3STAG2;CCND1.. ..BIRC3.. .. BRAFBRCA1;LPAR4;COL6A6.. BRAF .. ..ARRB1;FAM21C;BRAF;COL6A6.. .. .. BRAF .. BRAFLPAR4..LPAR4.. .. .. .. .. .. ..ARRB1;BRAFARRB1BRCA1; IRC3;TRIP12.. .. .. ..
582 51 40_T .. .. ATM .. .. .. .. .. .. .. .. .. .. .. .. .. .. ..SLC25A5.. .. .. .. ..PRSS3;PRSS1.. .. .. .. .. .. .. .. .. .. .. .. .. ..
52 3 M007_Colon .. .. ATM .. .. .. .. .. .. .. .. .. .. .. .. .. .. ..CACNA1B.. .. .. .. .. .. .. .. .. .. .. .. ..CACNA1B.. .. .. .. .. ..
84 24 M028_PB ..TP53(2).. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. ..ABCC9.. .. .. .. .. .. .. .. ..
115 5 146_T .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. ..DLGAP1NPY2R.. .. .. .. .. .. .. .. .. .. .. .. .. ..
381 27 28_T .. ..CCND1;ESPL1;ATM..MLL2 .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. ..ANK2 .. ..GHRHR.. .. .. .. .. .. .. .. .. ..TBC1D1;.. .. ..
50 36 38_T .. ..ATM(2)WHSC1;.. .. .. .. .. .. .. .. .. .. .. .. .. .. .. ..ACSL4.. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. ..
55 20 42_T .. .. ATM .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. ..
35 23 M001 .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. ..
66 13 M019_PB ..BIRC3;..ATM .. ..BIRC3;a.. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. ..BIRC3.. .. .. ..
89 1 M027_PB_UN ..TP53(2)CCND1.. .. .. .. .. .. .. PIM1 .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. ..
63 18 61_T .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. ..VIPR2 .. .. .. ..VIPR2.. .. .. .. .. ..SOX17.. .. .. .. .. .. ..
68 1 M015_PB_UN ..MAP3K14(A67G)CCND1.. ..MAP3K14(A67G).. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. ..DLGAP1.. .. .. .. .. .. .. ..MAP3K14.. .. .. .. .. ..
57 0 M016_Spleen ..MAP3K14(G53G).. .. ..MAP3K14(G53G).. .. .. .. .. .. .. .. .. .. .. .. .. GLI3 .. .. .. .. .. .. .. .. .. .. .. ..MAP3K14GLI3 .. .. .. .. ..
45 4 M011_LN ..MAP3K14(G53G)CCND1.. ..MAP3K14(G53G).. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. ..MAP3K14.. .. .. .. .. ..
114 MCL.1500 ..MAP3K14(K54N);BIRC3;TP53.. .. ..MAP3K14;BIRC3.. .. .. .. .. .. .. .. .. .. .. .. .. .. .. ..GRM7GRM7GRM7.. .. .. ..ABCC6.. ..MAP3K14;..BIRC3.. .. .. ..
36 MCL.1177 .. .. ATM .. .. ..NOD2.. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. ..
62 MCL.1180 .. TP53 .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. PCLO .. .. .. .. .. .. FAT4 .. .. .. .. ..
73 MCL.1183 .. .. ..WHSC1.. .. .. .. .. ..IL11RA.. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. ..
243 MCL.1499 .. .. .. ..MLL5;PRDM9.. .. .. .. .. .. .. .. .. .. .. .. .. .. ..CAMKK2.. .. .. .. .. .. .. ..ABCA6.. .. .. .. ..CAMKK2;SCD5.. .. ..
101 19 128_T .. .. .. ..MLL2 .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. ..GRM8GRM8GRM8NOS1AP.. .. .. .. .. .. .. .. .. .. .. .. ..
58 2 M013_LN .. .. ATM .. .. .. .. .. .. .. .. .. .. .. .. .. .. ..DRD5DRD5 .. .. .. ..GABRB1;DRD5PRKG1.. .. .. .. .. .. .. .. .. .. .. .. ..
67 16 126_T .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. RYR2RYR2 .. .. .. .. .. RYR2RYR2 .. .. .. .. .. .. .. .. .. .. .. ..
155 MCL.1802 .. ..(2)CCND1;ATM;TFDP1.. .. .. .. .. .. .. .. .. .. .. .. .. .. .. RYR3 .. .. .. .. .. .. RYR3 .. .. .. .. .. .. .. .. .. .. .. .. CSN2
161 17 46_T ..PARP4..WHSC1.. .. ..INPP5D.. .. .. .. .. .. .. ..INPP5DINPP5D.. .. .. ..GRM8GRM8GRM8.. .. .. .. .. .. ..MAP3K6.. .. .. .. .. ..
82 17 14_T .. .. ATM;EWSR1..a;CARD11.. .. .. .. .. .. .. .. .. ..PLCE1PLCE1PLCE1;CACNA1DPLCE1;CACNA1D..PLCE1..CACNA1D..CACNA1DCACNA1D.. PYGL ..CACNA1D..CACNA1D.. .. .. .. PYGL ..
354 33 71_T ..MAP3K14(G53G).. .. ..MAP3K14(G53G).. .. ..HSP90AB1.. .. .. .. .. ..PIP4K2APIP4K2A.. .. .. .. .. .. .. .. ..HSP90AB1.. .. .. ..MAP3K14..HERC2.. .. .. ..
230 41 13_T BRCC3..CCND1;ATM;SIN3ASETDB1a;CARD11.. .. ..HSP90AB1;.. .. .. .. .. .. .. .. ..PTCH1..PTCH1.. .. .. .. ..HSP90AB1.. .. .. .. ..PTCH1.. .. .. .. ..
66 13 M026_LN .. TP53CDK4;.. .. .. .. .. ..CDK4;.. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. ..RASGRP1.. .. .. .. .. ..
854 30 47_T .. .. .. .. .. .. .. .. DLL3 .. .. .. .. .. .. .. .. .. .. .. .. .. .. ..PRSS3;NMBR;PRSS1.. .. .. OGT .. .. .. .. .. .. .. .. .. ..
265 21 25_T BRIP1.. .. ..PRDM9CARD11.. ..NOTCH1.. .. .. .. .. .. .. .. ..CACNA1B.. .. .. .. .. .. .. .. .. .. .. .. INVSCACNA1B.. .. .. .. .. ..
67 21 M031_LN .. ..ATM(2);SP1PLOD1.. .. .. SP1 .. LIFR .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. SP1 .. .. .. .. .. .. .. .. .. .. ..
82 5 M012_LN ..BIRC3;..ATM ..MLL2BIRC3;a.. .. .. .. .. .. .. ..CAPZA3..SYNJ2SYNJ2GRIN2CGRIN2C.. .. ..GRIN2CGRIN2CGRIN2C.. .. .. .. .. .. .. ..BIRC3.. ..PDHA2..
99 5 M030_PB ..IKBKB;..ATM(2)..MLL2IKBKB;a.. .. .. IKBKB.. .. IKBKB..DNAJC6.. .. .. .. .. .. .. .. .. .. .. .. .. IKBKB.. .. .. IKBKB..U E4B;WWP2.. .. .. ..
35 MCL.1184 .. .. .. ..MLL3 .. .. .. .. .. .. ..PARD3..PARD3.. .. .. .. .. .. .. .. ..PARD3.. .. .. .. .. .. .. .. .. .. .. .. .. ..
86 7 M008_PB_Pre .. ..ATM(2)WHSC1;BCL6;WHSC1.. .. .. .. .. ..BCL6; .. .. PSD2 ..INPP5AINPP5A.. .. .. .. .. .. ..GUCY1A3.. ..SLC27A5ABCA13.. .. .. KIF7HERC4..GUCY1A3.. ..
53 7 M025_LN_UN .. ..ATM(2)..MLL2 .. .. LYN ..MTOR.. .. LYN ..SMURF1.. .. .. .. ..ACACB;MTORMTOR.. .. .. .. ..ACACB;MTORABCC9.. .. ..SMURF1UBR5;SMURF1ACACB;MTOR..ACACB..
116 23 39_T ..BIRC3;..ATM(2).. ..BIRC3;a.. ..ABCB11GYS2 .. .. ..CERS6.. ..PIK3C3PIK3C3.. .. .. .. .. ..GRID2;MTNR1A.. .. GYS2ABCB11.. .. .. ..BIRC3GYS2 .. GYS2 ..
148 MCL.1501 .. ..CCND1.. .. .. .. .. .. .. .. ..GNAI1GNAI1.. .. .. ..GRIN2ANAI1;GRIN2A.. .. ..GNAI1;GRIN2ACHRNB4;GRIN2ANAI1;GRIN2A..GNAI1.. .. .. .. .. .. .. ..AK2;PFAS.. ..
99 41 33_T ...;ITPR1ATM .. .. .. .. .. ..NOS3 .. .. ..NOS3 .. .. ITPR1..ITPR1;NOS3.. .. ITPR1..ITPR1..ITPR1..ITPR1;NOS3S3 ..ITPR1.. .. .. .. .. .. ITPR1..
185 MCL.1807 .. ..CCND1;RB1..MLL3 ..CREB5NFKBIENOTCH2;RB1CREB5 PPP2R2B.. .. ..PPP2R2B.. .. .. .. ..CREB5NFKBIE.. ..SHANK2.. ..CREB5CREB5CREB5.. .. .. .. .. ..CREB5;PPP2R2B..CREB5..
239 20 138_T BARD1;..ATM(2).. .. .. .. .. .. ..S1PR1.. ..S1PR1.. .. .. .. .. .. .. .. .. ..S1PR1.. .. .. .. .. .. ..CACNA2D3CDON.. .. .. .. ..
45 12 M014_LN ..BIRC3;..ATM .. ..BIRC3;a.. .. .. ..S1PR1.. ..S1PR1.. .. .. .. .. .. .. .. .. ..S1PR1.. .. .. .. .. .. .. .. ..BIRC3.. .. .. ..
264 5 122_T .. CTSV .. .. .. .. .. .. .. ..S1PR1.. ..S1PR1.. ..DGKB.. .. .. .. ..DGKB..S1PR1.. .. .. .. .. ..LRP6;PSEN1.. ..RHOBTB2.. .. .. ..
67 7 M023_LN .. CTSL ..WHSC1;ETV6.. .. .. .. .. .. .. .. ..SMPD2;GBF1 .. .. .. ..GLP1R.. CTSL; .. ..GLP1R;GABRG2;CHRNB4;..GLP1R.. .. .. .. .. .. .. .. .. .. .. ..
75 MCL.1505 ..TRAF2;TP53E2F ; ..PLOD2TRAF2.. .. E2F3; ..IFNGR1.. ..TRAF2;EHD1.. .. .. .. ..TRAF2.. .. .. .. .. .. .. ..ABCB5.. ..TRAF2;.. .. ..PAPSS2.. ..
63 16 24_T .. .. ..WHSC1.. .. .. .. ..COL6A5.. .. .. .. ..COL6A5.. ..CACNA1CCACNA1C.. .. ..CACNA1CCHRNA9CACNA1C;SLC2A2..SLC2A2..CACNA1C..CACNA1C.. .. .. ..SLC2A2SLC2A2
120 6 M004_PB .. TP53CCND1;.. .. ..PTGS2..-ADCY9PRKAA1;..PRKAA1DCY9.. .. FLNB .. ..ADCY9;TACR3AD Y9P KAA1FLNB;ADCY9ADCY9TACR3ADCY9ADCY9;PCLOADCY9PRKAA1BCA5DCY9..FLNB;.. ..PRKAA1DCY9PRKAA1..
152 MCL.1502 ..TP53;..RB1;ATM.. .. .. .. .. RB1;ITGAV;.. .. .. ..NEDD4ITGAVSYNJ1SYNJ1.. .. ..ITGAV;.. .. .. .. .. .. .. .. .. .. IL1A; ..NEDD4.. .. .. ..
128 MCL.1810 .. .. ATM .. .. .. .. .. .. KDR .. .. .. .. KDRKDR;VWF.. ..GRIN2AGRIN2A.. KDRPPAP2AGRIN2AGRIN2AGRIN2A.. .. .. .. .. .. .. .. .. .. .. .. ..
97 32 M010_LN ..CASP8;..ATM .. .. ..CASP8..NCOA3LAM 1;COL6A6.. .. .. .. ..LAMA1;COL6A6.. .. .. .. .. .. .. .. .. .. .. .. .. .. ..PRICKLE2.. .. .. .. .. SIK2 ..
68 12 M029_PB TOP3ATP53 ..WHSC1;-.. .. .. ..NOTCH2;LAMA3;.. .. .. .. ..LAMA3.. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. ..
933 109_T RBBP8.. .. IGF1R.. ..NOD2PLCG2ADCY2;IGF1RLAMA5;I F1R;COL1A2;COL6A6..SIRT1 IGF1RADCY2ABCC1HSP 8;IGF1R;ZFYVE9L M 5;I F ;COL1A2;COL6A6P CGPLCG2SLC25A5;AD Y ;C CNA1C;PLCG2ADCY2; ACNA1CSLC2IGF1R; RHGEF12;PLCG2AD Y2;PLCG2AD Y ; ACNA1CGABRA4;RXFP3AD Y2;CACNA1CY ;SLC2A1;CACNA1CDCY2;HSPA8SLC2A1;PTPRFBCC1ADCY2;CACNA1C..HSPA8;CACNA1C.. ..SIRT1;IGF1RPOLR2B;ADCY2;POLE2ADCY2;SIRT1;S C A1..
95 8 98_T .. .. ATMMET;MLL3 .. .. .. .. METIL6ST .. .. .. METMETPIP4K2APIP4K2ACACNA1IGRIA2.. MET ..GRIA2GRIA2C CNA1I;GRIA2.. .. .. .. .. ..CACNA1I.. .. ..PDE8B.. ..
108 1 M003_PB .. CCND1.. .. .. .. .. .. .. .. .. .. ..FOLR4RASGRF1;.. .. .. .. .. .. ..SLC17A6GABRA1.. .. .. .. .. .. ..RASGRF1.. .. ; .. .. ..
70 4 M024_LN .. .. ATM;ETV5..a;CARD11..SOS2;CARD11SOS2 .. SOS2 .. .. .. .. SOS2MTMR3;PIKFYVETMR3;PIKFYVE.. .. .. SOS2SOS2 .. .. .. .. SOS2 .. .. SOS2 .. SOS2KIF3A.. .. .. .. SOS2
142 MCL.1813 .. TP53RB1;WHSC1;-MLL2TIRAP.. .. RB1;ANGPT2;FGF21;THBS2.. .. .. .. ..THBS2.. .. .. .. .. .. .. ..CRHR2.. .. .. .. .. .. ..MECOM;FGF21;NTF3LRP2 .. ..ENTPD6.. ..
73 12 M020_PB .. ..ATM(2).. .. .. .. .. ..TNC;COL9A1.. .. .. .. ..TNC;COL9A1;CTNNB1.. .. .. .. ..CTNNB1.. .. .. .. .. .. .. .. ..CTNNB1.. .. .. .. .. .. ..
660 75_T ..SPTAN1CCND1;ANAPC7WHSC1.. .. .. ..ADCY2;TNC; .. ..ADCY2;CXCR5..GBF1;DNAJC6TNC;DIAPH1.. ..ADCY2;PDE4CCPT1A..ADCY2;GRM7ADCY2;GRM7ADCY2ADCY2ADCY2CPT1A..ADCY2..RAPGEF2FAT4UBA1;ANAPC7CPT1A;ADCY2;PDE4CADCY2;CPT1A..
146 MCL.1803 .. .. .. ..OGDHL.. ..CD79B.. .. .. .. .. .. .. VWF .. .. .. .. CD36 .. .. .. .. .. .. .. CD36 .. .. .. .. .. .. CD36 .. .. ..
184 22 45_T ..CASP8CDKN2DWHSC1OGDHLTNFRSF11ACASP8.. .. .. ..CDKN2D.. .. .. VWF .. .. RYR3HTR1A.. .. .. ..HTR1A;RXFP3RYR3 .. ..PTPRF.. .. .. .. FAT4 .. .. .. ..TNFRSF11A
389 74 35_T .. ..CCND1FLI1 .. .. .. .. .. .. .. .. .. ..CHMP2BVWF .. .. .. .. .. .. .. ..PRSS3;GPR83.. PCLO .. .. .. .. .. .. .. .. .. .. .. ..
92 23 M022_LN .. ..ATM(2)WHSC1;.. .. .. .. .. VWFLEPR .. .. ..CHMP4CVWF .. ..GRM5;GRIN2AI LEPR ..GRM5GR 5;GRIN2ALEPR; M5;GRIN2AGRIN2A.. .. .. .. .. .. .. .. .. LEPR .. .. ..
922 MCL.1498 .. ..CCND1..MLL3 .. ..NFKBIENOTCH4HSP90AA1;.. ..PARD3;CXCR5..NEDD4;PARD3VWF .. ..STIM2..NFKBIERDX .. ..GABRA3;PARD3.. PCLOHSP90AA1..ABCB7;ABCA4.. APCSTK3;RAPGEF2..NEDD4..TWISTNB.. ..
1230 MCL.1808 .. ..CDC27;SMC1A..SETD1A;PRDM2;SETD2.. .. .. .. ..S1PR1.. ..S1PR1.. VWFDGKG..TBXA2R.. .. ..DGKG;PLA2G4FL 2 4FTBXA2R;S1PR1.. .. ..PPP1R3A..PLA2G4F..PLA2G4F..CDC27.. .. .. ..
108 MCL.1504 ..TP53;..;ATM .. .. .. .. ..NOTCH3;VWF;EGF COL1A2.. EGF; .. .. EGFVWF;EGF;COL1A2IPPKIPPKCACNA1SCACNA1SPP RGC1A.. EGF ..KISS1R;GRID2..CACNA1S..PPARGC1A..C CNA1S..C CNA1S;EGF;..RHOBTB1PPARGC1A..PPARGC1A..
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 Pathways targeted by recurrent somatic CNVs in MCL 
We used DAVID to run pathway and GO term enrichment analysis on the list of genes that 
reside in the MCRs of recurrent gains and deletions (Supplementary Table 2.9). The 
minimum number of nine genes had to be present for a pathway or GO term to be included 
in the analysis. DAVID calculates the enrichment scores by dividing number of genes in 
the list that are associated with a term divided by the total number of gene in that term. The 
background is calculated by dividing the total number of genes in a term by the total 
number of genes in the genome. The p-value is estimated by testing the random chance of 
association between the term and the gene list. The results showed an association of the 
gene list with 143 GO terms and pathways. Results of GO and pathway enrichment analysis 
closely resembled the significant pathways which were targeted by SNVs/indels in the 
cases of MCL. The most striking overlaps between the associated pathways and genes in 
list of recurrent CNVs and SNVs/indels were, namely JAK-STAT signaling and positive 
regulation of interleukin-6 production (LEPR, PTPN11, IL6), lipoprotein metabolic 
process (PIP4K2A, LPA, ABCA1), PI3K signaling (PIK3CG, MYLK), cytokine and 
chemokine interactions, cell adhesion and cell migration (RHOA, ARHGAP29, ITGB1 ), 
G-protein coupled receptor signaling (ADCY2, RAC2, GNA1-3) and Rho protein signal 
transduction (SPATA13, ECT2, TIAM2). SNVs and CNVs were also recurrent in 
neurotransmitters that are involved in metastasis of cancer (Entschladen et al. 2005)  
Overall, the recurrent CNVs in MCL were enriched in genes with roles in regulation of 
several main cellular function, such as (i) inflammatory and immune responses, (ii) cell 
cycle, apoptosis, senescence, telomerase activity, (iii) cellular migrations and invasion and 
(iv) inter and intracellular signal transduction (Table 4.2).  
Table 4.2. The list of over represented pathways and gene ontologies in the 
region of recurrent CNVs in MCL. 
Pathways and GO terms P-value 
Fold 
enrichment 
positive regulation of peptidyl-serine phosphorylation of STAT 
protein 7.44E-08 2.86 
natural killer cell activation involved in immune response 1.29E-06 2.71 
T cell activation involved in immune response 8.65E-06 2.47 
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acute inflammatory response 2.45E-03 2.42 
phospholipid efflux 5.90E-03 2.25 
keratinization 1.64E-08 2.21 
leukocyte tethering or rolling 1.23E-02 2.20 
Rho-Selective Guanine Exchange Factor AKAP13 Mediates 
Stress Fib Form. 2.06E-02 2.15 
replicative senescence 2.51E-02 2.15 
ER-associated misfolded protein catabolic process 2.51E-02 2.15 
response to exogenous dsRNA 2.39E-05 2.11 
intrinsic apoptotic signaling pathway in response to oxidative 
stress 1.22E-02 2.10 
hematopoietic stem cell proliferation 2.39E-02 2.05 
lipoprotein metabolic process 2.62E-05 2.03 
regulation of type I interferon-mediated signaling pathway 1.49E-03 1.98 
negative regulation of actin filament polymerization 4.55E-02 1.98 
cellular response to interleukin-4 5.32E-03 1.91 
negative regulation of cell-cell adhesion 4.15E-02 1.91 
B cell proliferation 1.32E-03 1.88 
positive regulation of mesenchymal cell proliferation 5.00E-03 1.87 
Erk and PI-3 Kinase Are Necessary for Collagen Binding in 
Corneal Epithelial 3.89E-03 1.86 
keratinocyte differentiation 4.66E-07 1.85 
tissue regeneration 3.40E-02 1.81 
Sonic Hedgehog (Shh) Pathway 4.01E-02 1.81 
Tumor Suppressor Arf Inhibits Ribosomal Biogenesis 3.86E-02 1.75 
negative regulation of adenylate cyclase activity 2.76E-02 1.74 
adenylate cyclase-modulating G-protein coupled receptor 
signaling pathway 5.31E-03 1.70 
Regulation of autophagy 5.08E-03 1.68 
positive regulation of protein kinase B signaling 6.23E-05 1.64 
humoral immune response 1.99E-03 1.61 
positive regulation of telomerase activity 4.65E-02 1.58 
JNK cascade 6.86E-03 1.58 
positive regulation of JUN kinase activity 4.13E-02 1.57 
positive regulation of epithelial to mesenchymal transition 3.67E-02 1.56 
regulation of actin cytoskeleton organization 1.65E-02 1.52 
B cell differentiation 4.04E-03 1.52 
nucleotide-excision repair, DNA incision 3.96E-02 1.51 
activation of MAPKK activity 2.49E-02 1.49 
 113 
cell-cell adhesion via plasma membrane cell adhesion molecules 1.99E-02 1.49 
Regulation of lipolysis in adipocytes 1.50E-02 1.48 
positive regulation of interleukin-6 production 3.70E-02 1.46 
cellular response to transforming growth factor beta stimulus 2.95E-02 1.46 
regulation of Rho protein signal transduction 9.47E-03 1.41 
Fc gamma R-mediated phagocytosis 1.16E-02 1.39 
regulation of cell migration 3.22E-02 1.35 
cytokine-mediated signaling pathway 6.33E-03 1.33 
ephrin receptor signaling pathway 2.89E-02 1.33 
Gap junction 2.77E-02 1.33 
positive regulation of peptidyl-tyrosine phosphorylation 3.55E-02 1.33 
Axon guidance 8.30E-03 1.32 
Cell cycle 1.23E-02 1.31 
Tight junction 1.32E-02 1.29 
Neurotrophin signaling pathway 2.36E-02 1.28 
negative regulation of protein kinase activity 4.83E-02 1.27 
Jak-STAT signaling pathway 2.15E-02 1.26 
cAMP signaling pathway 8.30E-03 1.25 
adaptive immune response 4.57E-02 1.22 
Cytokine-cytokine receptor interaction 1.95E-02 1.20 
Endocytosis 3.23E-02 1.17 
intracellular signal transduction 1.89E-02 1.15 
With a p-value of =<0.05 in MCRs of recurrent copy number gains and losses. 
 
Finally, we detected a pattern of mutual exclusivity between mutations of focal adhesion 
pathway and deletions of chr1p21. Overall, our results strongly indicate that pathways 
regulating cell adhesion and migration were frequently altered in the cases of MCL.  
Concordance and mutual exclusivity of somatic SNVs and CNVs in MCL 
Finally, we searched for patterns of concordance and mutual exclusivity among the 
candidate driver genes and significant pathways that were the targets of recurrent CNVs 
and SNVs in the 67 MCL cases. Patterns of mutual exclusivity and concordance of 
alterations help to identify the genetic alterations that function via the same pathways, or 
two completely different pathways. We detected concurrence and mutual exclusivity 
between CNVs, SNVs and pathways, and associations between clinical parameters and 
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genetic alterations. The most notable co-occurrence of CNVs and SNVs were as follows: 
(i) del-1p21 and del 9p, (ii) del 2q and diffuse structure and blastoid subtype, and (iii) 
mutations of WHSC1 and gain of chr3 (Figure 4.3). Patterns of mutual exclusivity were 
observed between (i) del 1p21 and focal adhesion and (ii) gains of 10p and deletions of 9q. 
The abundance of deletions of 1p21 in cases of MCL with mutations of IGHV was also 
noticeable. Cases harboring deletions of 1p21 included 100% (13 cases) SOX11 positive 
phenotype and 78% (11 of 14) unmutated IGHV. Interestingly, 75% of the MCL cases (6 
of 8) with diffuse structure, 22% (2 of 9) of MCL cases with modular structure and 16% 
(1 of 6) of MCL cases with mantle zone structure had deletions of chr1p21. Moreover, 52% 
(14 of 27) of classical cases, 80% (4 of 5) of blastoid cases and 0% (0 of 4) of small cell 
cases were harboring del of 1p21. The site of the tumors between the two groups did not 
show a noticeable difference (45% of PB and 42% LN) except extranodal MCL cases 
which were more abundant in the group with the deletions (80% of extranodal cases). We 
will discuss some of these patterns in greater detail in the discussion.
 115 
 
Figure 4.3. The most recurrent CNVs in MCL and clinical features of patients. 
Abbreviations: Low (L), High (H), Mutated (M), Un-mutated (U), Lymph node (LN), Peripheral Blood 
(PB), Spleen (Spl), Colon (Col), extra nodal (N), Classic(C), SC (Small cell), Blastoid (B), Diffuse (D), 
Nodular (N), Mantle zone (MZ), P (positive), N (Negative). Colors in the CNV plot: (Blue=Heterozygous 
loss, Red=Copy number gain, Black: Homozygous loss, Green= NLOH, gray=data unavailable) 
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M014 1 0 0 0 3 0 0 0 0 0 0 0 0 0 0 0 0 3 0 0 0 1 0 0 3 1 0 0 0 0 0 0 0 - - P U LN C - NA
M020 1 0 0 3 0 0 0 0 0 0 0 3 0 0 0 0 0 0 1 3 1 0 0 0 0 1 0 0 0 3 0 Y Y - - P U PB C - NA
M012 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 Y - - P M LN C - NA
13 1 1 0 2 0 0 0 0 0 3 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 3 0 3 0 0 Y - M - L - - - NA
42 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 3 3 0 3 0 Y - M - L - C N NA
28 1 1 # 0 0 3 0 0 0 0 0 0 0 1 3 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 0 Y - F - H - C D L
MCL.1501 1 - - - 3 - - - - - - - - - - - - - - - - - - - - - - - - - - 0 0 - - - - L St - - NA
M025 1 0 0 3 0 0 0 1 1 0 0 0 0 S 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Y - - P L LN C - NA
40 1 0 # 0 0 0 0 0 0 0 0 0 0 0 0 ? 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 1 0 y - M - H - C N L
M007 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 Y - - P U Col C - NA
M031 1 0 0 0 0 0 1 0 0 0 0 0 0 3 # 3 0 0 1 0 1 0 0 0 0 1 3 0 0 0 0 0 0 - - P U LN B - NA
M002 1 0 0 0 0 0 0 0 0 3 3 3 0 S # 0 1 0 0 0 0 0 1 0 0 1 3 0 0 0 0 0 Y - - P U Tn B - NA
25 1 0 # 0 0 2 0 0 0 1 0 0 0 0 0 # 1 1 3 0 0 0 0 1 0 0 0 0 0 0 0 0 0 Y - F - L N C D H
M022 1 0 3 0 0 0 0 0 0 0 0 0 0 0 # 1 0 0 0 0 0 0 0 0 3 2 0 2 0 3 3 1 1 Y Y Y - P U LN B - NA
M030 1 0 3 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 022q0 Y - - P U PB C - NA
47 1 1 3 0 0 0 0 0 0 0 0 0 0 3 1 1 1 0 3 0 0 0 0 0 0 0 0 2 2 1 0 0 1 0 Y - F - M - - D -
M028 1 0 3p 0 0 0 0 0 0 0 0 0 3 0 S 1 1 2 0 3 3 0 1 0 1 0 1 0 0 0 3 3 0 0 Y - - P U PB C - NA
33 1 0 3p 3 3 3 0 1 1 1 3 0 3 0 3 0 0 0 3 3 3 0 1 0 0 3 0 0 0 1 3 3 0 3 0 Y - M - M - C D INT
M019 1 3 0 3 0 0 0 0 1 1 0 0 0 0 3 0 0 0 0 0 0 0 1 1 1 3 1 0 0 0 1 0 0 0 Y - - P U PB B - NA
126 0 3 0 # 0 0 0 0 0 0 0 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 Y - M - L - - D -
35 1 0 # 3 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 0 0 0 0 022qY y - F - H - - D -
38 1 0 # 3 0 0 0 0 0 1 0 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 Y Y F - L - - Z -
M008 1 0 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 3 3 0 0 1 0 0 0 0 0 1 0 0 1 0 Y Y - P U PB C - NA
M023 1 0 3p 3 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 Y Y - P U LN C - NA
24 0 0 3 3 0 3 0 0 0 0 0 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Y Y Y M - H - C N L
98 0 0 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 3 1 0 1 0 0 1 Y Y - M - L - C N L
128 0 0 # 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 Y - F - L - - N -
M001 0 0 3 2 0 3 1 1 1 0 0 0 1 0 0 0 0 0 1 3 1 0 0 0 0 0 0 1 0 3 3 0 0 0 - - P U LN C - NA
M010 0 0 3 0 0 0 1 1 1 0 0 0 0 3 0 0 0 0 1 3 1 1 0 1 3 0 0 0 0 3 0 0 Y Y - - P U LN C - NA
45 0 0 3 0 0 0 1 0 0 3 0 0 0 0 ? 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 Y Y Y M - M - C N L
46 0 0 3 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Y Y F - H - - D -
M029 0 0 1 3 0 2 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 3 0 2 0 0 Y Y Y - P U PB B - NA
M026 0 0 1 0 3 0 0 0 0 0 0 0 0 0 S 0 0 1 0 0 0 0 1 0 0 0 0 0 0 1 0 0 0 0 - - P M LN C - NA
61 0 0 # 0 0 0 0 0 0 0 0 0 0 0 3 0 0 1 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 - F - L - - Z -
122 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Y - M - L - C N L
138 0 1 0 0 0 0 1 1 1 3 3 0 1 3 ? 0 0 0 1 3 1 0 0 0 0 0 0 0 1 0 0 0 Y - M - H - - N -
39 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 3 1 1 0 0 3 0 0 0 0 0 0 0 0 - M - H - C Z L
71 1 0 1 3 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Y - F - M - C N L
M015 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Y - - N M PB SC - NA
M016 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 - - N M Spl SC - NA
M004 0 5 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 3 0 Y 0 - - N M PB C - NA
M009 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 Y Y - - N M PB - - NA
M003 0 0 0 0 0 0 0 0 0 0 0 0 0 R 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 Y 0 - - N M PB SC - NA
M027 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 - - N M PB SC - NA
M024 0 0 0 0 0 0 0 0 0 3 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 0 0 0 0 0 Y 0 - - P M LN B - NA
M011 0 0 0 0 0 0 0 0 0 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 1 0 0 - - P U LN C - NA
M013 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 - - P U LN C - NA
14 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 - F - H - - Z -
146 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 - M - H - - D -
75 - - - # - 3 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - Y Y Y - M - M - C Z L
109 - - - # - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - Y Y - - F - H TC C Z L
MCL.1500 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 0 0 - - - - H Spl - - NA
MCL.1505 - - 0 - - - - 3 - - - - - - - - - - - - - - - - - - - - - - - - - - - - 0 0 - - - - L InM - - NA
MCL.1813 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - Y 0 Y - M - L LN - - NA
MCL.1180 - - 0 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 0 0 - - M - L LN - - NA
MCL.1183 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 0 0 Y - M - L LN - - NA
MCL.1184 - - - - - 3 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 0 0 - - - - L LN - - NA
MCL.1498 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - Y 0 - - - - L LN - - NA
MCL.1499 - - 0 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 0 0 - - - - L LN - - NA
MCL.1502 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - Y 0 - - - - L LN - - NA
MCL.1504 - - - - - - - 3 - - - - - - - - - - - - - - - - - - - - - - - - - - - - Y 0 - - - - H LN - - NA
MCL.1802 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 0 0 - - F - H LN - - NA
MCL.1803 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - Y 0 - - M - H LN - - NA
MCL.1808 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - Y 0 - - M - L LN - - NA
MCL.1810 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - Y 0 - - F - L LN - - NA
MCL.1807 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 0 0 - - M - H LN - - NA
MCL.1177 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 0 0 - - F - L LN - - NA
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4.4. Discussion 
Overall, the result of pathway analysis of somatic SNVs and CNVs in MCL were in 
agreement and showed enrichment of a similar set of pathways that are involved in 
functions such as regulation of cell interactions with TME, regulation of PI3K, 
inflammation, migration, and invasion. Some pathways were specifically enriched in SNVs 
such as epigenome modifiers, and some were unique to CNVs such as Rho protein signal 
transduction.  
 Alterations affecting NF-kB signaling pathways in MCL 
The results of pathway analysis for recurrent somatic CNVs and SNVs showed significant 
enrichment of canonical and non-canonical NF-kB signaling, BCR and TNF signaling. NF-
kB signaling was significantly mutated in a total of 62% cases in MCL. MCL cases were 
harboring recurrent SNVs in CARD11, MAP3K14, BIRC3 and TNFRSF11A, Recurrent 
CNVs in CARD11, BIRC3, TRAF2, and rare mutations in TRAF2. Overall, the incidence of 
SNVs in members of these pathways was higher than CNVs. Except for few cases, 
mutations of the three pathways were mutually exclusive. Notably, mutations of NF-kB 
signaling and lysine degradation were also mutually exclusive (Figure 4.3). MAP3K14 is 
one of the driver genes identified in this study which was harboring mutation hotspots in 
MCL and several other lymphoid malignancies. MAP3K14 is one of the key regulators of 
NF-kB signaling and is an oncogene in many lymphoid malignancies. Mutations of 
MAP3K14 result in constitutive activation of NF-kB. Mutations of TNF and BCR signaling 
can lead to the same phenotype. TNF and BCR signaling transduce inter cellular signals to 
the downstream NF-kB pathway which in turn activates transcription of genes involved in 
cell proliferation, survival, cytokine and chemokine production, and inflammation 
(Compagno et al. 2009; Hoesel and Schmid 2013). The role of NF-kB and BCR signaling 
in the development of lymphoma and resistance to therapy was reported previously.  
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Figure 4.4. The KEGG reference map for NF-kB signaling and the mutated 
components.  
The reference map is extracted from KEGG database (Kanehisa et al. 2012). Genes highlighted in colors 
shows the components of NF-kB, BCR, and TNF signaling pathways that were mutated in the MCL cases 
(red: recurrent truncating mutations; orange: recurrent coding and noncoding mutations, Green: Rare 
truncating mutations, Blue: rare noncoding and silent mutations).  
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Figure 4.5. Mutual exclusivity of mutations in components of NF-kB, BCR, and 
TNF signaling pathways.   
I generated the mutation plot using a cBioPortal OncoPrinter tool. The plot illustrates the list of mutated 
components of NF-kB, BCR, and TNF signaling pathways per patient that which was detected by our 
study. Y-axis is showing the percentage of the MCL cases with mutations in each gene.    
 Alterations of transcriptional regulators in MCL 
Another cellular function that was significantly mutated in our dataset was regulation of 
transcription. We detected significant enrichment of the following pathways: “transcription 
initiation from RNA polymerase II promoter,” “transcription misregulation in cancer,” 
“chromatin remodeling” and “histone modification” and “regulation of splicing” in both 
recurrent CNV and SNV in the cases of MCL. We detected recurrent somatic SNVs in 
members of these pathways such as BCOR, SMARCA4, WHSC1, MLL2 and SP140, rare 
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mutations in genes such as HDAC2 and SMURF1, and recurrent CNVs in HDAC1, 
SMURF1, and SP140. Compared to the other candidate driver pathways, a larger number 
of genes were harboring rare mutations. Except for the three genes, SMARCA4, WHSC1, 
and MLL2 which are the known targets of somatic mutations in MCL, mutations in the rest 
of the genes have not been detected previously in MCL. Notably, we spotted two patterns 
of mutual exclusivity between mutations of chromatin modifications and NF-kB signaling, 
and co-occurrence between mutations of WHSC1 and gains of chr3q. The pattern of mutual 
exclusivity might indicate that these mutations provide a similar selective advantage for 
MCL cells. Hence it is possible that NF-kB signaling is one of the pathways affected by 
changes in chromatin state. Trace of epigenetic changes in the development of MCL was 
detected previously demonstrating that chromatin state is associated with genes’ mutation 
rate (Jenny Zhang et al. 2014). A similar hypothesize applies for mutations of WHSC1 and 
gain of chr3q, and therefore these mutations might induce development and progression of 
MCL through a similar path.  
Another significantly mutated pathway with a role in post transcriptional modification is 
ubiquitin mediated proteolysis which was harboring mutations in 8% of its components in 
25% of the MCL cases. Recurrent mutations of two members of this pathway, BIRC3, and 
UBR5, were previously reported in MCL (Meissner et al. 2013). We did not detect 
recurrent mutations in UBR5 in our set of MCL cases. However, our pathway analysis 
revealed several novel targets of SNVs in MCL which were not detected with the 
approaches employed in the previous sections namely UBE4B, NEDD4, HUWE1, CDC27, 
and BRCA1. Notably, HUWE1 is a paralog of UBR5 and regulate TP53 and c-Myc. 
Ubiquitin mediated proteolysis is a mechanism that regulates protein levels post 
transcriptionally. This mechanism regulates expression of many genes such as MAP3K14 
and S1PR1. Finally, two of the recurrently mutated genes which were identified in the 
second chapter (HNRNPA2B1 and HNRNPH1) are also categorized as members of 
transcriptional regulators because of their main role in mRNA splicing. Importantly, our 
results showed that noncoding mutations tend to reside in proximity to the splicing regions 
in the cases of MCL, which suggest that splicing alterations might be prevalent in MCL.  
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 Alterations in pathways regulating signal transduction and cell 
migration 
Pathways that regulate cell interactions, adhesion, and motility, were the most frequently 
altered in the cases of MCL namely G-protein coupled receptor signaling, 
phosphatidylinositol signaling, Sphingolipid signaling, cAMP signaling, endocytosis, 
PI3K-Akt pathway, Rho signaling, ECM receptor and focal adhesion. Several members of 
these pathways were harboring recurrent CNVs and SNVs, such as S1PR1 (Sphingolipid 
signaling, GPCR signaling), MYLK2, MYLK, USH2A, SPATA13, ABL2, FLRT2 (focal 
adhesion), PIK3C2G, PLCZ1, PIP4K2A, PIK3C3, DGKG, DGKA (cAMP-PKA signaling, 
PI3K-Akt signaling, ERK-MAPK signaling), SEMA3C and B (Axon guidance), ROBO1, 
ROBO2, SLIT2, and SLITRK5 (ROBO-SLIT signaling). Mutations of members of Rho 
GTPase signaling and GPCR signaling were recurrently affected by recurrent CNVs or 
SNVs. For example, we found recurrent SNVs/indels in regulators of these pathways 
(ABL2, OBSCN, PREX2, TRIOBP, SPTBN1, DLC1, SPATA13, TRIM29, MYLK, 
ARHGAP25, ARHGAP29), recurrent gains in the key players of these pathways  (RAC1, 
GNA12, RHOA, ROCK1, RHOC), and recurrent losses in five other regulators of this 
pathway namely S1PR1, PPAP2B, GNAI3, GNAQ, S1PR3, CDC42,  MIR31, RAC2).  
Notably, alterations of members of Rho GTPase and GPCR signaling in MCL were more 
targeted by CNVs than SNVs/indels such as gains of 3q which were co-occurring with 
SNVs of WHSC and were more common in the blastoid and diffuse subtypes of MCL 
when co-occurred with deletions of 1p21. Moreover, GTPase and adhesion molecules were 
also over represented the list of biallelic mutations. Importantly, SMURF1, PIAS3, HACE1, 
FBXL19, and HUWE1, which were harboring recurrent CNVs and SNVs in the cases of 
MCL in our study, are involved in the post transcriptional modification of Rho GTPase 
(Porter, Papaioannou, and Malliri 2016). Finally, we detected a pattern of mutual 
exclusivity between mutations of focal adhesion pathway and deletions of chr1p21. 
Overall, our results strongly indicate that pathways regulating cell adhesion and migration 
are frequently altered in MCL. Evidence of the altered expression of Rho GTPase 
(ARHGAP29, and ROCK1), PI3K-AKT, ERK signaling and focal adhesion were recently 
reported in MCL (Balsas et al. 2017; Hartmann et al. 2010; Yanardağ Açık et al. 2016). 
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Also, the role of neurotransmitter in chemotaxis of leukocytes and metastasis of several 
types of cancer was previously detected (J. Y. Wu et al. 2001). 
 
Figure 4.6. Circos plot showing recurrent CNVs for five chromosomes: Chr6, 
Chr3, Chr1, Chr22, and chr7 and few of the most important 
candidate genes.  
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Figure 4.7. The circos plot of the CNV and LOH events in chr22 and the loci with 
SNVs and indels in the cases of MCL.  
Colors of labels are showing count of SNVs/indels in the mutated genes (Blue<2; 2=<Red<4; 
black: 4=<Black). 
 Mutations in AKT/WHSC1/mTORC2 signaling cascade in MCL 
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A very recent study on prostate cancer showed that overexpression of WHSC1 in 
cooperation with the loss of PTEN induces progress, recurrence, and metastasis to the 
distant sites such as lymph node and lung (N. Li et al. 2017). They found that 
overexpression of WHSC1 induces metastasis features by (i) activating a positive feedback 
loop in AKT/WHSC1/RICTOR signaling and (ii) reprogramming of the epigenome in a 
specific set of genes such as RAC1 and FOXO1 (N. Li et al. 2017). Li et al. also suggested 
a mechanism for the positive feedback loop involving AKT-mediated phosphorylation of 
WHSC1 and overexpression of RICTOR. AKT phosphorylation stabilized WHSC1 by 
preventing interactions of three ubiquitin ligases CUL4B, DDB1, and CDT2 with WHSC1. 
WHSC1 is a gene that is recurrently mutated in MCL harboring two mutation hot spots. In 
addition, our findings indicate that somatic SNVs and CNVs in MCL recurrently target 
pathways with roles in cell motility and invasion such as focal adhesion, Rho/Rac GTPase 
signaling, PI3K-Akt, mTORC signaling. Notably, RICTOR was harboring mutations in two 
MCL cases, and CUL4B was harboring a homozygous mutation in a single case. Moreover, 
we detected a pattern of co-occurrence of 3q gain and WHSC1 mutations and mutual 
exclusivity of focal adhesion and chromosome 1. ECT2 is a candidate target of recurrent 
gains of 3q which has a role in activation of RAC1. The gain of ECT2 and mutations of 
WHSC1 possibly have an activating role on RAC1 which lead to further induction of 
pathways with a role in migration. Overall, our findings suggest that activation of 
AKT/WHSC1/RICTOR is possibly one of the molecular mechanisms causing recurrence 
and dissemination of MCL.  
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Chapter 5.  
 
Conclusions, Discussion and Future Directions 
MCL is a rare, incurable and aggressive lymphoma with high relapse and mortality rate. 
The development of novel array-based and sequencing-based technologies significantly 
improved the identification of driver genes and pathways of MCL. However, the 
understanding of molecular mechanisms leading to the development of MCL is still 
limited. In this study, we aimed to improve the knowledge on molecular mechanisms 
underlying the pathogenesis of MCL by detecting significantly altered driver genes and 
pathways that were not implicated in the biology of MCL before. We performed a meta-
analysis on 67 MCL whole exome sequencing data using two previously published datasets 
(44 patients) and one novel data set (24 patients). We hypothesized that by using a 
systematic pipeline, a unified set of bioinformatics tools and a large sample size, we would 
identify driver genes and pathways that are targets of SNVs and CNVs in MCL and were 
not identified by previous studies of MCL. Our study provides a novel insight into the 
biology of MCL that can help in developing new prognostication, stratification and 
therapeutic approaches of MCL.  
We analyzed somatic SNVs, indels, and CNVs in 67 MCL cases using various approaches. 
By using Oncodrive-fm and MutsigCV, we identified nine significant genes that are 
previously known drivers of MCL, such as CCND1, BIRC3, ATM and TP53 and eight novel 
candidate drivers with no previous reports of recurrence of mutations or pathogenic roles 
in MCL namely S1PR1, SP140, PTPRD, DST, DPYD, LRP1B, FAT1, FAT4 and DNAH9. 
We also analyzed the recurrent noncoding and silent mutations which resulted in 
discovering two other potential driver genes namely MAP3K14 and HNRNPH1. We 
detected four mutation hotspots in MAP3K14 in six types of B-cell lymphoma and recurrent 
noncoding mutations in HNRNPH1. Our results suggested that these mutations result in 
the higher stability and levels of both proteins. The analysis of biallelic mutations showed 
enrichment of focal adhesion, PI3K signaling, ECM-receptor interactions and GTPase 
signaling and led to identification of several potential tumor suppressor genes. The higher 
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risk of gaining deleterious mutations in tumor suppressor genes in a single X chromosome 
in males and presence of several potential TSG with roles in cell migration in this 
chromosome might explain the higher prevalence of MCL in males than females. The 
results of pathway analysis in cases of MCL, further supported the findings of the analyses 
of CNVs and SNVs. The pathway/GO enrichment analysis of CNVs and FM-bias analysis 
of SNVs and indels in the cases of MCL, revealed similar subsets of significant pathways 
that had roles in signal transduction, cell migration and invasion, inflammatory responses, 
and transcriptional regulation. We identified several potential driver genes that were 
members of aforementioned pathways and were harboring recurrent SNVs and CNVs such 
as ARHGAP29, DGKG, PIP4K2A, PIK3C2G (PI3K signaling), MYLK, COL4A6, LAMA2, 
RAC1, S1PR1, CUL4B (cell adhesion and motility), CARD11 (NF-kB signaling) and 
HDAC2, SP140, SP1, HNRNPH1, USH2A, HACE1, NEDD4L (transcription regulation). 
5.1. Frequent alterations in pathways regulating MCL cells and 
TME interactions 
TME in B-cell lymphoma is composed of various types of normal cells such as immune 
cells, endothelial cells, and fibroblastic cell. Bidirectional interactions between tumor cells 
and tumor microenvironment is critical for development, survival, and progression of 
tumor cells. TME evolves with malignant transformation of B-cells and obtains changes in 
gene expression to support the development of hallmark of cancer (Scott and Gascoyne 
2014). Tumor cells and TME interact via ligand receptors signalings using chemokine and 
cytokines, cell surface receptors, growth factors and adhesion molecules as transducers of 
signals. Interactions between the tumor cell and TME play important roles in tumor 
development, metastasis, and resistance to therapy (Scott and Gascoyne 2014). For 
example, TME induces activation of signaling pathways that can help malignant B-cells 
survive the therapy. Also, tumor cells acquire genetic and epigenetic alterations in 
pathways and signaling molecules and receptors that regulated interactions with TME. 
TME supplies cytokines, chemokines, adhesion molecules, survival factors and growth 
factors to induce constitutive activation of signaling pathways in tumor cells to promote 
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growth, survival and malignant proliferation of tumor cells such as NF-kB and STAT3 
signaling (Scott and Gascoyne 2014). Tumor cells might also gain alterations in members 
of these signaling pathways to obtain autonomous constitutive proliferation and survival 
independent of TME. Interactions with TME are crucial for the survival and development 
of MCL cells. Studies showed that TME and the pathways operating downstream of the 
extracellular signals are involved in development, progress, invasion, and resistance to the 
therapy in MCL. Changes in tumor cells and TME are reciprocally regulated resulting in 
the adaptation of TME to the new characteristics of tumor cells that arise by genetic 
alterations. Normal cells in TME adapt to the new changes in the tumor cells and maintain 
the same phenotype. Previous studies have demonstrated the role of TME in the 
development and progression of MCL by analyzing gene expression profile of tumor cells 
and normal cells (Inamdar et al. 2016). However, the knowledge on the causal alterations 
underlying differential expressions of the associated genes is very limited. Our study 
increased the understanding of the genetic alterations that impact interactions of MCL cells 
with TME. Our findings showed significant accumulation of mutations in cell migration, 
focal adhesion, cytoskeleton organization, invasion, and signal transduction.  
 Role of NF-kB signaling in biology of MCL 
NF-kB, BCR, and TNFR signaling were three of the most significantly mutated pathways 
detected in our study harboring rare and recurrent mutations. Activations of canonical and 
non-canonical NF-kB signaling play significant roles in the development of many types of 
B-cell lymphoma (Jost and Ruland 2007). Mutations arise in various members of canonical 
and non-canonical NF-kB triggering activation of these pathways. The gene that is mutated 
and activated is related to the subtype of B-cell lymphomas. For example, mutations in 
components of non-canonical NF-kB signaling are common in MM but not in GCB-
DLBCL (Klein and Heise 2015). In our study, we detected recurrent mutations in 
components of both canonical (CARD11) and non-canonical NF-kB pathways 
(TNFRSF11A, BIRC3, and MAP3K14). Importantly, our study revealed hotspot mutations 
in MAP3K14 which were recurrent in about 10% of MCL, as well as several other B-cell 
lymphomas (CLL, SMZL, NMZL, MM, and WM), and canine B-cell lymphoma. 
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Furthermore, we showed that the silent hotspot mutations (G33G and G53G), which were 
overlooked by previous studies, likely cause aberrant MAP3K14 splicing, partial deletion 
and stability of NIK, and constitutive activation of NF-kB signaling. Our computational 
analysis predicted that the recurrent mutations in the first exon of MAP3K14 most likely 
have a driver role in the development and progression of MCL and other B-cell 
lymphomas. We further discussed the emergence of MAP3K14 hotspot mutations at 
relapse biopsies, and suggested the possible association of these mutations with relapse in 
MCL and the five relevant types of lymphoma. These mutations may have application as 
biomarkers for prognosis of the leukemic variant of MCL with poor outcome. Lymphomas 
with constitutive activation of non-canonical NF-kB signaling are resistance to ibrutinib 
which is a BTK inhibitor (M. L. Wang et al. 2013). Ibrutinib has a high response rate of 
70% and act through canonical NF-kB signaling, and therefore it can inhibit constitutive 
activation of canonical NF-kB in the cases carrying mutations in this pathway, but cases 
with alterations of non-canonical signaling are resistance to this therapy (Rahal et al. 2014). 
NIK inhibitors have been suggested as a better approach for the treatment of patients with 
activation of the noncanonical signaling pathway (Demchenko et al. 2014). Our findings 
on potential functions of clusters of mutations in the first exon of NIK indicate that these 
mutations can be used as a biomarker for predicting the outcome of therapies in MCL. In 
addition, for developing effective therapeutic approaches using NIK-inhibitors, it is 
important to consider these mutations and their potential impact on interactions of NIK 
with inhibitors.  
Constitutive activation of canonical and non-canonical NF-kB signaling has a key role in 
the development of many types of B-cell lymphoma by inducing proliferation, survival, 
and production of inflammatory factors such as TNFα, IL-6, IL-8. (Demchenko et al. 
2010). IL-6 and TNFα induce acute inflammation and results in autocrine activation of NF-
kB and IL6-STAT3 signaling, and recruitment of inflammatory cells which can further 
activate NF-kB and IL6-STAT3 pathways through extrinsic mechanisms and by secreting 
cytokines (Fan, Mao, and Yang 2013). The chronic inflammatory response is one of the 
enabling hallmarks of cancer that initiates the malignant transformation of the cell and have 
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important roles in shaping TME of MCL cells. Our findings indicate that the pathways 
involved in regulation of inflammatory responses are recurrently mutated in MCL.  
 Role of JAK-STAT signaling in biology of MCL 
Previous studies showed that IL-6 is overexpressed and STAT3 is constitutively active in 
cases of MCL which induces transcription of genes involved in inflammatory responses 
(L. Zhang et al. 2012). Our findings showed that JAK-STAT signaling, chemokine, and 
cytokine signaling were significantly mutated in the MCL cases. Genes in JAK-STAT 
pathway were more commonly altered by CNVs than SNVs in our study. This might 
indicate that CNVs are the main cause of induction of inflammatory mechanisms in MCL. 
STAT3 is a transcription factor and a member of JAK/STAT signaling pathway (Peyser and 
Grandis 2013). STAT3 is involved in regulation of diverse cellular functions and act as an 
oncogene in various types of tumor. One of the main functions of STAT3 is activation of 
inflammatory responses and expression of cytokines upon stimulation by extracellular 
cytokines and chemokines such as IL-6 (Peyser and Grandis 2013). Constitutive activation 
of STAT3 is common in cancers and induce production of pro-inflammatory cytokines, and 
proliferation and survival of tumor cells (H. Yu and Jove 2004). PTPRD and S1PR1 are 
respectively, inhibitor and activator of STAT3 (Peyser and Grandis 2013). Deactivating 
mutations of PTPRD and activation of S1P-S1PR1 signaling are two of the mechanism that 
triggers activation of STAT3 in cancers. Normal cells in TME protects MCL cells by 
secreting high levels of IL-6 cytokine which induce activation of STAT3 (L. Zhang et al. 
2012). Activated STAT3, in turn, activates production of IL-6 forming a positive feedback 
loop promoting tumor growth. STAT3 also transactivates S1P/S1PR1 leading to the same 
positive feedback loop with IL-6 (H. Lee et al. 2010). Studies demonstrated the 
S1PR1/STAT3 mechanisms is reciprocally regulated in tumor cells and TME (H. Lee et al. 
2010). If activation of STAT3 is initiated by mutations such as activating mutations of 
S1PR1 or deactivating mutations of PTPRD, TME adapt to the change in tumor cells. 
Gene-expression studies of MCL showed that STAT3 is constitutively active in about 50% 
of MCL cases with higher occurrence in leukemia cases with mutated IGHV status (Baran-
Marszak et al. 2010; Lai et al. 2003). Few alterations targeting components of STAT3 
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signaling were reported previously in MCL (Chim et al. 2003). Our analysis resulted in 
detection of recurrent SNVs and losses in S1PR1 and PTPRD, recurrent gains in IL6 and a 
single amplification in IL6R.  
5.2. Genetic alterations in MCL targeting signaling networks that 
control cell migration 
Migration and invasion of cancer cells to other tissues is a multistep process involving 
dissociation of cells from their primary tissue, breaking down the surrounding cells, cell 
migration to the new site, intravasation and extravasation, attachment to the cells of the 
new tissue, and angiogenesis (van Zijl, Krupitza, and Mikulits 2011). Tumor cells can 
invade other tissues by gaining alterations that enable the hallmarks of metastasis. MCL 
spreads throughout the body in 90% of the patients. Studies showed that interactions of 
MCL cells and normal cells in TME and cooperation of chemokines, cytokines, and 
adhesion molecules play critical roles in invasion and migration of MCL cells to other 
tissues (Rosich et al. 2014). However, the knowledge on genetic alterations and driver 
genes that cause dissemination MCL cells is limited. Our study revealed significant 
accumulation of damaging (high FI score) mutations or high number of mutations in genes 
of pathways that regulate processes of cytoskeletal rearrangements, cell migration, and cell 
adhesion in MCL, such as ECM-receptor interactions, focal adhesion, regulation-of-actin-
cytoskeleton, axon guidance, and Rap1 signaling. The most recurrent SNVs in these 
pathways were in LAMA2, COL6A6, COL2A1, CUL4A, ITGA1, ITGA8, MYLK, MYLK2, 
FLRT2 and VWF. ECM-receptor interactions and focal adhesion were also significantly 
overrepresented in the list of genes with biallelic mutations in the cases of MCL, suggesting 
a potentially key role in pathogenesis and dissemination of this disease. Notably, studies 
showed that PTPRD also regulates cell adhesion which might be the function that is altered 
by PTPRD mutations in MCL. After cells detached from the primary site, they break down 
the surrounding cells (O’Hayre, Degese, and Gutkind 2014). Alterations of epigenetic 
modifiers and PI3K/AKT and ERK signaling pathway can impact regulation of MMP 
enzymes involved in the invasion. In fact, our results showed a high number of SNVs and 
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CNVs in genes with a role in PI3K/AKT signaling. We also detected enrichment of several 
pathways that function upstream of PI3K/AKT namely phosphatidylinositol signaling, 
cAMP signaling, and phospholipase-D signaling. Alterations of these pathways can lead to 
the changes in PI3K/AKT signaling. Finally, cells migrate to a new microenvironment. Our 
results showed that pathways regulating cell migrations including PI3K/AKT, sphingolipid 
metabolism, chemokines, cytokines, axon guidance, and GTPase signaling were targets of 
recurrent SNVs and CNVs in MCL. Genes of Rho GTPase signaling were mostly targeted 
by recurrent CNVs and rare SNVs/indels in the cases of MCL (Supplementary Table 2.8) 
such as ECT2, RAC1, RHOA, ROCK1, residing in the MCRs of the recurrent gains of 3q, 
7p21, 3p, 18q21; RHOC, CDC42, ARHGAP29 and MIR31 were in the MCRs of recurrent 
losses of 1p13.2, 17p, 1p21, and 9p. RAC, RHO, and CDC42; ARHGAP25, RHOBTB1, 
and ADAM30 harboring rare mutations. Rho GTPase are the key regulators of metastasis 
in cancer and control cell movements and cytoskeleton reorganization. Mutations in Rho 
and Rac GTPase were also detected in other types of lymphoma, such as mutations of 
RHOA in ATL and AITL (Kataoka et al. 2015; Sakata-Yanagimoto et al. 2014), and 
mutations of ARHGAP25, ARHGAP32 and SEMA3A in SMZL (Martinez et al. 2014). 
Altered expressions of Rho GTPase as the result of copy number alterations were reported 
previously in a wide range of cancers (Porter, Papaioannou, and Malliri 2016). Differential 
expression of RAC, RHO, and CDC42 are associated with migration, invasion, and 
metastasis. Alterations in guanine nucleotide exchange factor (GEF) and regulators of Rho 
GTPase can also induce metastasis and progression of cancer (Porter, Papaioannou, and 
Malliri 2016). We detected recurrent SNVs and CNVs in several GEF such as SPATA13, 
PRKCQ, and ECT2. Importantly, we also detected recurrent alterations in five genes that 
regulate Rho GTPase members namely SMURF1, PIAS3, HACE1, FBXL19, and HUWE1. 
Finally, our study showed significant enrichment of GPCRs and cell surface receptors that 
are crucial for triggering cell migration. For example, we detected recurrent SNVs and 
CNVs in S1PR1, LPA, S1PR3, GNA12. Overall, these findings strongly indicate that 
alterations of these pathways are the cause of MCL invasion and migration to the distant 
sites.  
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GTPase, GPCR, and cell adhesion  
MCRs of the recurrent deletions of 1p21 were harboring loci for S1PR1, ARHGAP29 and 
COL1A11. The target of this deletion is unknown. Our findings suggest that ARHGAP29, 
S1PR1, and COL1A11 might be the targets of the recurrent deletions of 1p21. 
Downregulation of ARHGAP29, was previously detected in MCL (Hartmann et al. 2010). 
Mutations of S1PR1 and deletions of 1p21 showed pattern of mutual exclusivity. Two 
cases of MCL was harboring gains in 1p21 in a region with RHOC locus. Another case of 
MCL with two LN and PB samples had 1p21 deletions only in PB samples. In addition, 
we detected a bias in tumor site of cases with deletions of 1p21, 9p, and gains of 3q. For 
example, deletions of 1p were mostly in cases taken from organs unless they co-occurred 
with a gain of 3q which was specific to PB sample. On the other hand, cases that had a gain 
of 3q but not deletions of 1p21 were from lymph nodes. This specific pattern, strongly 
suggests that recurrent deletion of 1p21 target genes involved in migrations and adhesion 
such as Rho GTPase and adhesion molecules.  
5.3. Transcriptional and translation regulation 
In this study, we identified significant enrichment of signaling pathways involved in pre 
and post-transcriptional and translational regulations in the somatic SNVs namely, 
transcription misregulation including chromatin remodeling, histone modification and 
ubiquitin degradation (referred to as lysine degradation in KEGG database). These 
pathways were significantly mutated in more than 50% of MCL patients. With integrating 
the data for SNV, CNV and pathways analysis, we identified several novel recurrently 
mutated genes in MCL such as HNRNPH1, HNRNPA2B1, SP1, SP140, NEDD4L, PRDM9, 
USH2A, HUWE1. HUWE1, SMARCA4, and HACE1 regulate Rho GTPase. SP140 was one 
of the significantly mutated genes in our study targeted by homozygous deletions and 
damaging SNVs and indels. Notably, we observed a pattern of mutual exclusivity between 
mutations of chromatin modifications and NF-kB signaling. The mutual exclusivity 
suggests that mutations in these pathways in MCL might be targeting the same cellular 
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function and providing a similar selective advantage for the tumor cells. In addition, we 
identified several components of these pathways as potential targets of the recurrent gains 
and amplification such as NEDD4L, SP1 and TERT and targets of recurrent heterozygous 
and homozygous deletions such as SF3B5, HDAC2, and HACE1. Mutations in TERT were 
previously reported in MCL (Panero et al. 2016), and the oncogenic and tumor suppressive 
roles of some of the other genes were implicated in other lymphomas (Hait et al. 2009). 
Therefore, these mutations possibly play a part in the development of MCL as well. The 
trace of epigenetic changes in the development of MCL was also detected previously 
demonstrating that chromatin state is associated with frequency of mutations in genes in 
MCL (Jenny Zhang et al. 2014). Recurrent mutations in several members of epigenome 
modification and ubiquitin-mediated proteolysis were previously detected in MCL such as 
MLL2, BIRC3, and UBR5 (Meissner et al. 2013). Ubiquitin-mediated proteolysis is a 
mechanism that regulates protein levels post-transcriptionally. This mechanism regulates 
expression of many key regulators in other signaling pathways. For example, BIRC3 and 
NEDD4L regulate expression of key regulators of PI3K-Akt signaling, NF-kB signaling 
and sphingolipid signaling such as PIK3CA and MAP3K14 (Vallabhapurapu et al. 2008; Z. 
Wang et al. 2016). Therefore, the impact of alterations in ubiquitination factors affecting 
the crosstalk between these pathways might be of interest for future functional studies. 
Both genes and their associated pathways were highly mutated in MCL cases of our study.  
5.4. Future directions 
The present study aimed to characterize the landscape of somatic mutations and copy 
number variations of MCL to identify driver genes and molecular mechanisms that are 
involved in development and progression of MCL. Identification of new driver genes and 
pathways can lead to the development of better stratifications and prognosis markers and 
can introduce novel targets of therapies in MCL. By detecting novel molecular mechanism 
and targets of genetic alterations, we might be able to suggest potential biomarker and 
novel targets for therapies. In this study, we used frontline bioinformatics tools and datasets 
to detected somatic alterations in 67 MCL cases and to analyze the functional impact of 
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the mutations on the protein to distinguish passenger mutations from drivers. We merged 
a new cohort of 24 MCL patients with two previously published cohorts. By using a 
cohesive set of algorithms for analysing the larger samples size of exome sequencing data, 
we discovered novel driver mutations and genes that were missing from the previous 
exome sequencing studies possibly because of the low frequency of these mutations in 
MCL, low sample size of the other studies and un-appreciation for noncoding and silent 
mutations. Our integrated analysis of somatic SNVs, CNVs and altered pathways in MCL, 
revealed the significant rate of mutations in pathways that regulate malignant B-cell 
interactions with TME and four key cellular functions namely immune surveillance, cell 
migration and invasion, transcription regulation, inflammatory responses and cell survival. 
One of the most significant findings to emerge from this study is a high number of 
mutations in pathways with roles in the regulation of cell adhesion, invasion, and 
migrations such as focal adhesion, ECM-receptor interactions, Rho GTPase, GPCR, 
phospholipid metabolism in MCL. We suggest that these novel driver pathways are the 
underlying causes of the widespread dissemination of MCL and the aggressive behavior of 
this disease. Furthermore, the present study is the first to identify the activating impact of 
the noncoding and silent hotspot mutations of MAP3K14 and HNRNPH1 in MCL and other 
types of lymphoma. In addition, our findings suggest several driver genes as valuable 
candidates for the development of diagnostic and prognostic biomarkers in MCL and other 
types of lymphoma. The findings of this research provided insights for a better 
understanding of the genetic alterations, driver genes and driver pathways that are the 
underlying mechanisms of progression, invasion, and metastasis of MCL. Taken together, 
these findings have significant implications for the development of new therapeutic 
approaches and prognosis biomarkers. Moreover, the scope of this study was limited in 
terms of access to the WES data for CNV calling for the cohort-Z and cohort-B. Because 
of the low number of available cases (24) for CNV analysis, employing statistical 
approaches for detection of targets of recurrent CNVs was not the optimal approach. The 
available algorithms require minimum sample sizes to generate reliable results that were 
larger than our sample size. Lack of expression data was another weakness of our study. 
Gene expression data is a valuable source of information that can facilitate accurate 
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identification of targets of recurrent CNVs. However, integrated analysis of recurrent 
SNVs, CNVs and mutated pathways, remarkably increased the accuracy of analysis and 
produced results that were in line with findings of gene-expression based studies and lead 
to the discovery of novel genes as well as most of the previously known targets of CNVs 
in MCL. Another source of weakness in this study was using bioinformatics algorithms 
that were limited to the identification of significant genes based truncating mutations. Our 
research showed that a large number of mutated genes in our cases of MCL were harboring 
noncoding and silent mutations close to the splicing regions. This finding implicates that 
driver genes are remaining unnoticed because of lack of appreciation of noncoding and 
silent mutations. One of the strengths of this study was using multiple approaches and 
bioinformatics algorithms for analyzing CNVs and SNVs, and integrating SNV and CNV 
data for detecting the driver genes. The second strength of this project was combining three 
WES datasets that were prepared in different conditions. Using a larger sample size helped 
us to detect mutations that occur with lower frequency. In addition, by using three different 
datasets and comparing the list of variants obtained from each cohort, we could distinguish 
false positives and technical artifacts that were specific to individual cohorts. Another 
strength of the study was using publically available datasets of somatic variants to collect 
mutations that were detected previously in our genes of interest in other cancers. This 
approach assists analysis of mutations and their functions by extending the list of mutations 
in the gene of interest. Using this method, we discovered oncogenic driver mutations 
(G33G, G53G) of MAP3K14 that were detected by previous sequencing-based studies but 
their significance and recurrence are being overlooked because of the predicted lack of 
effect on the protein. In addition, the focus of sequencing-based studies is mainly on coding 
and non-synonymous mutations the challenges in predicting the function of silent and 
noncoding mutations. As a result, most of the data available in the cancer mutation 
databases such as COSMIC are lacking synonymous and noncoding mutations (Parry et al. 
2013; Jenny Zhang et al. 2014). For instance, we found G33G and G53G mutations in five 
patients, four of which were already studied by Zhang et al. (2014) and Bea et al. (2013); 
However, neither of the studies reported silent and noncoding mutations (Beà et al. 2013; 
Jenny Zhang et al. 2014) and we are the first study that identified the significance of 
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recurrent G33G and G53G mutations and the recurrence of mutations (G33G, G53G, A67G 
and A84G) in the first exon of MAP3K14. Therefore, it is likely that the silent mutations 
of G33G and G53G are more frequent in lymphoma than what was estimated in the present 
study and mutations might be occurring in a wider range of B-cell lymphomas. In addition, 
the sequencing read depth for MAP3K14 was low in our dataset and an additional novel 
MCL cohort available in Morin lab. For this reason, a further targeted sequencing study 
could assess the occurrence of MAP3K14 mutations in MCL and other types of lymphoma 
associated with activation of NF-kB signaling such as ABC-DLBCL. MM, CLL, SMZL, 
and WM have similar biology to MCL, and constitutive activation of NF-kB signaling is 
one the key events in the biology of these lymphomas. It would also be necessary to assess 
the impact of silent and not-synonymous mutations of MCL on regulatory motifs. Based 
on our results, we expect a large number of driver genes to be identified in MCL by this 
analysis. Further investigation and experimentation into the gene expression profile of the 
candidate genes are recommended.  
Finally, functional studies of the novel driver mutations, genes and pathways are necessary 
to confirm the function of mutations in the protein and the driving role of the genes in the 
development of lymphoma. The impact of clusters of mutations of MAP3K14 on splicing 
can be confirmed by RNA-sequencing of the affected cases. It is also interesting to study 
the impact of the four clusters of mutations of MAP3K14 in living cells and animal models. 
In the discussion, we hypothesized that mutations of G53G and K54N might have a 
different mechanism of function than the rest of hotspot mutations of MAP3K14. The 
mutational hotspots in MAP3K14 might have a great value in the development of diagnostic 
and prognostic biomarkers for the leukemic subtype of MCL with poor outcome. Further 
research on these mutations would improve the understanding of NIK functions and might 
result in the identification of the unknown partners and novel motifs involved in regulation 
of NIK stability. Finally, our results showed a translocation in the breakpoint between 
recurrent gains and deletions of 10p. We hypothesize that analyzing the breakpoints of 
recurrent CNVs and recurrent noncoding mutations, will result in the identification of more 
structural variants in MCL.  
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Supplementary Figure 2.1. 
Supplementary Figure 2.1. The density plots showing distribution of VAFs for 
mutations in each sample in the three MCL cohorts. 
 
0.0
0.5
1.0
1.5
2.0
0.00 0.25 0.50 0.75 1.00
variant_allele_fraction
de
ns
ity
M003
0.0
0.5
1.0
1.5
0.00 0.25 0.50 0.75 1.00
variant_allele_fraction
de
ns
ity
M004
0.0
0.5
1.0
1.5
2.0
0.00 0.25 0.50 0.75 1.00
variant_allele_fraction
de
ns
ity
M007
0
1
2
0.00 0.25 0.50 0.75 1.00
variant_allele_fraction
de
ns
ity
M008
0
1
2
3
4
0.00 0.25 0.50 0.75 1.00
variant_allele_fraction
de
ns
ity
M009
0.0
0.5
1.0
1.5
2.0
2.5
0.00 0.25 0.50 0.75 1.00
variant_allele_fraction
de
ns
ity
M010
0
1
2
0.00 0.25 0.50 0.75 1.00
variant_allele_fraction
de
ns
ity
M011
0
1
2
3
4
0.00 0.25 0.50 0.75 1.00
variant_allele_fraction
de
ns
ity
M012
0
1
2
3
4
0.00 0.25 0.50 0.75 1.00
variant_allele_fraction
de
ns
ity
M013
0.0
0.5
1.0
1.5
2.0
0.00 0.25 0.50 0.75 1.00
variant_allele_fraction
de
ns
ity
M014
0
1
2
0.00 0.25 0.50 0.75 1.00
variant_allele_fraction
de
ns
ity
M015
0.0
0.5
1.0
0.00 0.25 0.50 0.75 1.00
variant_allele_fraction
de
ns
ity
M016
0.0
0.5
1.0
1.5
0.00 0.25 0.50 0.75 1.00
variant_allele_fraction
de
ns
ity
M019
0.0
0.5
1.0
1.5
2.0
2.5
0.00 0.25 0.50 0.75 1.00
variant_allele_fraction
de
ns
ity
M020
0
1
2
3
0.00 0.25 0.50 0.75 1.00
variant_allele_fraction
de
ns
ity
M023
0
1
2
0.00 0.25 0.50 0.75 1.00
variant_allele_fraction
de
ns
ity
M024
0
1
2
3
4
0.00 0.25 0.50 0.75 1.00
variant_allele_fraction
de
ns
ity
M025
0.0
0.5
1.0
1.5
0.00 0.25 0.50 0.75 1.00
variant_allele_fraction
de
ns
ity
M027
0.0
0.5
1.0
1.5
2.0
0.00 0.25 0.50 0.75 1.00
variant_allele_fraction
de
ns
ity
M028
0
1
2
3
0.00 0.25 0.50 0.75 1.00
variant_allele_fraction
de
ns
ity
M029
0
1
2
0.00 0.25 0.50 0.75 1.00
variant_allele_fraction
de
ns
ity
M030
0
1
2
3
0.00 0.25 0.50 0.75 1.00
variant_allele_fraction
de
ns
ity
M002
0.0
0.5
1.0
1.5
2.0
0.00 0.25 0.50 0.75 1.00
variant_allele_fraction
de
ns
ity
M001
0.0
0.5
1.0
1.5
2.0
2.5
0.00 0.25 0.50 0.75 1.00
variant_allele_fraction
de
ns
ity
M001
0.0
0.5
1.0
1.5
2.0
0.00 0.25 0.50 0.75 1.00
variant_allele_fraction
de
ns
ity
M010
0.0
0.5
1.0
1.5
2.0
2.5
0.00 0.25 0.50 0.75 1.00
variant_allele_fraction
de
ns
ity
M023
0
1
2
3
0.00 0.25 0.50 0.75 1.00
variant_allele_fraction
de
ns
ity
M026
0.0
0.5
1.0
1.5
0.00 0.25 0.50 0.75 1.00
variant_allele_fraction
de
ns
ity
M026
0
1
2
3
0.00 0.25 0.50 0.75 1.00
variant_allele_fraction
de
ns
ity
M031
0
1
2
3
0.00 0.25 0.50 0.75 1.00
variant_allele_fraction
de
ns
ity
M031
0
1
2
3
0.00 0.25 0.50 0.75 1.00
variant_allele_fraction
de
ns
ity
MCL.1177
0
1
2
3
0.00 0.25 0.50 0.75 1.00
variant_allele_fraction
de
ns
ity
MCL.1180
0
1
2
0.00 0.25 0.50 0.75 1.00
variant_allele_fraction
de
ns
ity
MCL.1183
0
1
2
3
0.00 0.25 0.50 0.75 1.00
variant_allele_fraction
de
ns
ity
MCL.1184
0
2
4
0.00 0.25 0.50 0.75 1.00
variant_allele_fraction
de
ns
ity
MCL.1498
 152 
 
Note: y-axis: density of mutations for each VAF; x-axis: Variant allele fractions with range of 0 to 
1. Colors: Yellows plots shows distributions of VAFs for each cases of cohort-B, Red plots shows 
distributions of VAFs for each cases of discovery cohort. For tumor purity of 100% the expected 
VAF for a clonal heterozygous and homozygous variant should be 0.5, 0 and 1.0. The optimal 
allelic fraction density distribution in a pure homogenous tumor sample will display two density 
peaks, the highest at 0.5 representing VAF in clonal heterozygous variants and the slightly smaller 
peak at 1.0 representing clonal homozygous variants. However, the actual tumor samples show 
different distributions of VAFs because of the presence of normal cells in the tumor biopsy, 
subclonal heterogeneity of some tumors, and copy number variations.
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Appendix B. 
 
Supplementary Tables 
Supplementary Table 2.1. 
 
Supplementary Table 2.1. Counts of SNVs and indels in all the MCL cases 
including those that were aligned using BWA-MEM 
aligner.   
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75_T1 660 5 BWA-MEM BWA-MEM 51 241 181 72 44 24 44 2 1 
109_T1 933 6 BWA-MEM BWA-MEM 42 257 255 158 91 57 64 4 5 
122_T1 264 9 - Low-VAF 35 80 60 21 6 4 27 30 1 
35_T1 389 9 BWA-MEM - 22 56 40 51 47 36 82 43 12 
47_T1 854 30 BWA-MEM - 18 99 83 88 124 98 285 45 14 
138_T1 239 4 - Low-VAF 18 77 47 15 9 13 58 1 1 
71_T1 354 19 BWA-MEM - 15 19 32 45 45 49 102 35 12 
MCL.1807 185 17 - - 12 36 13 7 10 1 55 34 17 
28_T1 381 30 BWA-MEM - 11 26 33 33 50 50 130 32 16 
13_T1 230 16 BWA-MEM - 11 17 22 35 24 26 69 16 10 
40_T1 582 17 BWA-MEM - 10 43 59 62 99 71 200 32 6 
25_T1 265 9 BWA-MEM BWA-MEM 8 35 37 22 27 19 84 31 2 
45_T1 184 6 - - 8 17 20 21 13 10 68 16 11 
MCL.1498 922 380 - - 7 49 87 129 251 105 170 85 39 
46_T1 161 1 - - 6 13 12 5 10 15 34 59 7 
146_T1 115 7 - - 6 8 7 6 13 7 21 40 7 
33_T1 99 1 - - 6 5 2 6 7 7 57 8 1 
MCL.1183 73 0 - - 6 4 4 1 3 5 21 11 18 
MCL.1810 128 4 - - 5 15 12 8 4 5 42 34 3 
MCL.1803 146 23 - - 5 11 11 10 15 13 36 37 8 
M008 86 4 - - 5 10 4 9 10 11 22 12 3 
MCL.1499 243 51 - Low-VAF 4 19 24 38 45 26 44 32 11 
M003 108 3 - - 4 2 4 3 6 2 21 38 28 
M002 87 3 - - 4 0 1 1 4 1 15 49 12 
M004 120 1 - - 3 13 9 9 7 3 21 38 17 
MCL.1502 152 9 - - 3 12 10 9 12 13 63 25 5 
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M028 84 6 - - 3 11 6 6 5 1 30 18 4 
128_T1 101 5 - - 3 2 13 3 8 4 40 26 2 
M019 66 4 - - 3 2 3 0 6 7 7 26 12 
M009 153 4 - - 3 2 2 3 2 8 38 87 8 
61_T1 63 2 - - 2 8 5 9 4 8 25 2 0 
MCL.1180 62 3 - - 2 6 3 5 3 11 21 7 4 
M013 58 4 - - 2 5 1 5 7 13 24 1 0 
MCL.1500 114 10 - - 2 4 4 13 17 8 33 21 12 
M010_LN 94 3 - - 2 2 7 8 3 17 19 41 14 
42_T1 55 1 - - 2 1 5 11 11 15 10 0 0 
M020 73 1 - - 2 1 4 1 6 4 30 20 5 
M001_LN 34 1 - - 2 1 2 3 2 10 16 3 1 
M011 45 3 - - 2 0 3 3 1 2 25 7 2 
M010_PB 75 2 - - 2 0 2 0 3 7 12 22 13 
MCL.1802 155 10 - - 1 10 21 19 8 12 42 32 10 
M030 99 6 - - 1 7 5 2 1 1 22 50 10 
MCL.1813 142 10 - - 1 7 4 6 6 9 60 41 8 
M027 89 2 - - 1 6 4 3 11 5 16 27 16 
M026_LN 66 0 - - 1 4 4 3 4 16 22 1 0 
M016_PB 63 1 - - 1 4 1 8 5 19 20 11 14 
39_T1 116 3 - - 1 3 7 10 5 11 73 5 1 
98_T1 95 1 - - 1 3 7 5 7 6 53 13 0 
M016_Spleen 54 3 - - 1 3 5 5 8 21 27 5 3 
M031_LN 64 3 - - 1 3 4 3 3 14 16 21 1 
M024 70 0 - - 1 3 4 1 3 1 32 19 6 
MCL.1177 36 0 - - 1 2 2 4 5 4 15 2 1 
M023_PB 54 2 - - 1 1 5 2 0 9 11 30 6 
M029 68 1 - - 1 1 3 2 0 1 9 42 9 
126_T1 67 0 - - 0 15 13 12 5 3 7 9 3 
MCL.1501 148 4 - - 0 7 16 6 4 8 39 56 12 
M026_PB 91 0 - - 0 5 8 0 1 14 16 25 25 
14_T1 82 3 - - 0 5 2 10 16 27 22 0 0 
M023_LN 66 1 - - 0 4 9 5 10 28 37 2 0 
24_T1 63 2 - - 0 4 9 12 9 9 19 0 1 
M015 68 6 - - 0 4 9 8 7 6 26 6 2 
M031_PB 62 3 - - 0 4 2 3 2 11 12 33 1 
M001_PB 36 1 - - 0 4 1 3 1 5 9 19 1 
M012 82 6 - - 0 4 0 3 1 8 48 16 2 
M007 52 3 - - 0 3 2 2 3 1 23 13 5 
M025 53 7 - - 0 3 0 6 11 5 24 3 1 
38_T1 50 1 - - 0 2 1 0 3 5 28 9 2 
M014 45 4 - - 0 1 7 0 1 3 14 15 4 
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MCL.1184 35 3 - - 0 0 2 0 4 13 10 6 0 
MCL.1504 108 5 - - 0 0 0 0 5 8 56 31 8 
MCL.1505 75 5 - - 0 0 0 1 2 2 19 27 24 
Abbreviations: Low-VAF: Distributions of VAFs for most of the mutations were towards the 
lower range possibly because of the low tumor purity or high subclonal heterogeneity.  
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Supplementary Table 2.2. 
Supplementary Table 2.2. Number of SNVs and indels before and after running 
ClipOverlap.  
Samples INDELs/SNVs Before Filter After Filter 
126_T1 INDELs 2 0 
126_T1 SNVs 471 107 
128_T1 INDELs 7 7 
128_T1 SNVs 190 129 
138_T1 INDELs 6 6 
138_T1 SNVs 1802 252 
146_T1 INDELs 11 9 
146_T1 SNVs 182 135 
24_T1 INDELs 4 4 
24_T1 SNVs 195 113 
33_T1 INDELs 3 3 
33_T1 SNVs 209 118 
38_T1 INDELs 3 3 
38_T1 SNVs 153 59 
98_T1 INDELs 4 3 
98_T1 SNVs 427 106 
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Supplementary Table 2.3. 
Supplementary Table 2.3. Counts of somatic SNVs, indels, and CNVs in the three 
MCL cohorts.  
Discovery Cohort Cohort-B Cohort-Z 
Sample ID N of Indels 
N of 
SNVs 
N of 
CNVs Sample ID 
N of 
Indels 
N of 
SNVs 
N of 
CNVs Sample ID 
N of 
Indels 
N of 
SNVs 
13_Tumor 19 245 41 M001-LN-ex_D 34 1 23 MCL.1177 0 64 
14_Tumor 3 113 17 M001-PB-ex_D 36 1 23 MCL.1180 3 86 
24_Tumor 2 111 16 M002-PB2_R 292 11 12 MCL.1183 6 137 
25_Tumor 9 293 21 M002-Tonsil-ex_D 86 3 12 MCL.1184 3 47 
28_Tumor 32 394 27 M003-PB-ex_D 105 3 1 MCL.1498 382 544 
33_Tumor 1 116 41 M003-PB2-ex_PRE 218 3 21 MCL.1499 51 196 
35_Tumor 10 421 74 M004-PB-ex_D 119 1 6 MCL.1500 13 105 
38_Tumor 1 57 36 M006-PB_D 13998 1  MCL.1501 4 156 
39_Tumor 3 127 23 M007-Colon_D 59 3 3 MCL.1502 10 151 
40_Tumor 18 654 51 M008-PB_PRE 82 4 7 MCL.1504 5 103 
42_Tumor 1 64 20 M009-PB_ PO 153 4 0 MCL.1505 5 70 
45_Tumor 6 188 22 M010-LN_D 94 3 32 MCL.1802 11 161 
46_Tumor 1 173 17 M010-PB_D 75 2 32 MCL.1803 24 132 
47_Tumor 32 937 ? M011-LN_D 44 3 4 MCL.1807 18 182 
61_Tumor 2 69 18 M012-LN_D 77 6 5 MCL.1808 148 1101 
71_Tumor 21 376 33 M013-LN_D 55 4 2 MCL.1810 5 143 
75_Tumor 5 691 NA M014-LN_D 42 4 12 MCL.1813 10 136 
98_Tumor 1 104 8 M015-PB_UN 63 6 1 - - - 
109_Tumor 6 981 NA M016-PB_UN 63 1 0 - - - 
122_Tumor 9 261 5 M016-Spleen_PRE 54 3 0 - - - 
126_Tumor 0 105 16 M018-PB_R 5703 64  - - - 
128_Tumor 5 127 19 M019-PB_D 66 4 13 - - - 
138_Tumor 4 250 20 M020-PB_D 74 1 12 - - - 
146_Tumor 7 133 5 M021-PB_UN 1793 3  - - - 
- - - - M022-LN_R 92 8 23 - - - 
- - - - M023-LN_D 66 1 7 - - - 
- - - - M023-PB_D 54 2 5 - - - 
- - - - M024-LN_D 71 0 4 - - - 
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- - - - M025-LN_UN 46 7 7 - - - 
- - - - M026-LN_D 66 0 13 - - - 
- - - - M026-PB_D 91 0 13 - - - 
- - - - M027-PB_UN 88 2 1 - - - 
- - - - M028-PB_D 79 6 24 - - - 
- - - - M029-PB_D 69 1 12 - - - 
- - - - M030-PB_D 99 6 5 - - - 
- - - - M031-LN_D 64 3 21 - - - 
- - - - M031-PB_D 62 3 21 - - - 
The CNV data for Cohort-B was extracted from the supplementary file of Bea et al. (Beà et al. 
2013). Abbreviations: diagnostic (D); untreated (UN); relapse (R); pretreatment (PRE); post 
treatment (PO). 
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Supplementary Table 2.4. 
Supplementary Table 2.4. List of somatic SNVs and indels detected in samples from 
67 cases of MCL. 
See Metadata_AMohajeri_2017 
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Supplementary Table 2.5. 
Supplementary Table 2.5.  List of significant genes that were detected in MCL 
using MutSigCV. 
Gene p-value q-value N-nonsilent N-silent N-noncoding 
B2M 0.00E+00 0.00E+00 2 0 0 
KLF11 0.00E+00 0.00E+00 2 0 0 
LUZP4 0.00E+00 0.00E+00 3 0 0 
TP53 0.00E+00 0.00E+00 17 0 1 
ZNF717 0.00E+00 0.00E+00 8 0 0 
ATM 1.89E-15 5.93E-12 42 0 1 
BIRC3 1.26E-08 3.40E-05 6 0 0 
WHSC1 6.29E-06 1.46E-02 11 0 0 
MUC4 6.96E-06 1.46E-02 10 1 1 
SP140 1.97E-05 3.71E-02 4 1 1 
ADAM30 3.70E-05 6.34E-02 8 0 0 
S1PR1 5.02E-05 7.89E-02 3 0 0 
TYRO3 1.41E-04 1.90E-01 3 0 2 
MEF2B 1.48E-04 1.90E-01 4 0 0 
MLL2 1.51E-04 1.90E-01 7 0 1 
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Supplementary Table 2.6. 
Supplementary Table 2.6. List of significantly mutated genes in 67 MCL that was 
detected using Oncodrive-fm. 
Gene P-Value Q-Value SIFT P-
Value 
PolyPhen 
P-Value 
Ensembl ID 
BIRC3 3.77E-15 2.13E-13 1.00E-08 1.00E-08 ENSG00000023445 
WHSC1 3.77E-15 2.13E-13 1.00E-08 1.00E-08 ENSG00000109685 
TP53 3.77E-15 2.13E-13 1.00E-08 1.00E-08 ENSG00000141510 
ATM 3.77E-15 2.13E-13 1.00E-08 1.00E-08 ENSG00000149311 
MAP3K14 2.63E-10 1.19E-08 0.001 1.00E-08 ENSG00000006062 
MEF2B 2.17E-09 8.18E-08 0.009 1.00E-08 ENSG00000213999 
TTN 1.83E-07 5.92E-06 1.00E-08 0.941 ENSG00000155657 
TYRO3* 0.0005 0.0117 0.0140 0.0030 ENSG00000092445 
RB1 0.0005 0.0117 0.0140 0.0030 ENSG00000139687 
LRP1B 0.0006 0.0132 0.0090 0.0060 ENSG00000168702 
FAT4 0.0008 0.0173 0.0090 0.0090 ENSG00000196159 
PTPRD 0.0014 0.0260 0.0140 0.0100 ENSG00000153707 
MLL3 0.0018 0.0293 0.0190 0.0100 ENSG00000055609 
FRG1* 0.0018 0.0293 0.0310 0.0060 ENSG00000109536 
DST 0.0020 0.0297 0.0010 0.2080 ENSG00000151914 
MLL2 0.0028 0.0372 0.0140 0.0220 ENSG00000167548 
CARD11 0.0028 0.0372 0.0140 0.0220 ENSG00000198286 
CCND1 0.0031 0.0384 0.0680 0.0050 ENSG00000110092 
MUC17* 0.0061 0.0729 0.0020 0.3740 ENSG00000169876 
ZNF717* 0.0064 0.0729 0.0090 0.0880 ENSG00000227124 
ZAN* 0.0079 0.0758 0.0010 1.0000 ENSG00000146839 
IGFN1* 0.0075 0.0758 0.0010 0.9420 ENSG00000163395 
S1PR1 0.0080 0.0758 0.0300 0.0340 ENSG00000170989 
GOLGA6L2* 0.0079 0.0758 0.0010 1.0000 ENSG00000174450 
RRP8* 0.0089 0.0804 0.0880 0.0130 ENSG00000132275 
PCSK2 0.0106 0.0921 0.0560 0.0250 ENSG00000125851 
MUC4* 0.0143 0.1194 0.0020 0.9870 ENSG00000145113 
SP140 0.0149 0.1204 0.0770 0.0270 ENSG00000079263 
ALMS1* 0.0162 0.1260 0.0140 0.1630 ENSG00000116127 
CSMD2 0.0185 0.1392 0.0290 0.0920 ENSG00000121904 
NBPF10* 0.0227 0.1652 0.0140 0.2420 ENSG00000163386 
DNAH9 0.0237 0.1673 0.0140 0.2550 ENSG00000007174 
FAT1 0.0257 0.1710 0.0140 0.2810 ENSG00000083857 
IGHV1-2 0.0255 0.1710 0.0140 0.2780 ENSG00000211934 
SYNE1 0.0279 0.1759 0.0190 0.2280 ENSG00000131018 
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DPYD 0.0280 0.1759 0.0140 0.3110 ENSG00000188641 
The genes marked with asterisk * were false positives resulted from technical artifacts. 
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Supplementary Table 3.1. 
Supplementary Table 3.1. Some of the genes harboring recurrent SNVs and CNVs 
in MCL cohorts.  
See Metadata_AMohajeri. 
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Supplementary Table 3.2. 
Supplementary Table 3.2. Genes with recurrent and biallelic mutations in MCL. 
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Supplementary Table 3.3. 
Supplementary Table 3.3. The chimeric reads of chr10, chr11, and chr13 that are supporting the translocation breakpoints.  
 
 
1				45			116	100.0%			11			-			69489601		69489645	 46			116			116	100.0%				10			+			21969608		21969678	
ACCTTTGCCATCTGGGAGCTGCCTTTTTTTCTGGTTCCTTAATCAT	 TGAATGACCTAGACCTAGCGTGGTGGCTCACGTCGGTAATCCCAGCACTTTGGGAGGTCAAGGCAGGCAG	
GGACAGACCTTTGCCATCTGGGAGCTGCCTTTTTTTCTGGTTCCTTAATCAT	 TGAATGACCTAGACCTAGCGTGGTGGCTCACGTCGGTAATCCCAGCACTTTGGGAGGTCAAGGC	
GACCTTTGCCATCTGGGAGCTGCCTTTTTTTCTGGTTCCTTAATCAT	 TGAATGACCTAGACCTAGCGTGGTGGCTCACGTCGGTAATCCCAGCACTTTGGGAGGTCAAGGCAGGCA	
GGACAGACCTTTGCCATCTGGGAGCTGCCTTTTTTTCTGGTTCCTTAATCAT	 TGAATGACCTAGACCTAGCGTGGTGGCTCACGTCGGTAATCCCAGCACTTTGGGAGGTCAAGGC	
TTGCCATCTGGGAGCTGCCTTTTTTTCTGGTTCCTTAATCAT	 TGAATGACCTAGACCTAGCGTGGTGGCTCACGTCGGTAATCCCAGCACTTTGGGAGGTCAAGGCAGGCAGATCA	
CAGACCTTTGCCATCTGGGAGCTGCCTTTTTTTCTGGTTCCTTAATCAT	 TGAATGACCTAGACCTAGCGTGGTGGCTCACGTCGGTAATCCCAGCACTTTGGGAGGTCAAGGCAGG	
GACCTTTGCCATCTGGGAGCTGCCTTTTTTTCTGGTTCCTTAATCAT	 TGAATGACCTAGACCTAGCGTGGTGGCTCACGTCGGTAATCCCAGCACTTTGGGAGGTCAAGGCAGGCA	
GACCTTTGCCATCTGGGAGCTGCCTTTTTTTCTGGTTCCTTAATCAT	 TGAATGACCTAGACCTAGCGTGGTGGCTCACGTCGGTAATCCCAGCACTTTGGGAGGTCAAGGCAGGCA	
CCTTTGCCATCTGGGAGCTGCCTTTTTTTCTGGTTCCTTAATCAT	 TGAATGACCTAGACCTAGCGTGGTGGCTCACGTCGGTAATCCCAGCACTTTGGGAGGTCAAGGCAGGCAGA	
-	 TGAATGACCTAGACCTAGCGTGGTGGCTCACGTCGGTAATCCC	
-	 TGAATGACCTAGACCTAGCGTGGTGGCTCACGTCGGTAATCCCAG	
-	 TGAATGACCTAGACCTAGCGTGGTGGCTCACGTCGGTAATCC	
-	 TGAATGACCTAGACCTAGCGTGGTGGCTCA	
-	 TGAATGACCTAGACCTAGCGCGGTGGCTCACGTCGGTAATCCCAGCACTTTGG	
-	 TGAATGACCTAGACCTAGCGTGGTGGCTCACG	
-	 TGAATGACCTAGACCTAGCGTGGTGGCTCACGTCGGTAATCCCAGCAC	
-	 TGAATGACCTAGACCTAGCGTGGTGGCTCACGTCGGTAATCCCAGCAC	
1				47			116	100.0%				11			-			69489601		69489647					47	 48			116			116	100.0%				10			+			21969608		21969676					69	
TGA	 ATGACCTAGACCTAGCGTGGTGGCTCACGTCGGTAATCCCAGCAC	
TGA	 ATGACCTAGACCTAGCGTGGTGGCTCACGTCGGTAATCCCAGCAC	
CAGACCTTTGCCATCTGGGAGCTGCCTTTTTTTCTGGTTCCTTAATCATTGA	 ATGACCTAGACCTAGCGTGGTGGCTCACGTCGGTAATCCCAGCACTTTGGGAGGTCAAGGCAGG	
TGA	 ATGACCTAGACCTAGCGTGGTGGCTCACGTCGGTAATCCC	
GACCTTTGCCATCTGGGAGCTGCCTTTTTTTCTGGTTCCTTAATCATTGA	 ATGACCTAGACCTAGCGTGGTGGCTCACGTCGGTAATCCCAGCACTTTGGGAGGTCAAGGCAGGCA	
GACCTTTGCCATCTGGGAGCTGCCTTTTTTTCTGGTTCCTTAATCATTGA	 ATGACCTAGACCTAGCGTGGTGGCTCACGTCGGTAATCCCAGCACTTTGGGAGGTCAAGGCAGGCA	
CCTTTGCCATCTGGGAGCTGCCTTTTTTTCTGGTTCCTTAATCATTGA	 ATGACCTAGACCTAGCGTGGTGGCTCACGTCGGTAATCCCAGCACTTTGGGAGGTCAAGGCAGGCAGA	
1			45			116	100.0%		10			-			21969608		21969652					45	 71				46			116			116	100.0%				11			+			69489601		69489671					71	
CTGGGATTACCGACGTGAGCCACCACGCTAGGTCTAGGTCATTCA	 ATGATTAAGGAACCAGAAAAAAAGGCAGCTCCCAGATGGCAAAGGTCTGTCCTCCCAGAGGACGAGGCGGC	
-	 ATGATTAAGGAACCAGAAAAAAAGGCAGCTCCCAGATGGCAAAGGT	
-	 ATGATTAAGGAACCAGAAAAAAAGGCAGCTCCCAGATGGCAAAGGTCTGTCC	
GGATTACCGACGTGAGCCACCACGCTAGGTCTAGGTCATTCA	 ATGATTAAGGAACCAGAAAAAAAGGCAGCTCCCAGATGGCAAAGGTCTGTCCTCCCAGAGGACGAGGCGG	
-	 ATGATTAAGGAACCAGAAAAAAAGGCAGCTCCCAGATGGCAAAGGTC	
-	 ATGATTAAGGAACCAGAAAAAAAGGCAGCTCCCAGATGGCAAAGGTCTGTCC	
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-	 ATGATTAAGGAACCAGAAAAAAAGGCAGCTCCCAGATGGCAA	
TGAGCCACCACGCTAGGTCTAGGTCATTCA	 ATGATTAAGGAACCAGAAAAAAAGGCAGCTCCCAGATGGCAAAGGTCTGTCCTCCCAGAGGACGAGGCGGCCTCGGAGGAGG	
CCAAAGTGCTGGGATTACCGACGTGAGCCACCGCGCTAGGTCTAGGTCATTCA	 ATGATTAAGGAACCAGAAAAAAAGGTAGCTCCCAGATGGCAAAGGTCTGTCCTCCCAGAGGAC	
CGTGAGCCACCACGCTAGGTCTAGGTCATTCA	 ATGATTAAGGAACCAGAAAAAAAGGCAGCTCCCAGATGGCAAAGGTCTGTCCTCCCAGAGGACGAGGCGGCCTCGGAGGAG	
GTGCTGGGATTACCGACGTGAGCCACCACGCTAGGTCTAGGTCATTCA	 ATGATTAAGGAACCAGAAAAAAAGGCAGCTCCCAGATGGCAAAGGTCTGTCCTCCCAGAGGACGAGGC	
-	 ATGATTAAGGAACCAGAAAAAAAGGCAGCTCCCAGATGGCAAAGGTCTG	
GGGATTACCGACGTGAGCCACCACGCTAGGTCTAGGTCATTCA	 ATGATTAAGGAACCAGAAAAAAAGGCAGCTCCCAGATGGCAAAGGTCTGTCCTCCCAGAGGACGAGGCGGCCT	
-	 ATGATTAAGGAACCAGAAAAAAAGGCAGCTCCCAGATGGCAAAGGTC	
-	 ATGATTAAGGAACCAGAAAAAAAGGCAGCTCCCAGATGGCAAAGG	
1				59			116	100.0%				11			+			69489469		69489527					59	 62			116			116	100.0%				13			+			34026947		34027001					55	
TCCCCCACTGTCGCAGCACGAGGGGCTCCCC	 	
GGAAGTCAGCCAGGAGGCAACTCACAGCTCCCCCACTGTCGCAGCACGAGGGGCTCCCC	 TGAACAAATGAGTAACCTGGAACAGCGATGTATATCAACATGAAAATGTCTTTTCTT	
ACTCACAGCTCCCCCACTGTCGCAGCACGAGGGGCTCCCC	 	
GGAAGTCAGCCAGGAGGCAACTCACAGCTCCCCCACTGTCGCAGCACGAGGGGCTCCCC	 TGAACAAATGAGTAACCTGGAACAGCGATGTATATCAACATGAAAATGTCTTTTCTT	
CTCACAGCTCCCCCACTGTCGCAGCACGAGAGGCTCCCC	 	
CTCACAGCTCCCCCACTGTCGCAGCACGAGGGGCTCCCC	 	
-	 NNAACAAATGAGTAACCTGGAACAGCGATGTATATCAACATGAAAATGTCTTTTCTT	
TCCCCCACTGTCGCAGCACGAGGGGCTCCCC	 TGAACAAATGAGTAACCTGGAACAGCGATGTATATCAACATGAAAATGTCTTTTCTTCAACTATTATATTCAGTTTCATTTCTAA	
-	 NNAACAAATGAGTAACCTGGAACAGCGATGTATATCA	
-	 NNAACAAATGAGTAACCTGGAACAGCGATGTATATCAACATGAAAATGTCTTTTCTT	
ACTCACAGCTCCCCCACTGTCGCAGCACGAGGGGCTCCCC	 TGAACAAATGAGTAACCTGGAACAGCGATGTATATCAACATGAAAATGTCTTTTCTTCAACTATTATATTCAGTTT	
CTCACAGCTCCCCCACTGTCGCAGCACGAGAGGCTCCCC	 TGAACAAATGAGTAACCTGGAACAGCGATGTATATCAACATGAAAATGTCTTTTCTTCAACTATTAAGTCAGTCTAG	
CTTCTGAGACTCTCACAGCTCCCCCACTGTCGCAGCACGAGGGGCTCCCC	 TGAACAAATGAGTAACCTGGAACAGCGATGTATATCAACATGAAAATGTCTTTTCTTCAACTATTA	
1				35			117	100.0%				13			-			34026947		34026981					35	 	38			116			117	100.0%				11			-			69489449		69489527					79	
TGATATACATCGCTGTTCCAGGTTACTCATTTGTTCA	 GGGGAGCCCCTCGTGCTGCGACAGTGGGGGAGCTGTGAGTTGCCTCCTGGCTGACTTCCAGTGCCCGGCCCAGAGGACGA	
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Supplementary Table 4.1. 
Supplementary Table 4.1. All the mutated pathways in the cases of MCL including 
the significantly mutated candidate drivers were detected using 
Oncodrive-fm.  
 See Metadata_AMohajeri. 
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Supplementary Table 4.2. 
Supplementary Table 4.2. Results of VarElect showed associations between 455 out 
of 1109 recurrently mutated genes (N>=2) with atleast one of the 
phenotypes.  
See Metadata_AMohajeri. 
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Supplementary Table 4.3. 
Supplementary Table 4.3. Driver pathways and their members that are targeted by 
CNVs in MCL. 
See Metadata_ AMohajeri. 
